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Chapter 11 
OVERVIEW
Despite 90 years of vaccination and 60 years of chemother-
apy, tuberculosis (TB) remains the world’s leading cause of 
death from an infectious agent, exceeding human immu-
nodeficiency virus/acquired immune deficiency syndrome 
(HIV/AIDS) for the first time (WHO 2015b, 2016a). 
The World Health Organization (WHO) estimates that 
there are about 10.4 million new cases and 1.8 million 
deaths from TB each year. One-third of these new cases 
(about 3 million) remain unknown to the health system, 
and many are not receiving proper treatment. 
Tuberculosis is an infectious bacterial disease caused 
by Mycobacterium tuberculosis (Mtb), which is transmit-
ted between humans through the respiratory route and 
most commonly affects the lungs, but can damage any 
tissue. Only about 10 percent of individuals infected 
with Mtb progress to active TB disease within their life-
time; the remainder of persons infected successfully 
contain their infection. One of the challenges of TB is 
that the pathogen persists in many infected individuals 
in a latent state for many years and can be reactivated to 
cause disease. The risk of progression to TB disease after 
infection is highest soon after the initial infection and 
increases dramatically for persons co-infected with HIV/
AIDS or other immune-compromising conditions. 
Treatment of TB disease requires multiple drugs for 
many months. These long drug regimens are challenging 
for both patients and health care systems, especially in 
low- and middle-income countries (LMICs), where the 
disease burden often far outstrips local resources. In 
some areas, the incidence of drug-resistant TB, requiring 
even longer treatment regimens with drugs that are 
more expensive and difficult to tolerate, is increasing. 
Diagnosis in LMICs is made primarily by microscopic 
examination of stained smears of sputum of suspected 
patients; however, smear microscopy is capable of detect-
ing only 50–60 percent of all cases (smear-positive). 
More sensitive methods of diagnosing TB and detecting 
resistance to drugs have recently become available, 
although they are more expensive. The time between the 
onset of disease and when diagnosis is made and treat-
ment is initiated is often protracted, and such delays 
allow the transmission of disease. Although bacille 
Calmette–Guérin (BCG) remains the world’s most widely 
used vaccine, its effectiveness is geographically highly 
variable and incomplete. Modeling suggests that more 
effective vaccines will likely be needed to drive tuberculo-
sis toward elimination in high-incidence settings. 
The basic strategy to combat TB has been, for 40 years, 
to provide diagnosis and treatment to individuals 
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who are ill and who seek care at a health facility. The 
premise is that, if patients with active disease are cured, 
mortality will disappear, prevalence of disease will 
decline, transmission will decline, and therefore inci-
dence should decline. The reality in many countries is 
more complex, and overall the decline in incidence (only 
about 1.5 percent per year) has been unacceptably slow.
Chemotherapy for TB is one of the most cost- 
effective of all health interventions (McKee and Atun 
2006). This evidence has been central to the global pro-
motion of the WHO and Stop TB Partnership policy of 
directly observed therapy, short course (DOTS) strategy, 
the package of measures combining best practices in the 
diagnosis and care of patients with TB (UN General 
Assembly 2000). The DOTS strategy to control tubercu-
losis promotes standardized treatment, with supervision 
and patient support that may include, but is far broader 
than, direct observation of therapy (DOT), where a 
health care worker personally observes the patient taking 
the medication (WHO 2013a). 
Thanks in part to these efforts and national and 
international investments, much progress has been 
made in TB control over the past several decades. 
Between 1990 and 2010, absolute global mortality 
from TB declined 18.7 percent, from 1.47 million to 
1.20 million (Lozano and others 2012) and by 
22 percent between 2000 and 2015 (WHO 2016a). By 
2015, an estimated 49 million lives had been saved 
(WHO 2016a). The internationally agreed targets for 
TB, embraced in the United Nations (UN) Millennium 
Development Goals (MDGs), sought “to halt and 
reverse the expanding incidence of tuberculosis by 
2015,” and this target has been met to some extent in 
all six WHO regions and in most, but not all, of the 
world’s 22 high-burden countries (WHO 2014c).
Despite progress, major gaps persist. Although the 
Sustainable Development Goals (SDGs) seek to end the 
tuberculosis epidemic altogether (WHO 2015a, 2015c), 
the decline in incidence has been disappointing. One of 
every three TB patients remains “unknown to the health 
system,” many are undiagnosed and untreated, and case 
detection and treatment success rates remain too low 
in the high-burden countries. Ominously, rates of 
multidrug- resistant (MDR) TB—defined as resistance to 
the two major TB drugs, isoniazid and rifampicin—are 
 rising globally (WHO 2011a) with the emergence of 
extensively drug-resistant (XDR) TB, resistant to many 
second-line drugs, as well as strains resistant to all cur-
rent drugs (Dheda and others 2014; Udwadia and others 
2012; Uplekar and others 2015). These are now primarily 
the result of transmission rather than inadequate treat-
ment (Shah and others 2017).
Moreover, the TB problem has become more  pressing 
because of co-infection with HIV/AIDS. While globally 
HIV/AIDS and TB co-infection represents only 
11 percent of the total TB burden, in some areas of Sub-
Saharan Africa with a high burden of TB, as many as 
three-quarters of TB patients are co-infected with HIV/
AIDS. In those countries, efforts to control TB are over-
whelmed by the rising number of TB cases occurring 
in parallel with the HIV/AIDS epidemic. And after 
decades of steady decline, the incidence of TB is also 
increasing in some high-income countries (HICs), 
mainly as the result of outbreaks in vulnerable groups 
(WHO 2015b). 
If the ultimate goal of controlling an infectious dis-
ease is to interrupt transmission, turning the tide on TB 
will require early and accurate case detection, rapid 
commencement of and adherence to effective treatment 
that prevents transmission, and, where possible, preven-
tive treatment of latent TB. It is universally understood 
that new strategies and more effective tools and inter-
ventions will be required to reach post-2015 targets 
(Bloom and Atun 2016; WHO 2015a). These interven-
tions must be not only cost-effective, but also affordable 
and capable of having an impact on a very large scale.
TB control will need three new advances— 
 development of new point-of-care diagnostics, more 
effective drug regimens to combat drug-susceptible 
and drug-resistant TB, and more effective vaccines. As 
argued in this chapter, these require new strategies and 
tools that include moving away from the traditional 
DOTS passive case finding and toward more active case 
finding in high- burden regions; service delivery that is 
targeted to the most vulnerable populations and inte-
grated with other services, especially HIV/AIDS ser-
vices; and care that is based at the primary health care 
and community levels. Specifically, in high-burden 
countries, many individuals with TB are asymptom-
atic, such that waiting for patients to become sick 
enough to seek care has not been sufficient to reduce 
transmission and incidence markedly (Bates and others 
2012; Mao and others 2014; Willingham and others 
2001; Wood and others 2007). A more active and 
aggressive approach is needed that tackles health 
system barriers to effective TB control. 
The strategies for controlling TB recommended by the 
WHO have evolved significantly over time. In the early 
formulations, the central tenets of the global TB control 
strategy were clinical and programmatic in nature, focus-
ing principally on the delivery of standardized drug regi-
mens; the underlying assumption was that the problem 
could be solved largely by existing biomedical tools (Atun, 
McKee, and others 2005; Schouten and others 2011). 
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Yet, in many LMICs, health system weaknesses in gover-
nance, financing, health workforce, procurement and 
supply chain management, and information systems have 
impeded TB control (Elzinga, Raviglione, and Maher 
2004; Marais and others 2010; Travis and others 2004) 
and not been adequately addressed by TB control efforts. 
The current global TB strategy, formulated as the End 
TB Strategy, is the most comprehensive ever, with three 
major pillars: 
• Integrated, patient-centered care and prevention
• Social and political action to address determinants 
of disease 
• Recognition of the urgent need for research to pro-
vide new tools (WHO 2015a).
Health systems are important and need to be strength-
ened. As with other health interventions, the success of 
tuberculosis treatment and control in a country is often 
determined by the strength of its health system (McKee 
and Atun 2006; WHO 2003). A health system can be 
defined in many ways, perhaps best as “all the activities 
whose primary purpose is to promote, restore, or main-
tain health” (WHO 2000, 5). 
In a sense, the major risk factor for acquiring TB is 
breathing. Thus, people of all social and economic statuses 
are at risk. While TB disproportionately affects the poor, 
the narrative that TB is a disease only of the poor is mis-
leading and counterproductive, if it leads either to further 
stigmatization of the disease or to the view that middle- 
and high-income countries need not worry about the dis-
ease. In the case of co-infection with HIV/AIDS, evidence 
suggests that HIV/AIDS is often more prevalent in 
better-off populations in Africa that suffer high rates of TB.
The analytical framework underlying this chapter defines 
key functions of the health system, ultimate goals, and con-
textual factors that affect the health system  (figure 11.1). 
It builds on the WHO framework (WHO 2000) as well 
as health system frameworks developed by Frenk (1994), 
Hsiao and Heller (2007), and Roberts and others (2004), 
and national accounts (OECD, Eurostat, and WHO 2011). 
It also draws on earlier studies by Atun (2012); Atun and 
Coker (2008); Atun, Samyshkin, and others (2006); Samb 
and others (2009); and Swanson and others (2012). 
Figure 11.1 Schematic Health Systems Framework
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The four key health system functions represented in 
the framework are as follows: 
• Governance and organization. The policy and reg-
ulatory environment; stewardship and regulatory 
functions of the ministry of health and its relation 
to other levels of the health system; and structural 
arrangements for insurers and purchasers, health care 
providers, and market regulators 
• Financing. The way funds are collected, funds and 
risks are pooled, finances are allocated, and health 
care providers are remunerated 
• Resource management. The way resources—physical, 
human, and intellectual—are generated and allo-
cated, including their geographic and needs-based 
allocation 
• Service delivery. Both population- and individual- 
level public health interventions and health care 
services provided in community, primary health care, 
hospitals, and other health institutions. 
Each of these functions is influenced by the eco-
nomic, demographic, legal, cultural, and political 
context. 
As the framework suggests, health system goals 
include better health, financial protection, and user satis-
faction. Personal health services and public health inter-
ventions should be organized to achieve an appropriate 
balance of equity (including reducing out-of-pocket 
[OOP] expenditures and impoverishment of individuals 
and families), efficiency, effectiveness (that is, the extent 
to which interventions are evidence based and safe), 
responsiveness, equity, and client satisfaction (as per-
ceived by the users of services).
This chapter is organized as follows. First, we pro-
vide a detailed discussion of the global burden of 
 disease and clinical context, followed by a review of 
approaches to diagnosis, treatment, and prevention. 
The aim throughout is to approach TB through a 
health system lens and, in the latter part of the chapter, 
to provide recommendations for improving delivery 
strategies and strengthening health systems, including 
care, supply chain, and information systems. Because 
the current tools for combating TB are seriously 
 inadequate, we conclude with sections on critical 
research and development and economic analyses of 
new  interventions for diagnosis, treatment, and vac-
cines. Throughout, emphasis is placed on data or mod-
eling of the economic costs and benefits, where 
available, of current or possible future interventions to 
combat this disease.
The chapter recommends moving toward active 
case finding in high-burden countries; greater investments 
in health systems; community-based rather than hospital- 
based service delivery; and greater support for research on 
new tools—that is, developing better diagnostics, treat-
ment regimens, and vaccines. Most of these approaches 
were included in earlier WHO policies, but were not 
emphasized. They are now part of the WHO’s End TB 
Strategy, with which this report is fully consistent (WHO 
2015a, 2015c).
HISTORICAL TRENDS, CURRENT BURDEN, 
AND GLOBAL RESPONSE
TB has been a major killer worldwide for centuries and 
has now exceeded HIV/AIDS and malaria as the world’s 
largest cause of death from an infectious disease (Dye 
2015; WHO 2016a). 
Historical Trends 
TB rates have been declining in North America 
and Western Europe since the early nineteenth century, 
prior to the introduction of chemotherapy in the 1950s. 
The decline may be partly due to the natural waning of 
the epidemic (Blower and others 1995), but the trend 
has been too prolonged for this to provide the whole 
 explanation. Researchers have recently suggested that 
dramatic differences between cities experiencing 
marked declines prior to chemotherapy (for example, 
New York City in the United States; London in the 
United Kingdom) and cities where TB remained high 
(Cape Town in South Africa) may be explained by the 
quality and organization of the local health system 
(Hermans, Horsburgh, and Wood 2015). Other potential 
explanations for the 150-year decline have been the sub-
ject of debate and include the following:
1. Reduced opportunities for transmission per case, 
which may have occurred due to lower living density, 
better ventilation within homes, patient isolation 
within sanatoriums, and declining contacts among 
elderly cases (McFarlane 1989) 
2. Reduced susceptibility of contacts, which may have 
been the result of improved nutrition and genetic 
pressures (Lipsitch and Sousa 2002; McKeown and 
Record 1962; Shetty and others 2006) 
3. Reduced virulence of the pathogen, although there is 
little evidence to that effect. 
While untreated TB has traditionally had a case 
fatality rate of 50 percent, there are differing opinions 
on the role of natural selection in resistance to pulmo-
nary TB in humans prior to the availability of TB drugs 
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(Lipsitch and Sousa 2002). It is not possible to disen-
tangle all of the factors that contributed to the decline 
of TB before the widespread introduction of chemo-
therapy or the reasons why progress has since stalled. 
What is clear is that the TB death rate in Western 
Europe fell 5 percent a year in the era before chemo-
therapy, with declines in the United States and Western 
Europe associated with active case finding, for example, 
X-ray screening. 
By the 1990s, however, TB had emerged as a major 
global health issue, driven largely by an increase in the 
number of cases in the former Soviet Union and Sub-
Saharan Africa. As the number of cases fell in other parts 
of the world, TB incidence per capita rose in these two 
regions. 
In the Russian Federation and other former Soviet 
countries, TB incidence and deaths rose sharply between 
1990 and 2000. Understanding precisely why is nearly 
as difficult as understanding the decline in Europe and 
North America. It is clear that there was a marked deteri-
oration in case finding and cure rates in Russia, but this 
likely does not explain all of the increase (Shilova and Dye 
2001). Other factors include enhanced transmission due 
to the mixing of prison and civilian populations; an 
increase in susceptibility to disease following infection, 
likely linked to alcoholism and stress; poor nutrition; 
emphasis on hospital-based treatment and extended 
 hospitalization; poor service delivery; the spread of drug 
resistance; and, more recently, the rise of HIV/AIDS infec-
tion (Atun, Samyshkin, and others 2005; Toungoussova, 
Bjune, and Caugant 2006). 
Current Burden 
Global Progress
Although the overall burden of disease remains large, 
substantial progress has been made in TB control world-
wide. Between 1995 and 2013, the TB case detection 
rate increased from 46 percent to 64 percent. In the same 
period, between 41 million and 56 million people were 
successfully treated, and by 2015 as many as 49 million 
lives were saved (Glaziou and others 2011; WHO 2015b, 
2016a). TB prevalence worldwide fell 47 percent by 2015, 
and the TB-attributable mortality rate had declined 
45 percent compared with a 1990 baseline. 
Since the mid-2000s, the global incidence of TB has 
been declining, albeit slowly, along with the absolute 
number of new TB cases reported each year. However, 
incidence rates remain discouragingly high in high- 
burden countries in South-East Asia and Sub-Saharan 
Africa (figure 11.2). 
Despite global progress, uncertainties remain in the 
burden and trends in TB. For example, while estimates 
of the WHO and of the Institute for Health Metrics and 
Evaluation (IHME) were similar on prevalence of TB in 
2012, the trends differed: the WHO estimated a decline 
in cases, while the IHME estimated an increase in cases 
over the same interval. 
The progress of individual countries, organized by 
major international TB targets and goals in 22 high- 
burden countries—that is, those defined by the WHO as 
the 22 countries accounting for approximately 80 percent 
of the world’s TB cases in 2015—is shown in table 11.1 
(WHO 2015b).
Figure 11.2 Estimated TB Incidence: Top-10 Countries, 2014
Source: WHO 2015b.
Note: TB = tuberculosis. The range shows the lower and upper bounds of the 95% uncertainty interval. The bullet indicates the best estimate.
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Table 11.1 2015 Target Assessment: Global, WHO Regions, and 22 High-Burden Countries
Indicator
TB/HIV: 2015 Global Plan Targets MDR-TB: 2015 Global Plan Targets
TB patients 
with known 
HIV status (%)
Notified 
HIV-positive 
TB patients 
started on 
ART (%)
People living 
with HIV newly 
enrolled in HIV 
care who were 
started on IPT
Estimated MDR-TB cases 
that were detected and 
notified (%)
Treatment 
success rate: 
confirmed 
MDR-TB cases, 
2011 cohort (%)
Target 100% 100% 50% 100% ê75%
Global
Global 48 70 45 48
WHO region
African (AFR) 76 69 74 47
Americas (AMR) 69 65 47 56
Eastern Mediterranean (EMR) 11 38 22 64
European (EUR) 59 54 61 46
South-East Asia (SEAR) 43 81 45 54
Western Pacific (WPR) 35 60 16 52
22 High-burden countries
AFR Congo, Dem. Rep 44 48 9 59
Ethiopia 71 68 40 72
Kenya 94 84 6 70
Mozambique 91 72 17 19 31
Nigeria 88 67 3.5 18 63
South Africa 90 66 >100 >100 45
Uganda 91 65 12 77
Tanzania 83 73 0.4 10 75
Zimbabwe 92 77 3.5 53 81
AMR Brazil 65 39 56
EMR Afghanistan 26 23 6 29
Pakistan 2.8 20 70
EUR Russian Federation 33 37
SEAR Bangladesh 1.1 100 0 22 68
India 63 88 57 50
Indonesia 2.3 21 13 60
Myanmar 12 74 19 22 71
Thailand 83 59 12
WPR Cambodia 82 89 55 24 86
China 39 67 8 50
Philippines 2.1 47 41
Vietnam 70 61 24 72
table continues next page
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Remaining Challenges 
Despite significant progress, TB remains a formidable 
global health threat. The overall rate of decline in inci-
dence, by any calculation, has been frustratingly slow 
(1.5 percent a year), and some countries and regions are 
still reporting rises in TB incidence, particularly in drug- 
resistant TB. Based on notification reports and surveys, 
there were an estimated 10.4 million new TB cases in 2015 
(WHO 2016a). Assuming lifelong latent infection, about 
one-third of humanity could still be infected with Mtb 
(Dye and others 1999; Sudre, ten Dam, and Kochi 1992). 
The estimation of TB incidence and prevalence 
remains imprecise, especially in high-burden countries 
where precision is most needed. Over the past decade, 
national surveys of the prevalence of tuberculosis dis-
ease have been undertaken in more than 20 countries, 
including 15 of the 22 highest- burden countries (WHO 
2015b). These prevalence surveys provide vital data in 
high-burden settings. Great investment is needed in 
high-quality routine surveillance that builds on existing 
systems and produces robust data for assessment and 
future planning (Dye and others 2008; WHO 2012b). 
Since a quarter of TB patients are in India, the National 
Survey planned for 2017–18 will be very important.
Many factors drive the persistence and fatality of the 
disease. First, case detection has been insufficient: in 
2014, only about 64 percent of people who developed 
TB were notified as newly diagnosed cases, leaving 
approximately 3 million to 4 million cases that either 
were not diagnosed or were diagnosed but not reported 
to national TB programs. 
The emergence of highly drug-resistant tuberculosis, 
including MDR TB (resistance to at least isoniazid and 
rifampicin) and XDR TB (MDR plus resistance to at 
least one fluoroquinolone and one injectable antituber-
cular antibiotic), has proved a serious hurdle for effective 
control of tuberculosis in many settings. The most recent 
estimates of the burden of MDR TB suggest that approx-
imately 480,000 new cases of MDR TB occur each year, 
of which only 20 percent are enrolled in treatment 
(WHO 2016a). Sufficiently strong surveillance and drug 
resistance laboratory testing are not yet adequate to 
establish whether MDR TB is rising or falling in most 
countries where MDR is of concern.
HIV/AIDS is another factor that challenges effective 
control of TB, especially in Southern African countries. 
Of the 10.4 million new cases of TB in 2014, 1.2 million 
occurred in HIV-positive individuals. Among the 
approximately 1.5 million deaths from TB in 2014, 
400,000 were among individuals co-infected with 
HIV/AIDS (WHO 2015b). Globally, around half of 
patients diagnosed with TB were tested for HIV/AIDS, 
although that number has increased to 79 percent in 
the African region. Treating TB patients co-infected 
with HIV/AIDS with antiretroviral therapy (ART) rose 
to 77 percent globally, which is crucial, given that treat-
ing HIV-positive patients with ART reduces the risk of 
clinical TB by 64 percent.
Although dramatic improvements in TB control have 
been achieved over the last 25 years, the benefits have 
not been equally distributed among geographic regions. 
Falling mortality rates were often fueled by rapid 
Table 11.1 2015 Target Assessment: Global, WHO Regions, and 22 High-Burden Countries (continued)
Indicator
TB/HIV: 2015 Global Plan Targets MDR-TB: 2015 Global Plan Targets
TB patients 
with known 
HIV status (%)
Notified 
HIV-positive 
TB patients 
started on 
ART (%)
People living 
with HIV newly 
enrolled in HIV 
care who were 
started on IPT
Estimated MDR-TB cases 
that were detected and 
notified (%)
Treatment 
success rate: 
confirmed 
MDR-TB cases, 
2011 cohort (%)
Target 100% 100% 50% 100% ê75%
Classification
≥80% tested ≥80% ≥50% ≥80% detected and notified ≥75%
50–79% tested 50–79% 25–49% 50–79% detected and 
notified
50–74%
<50% tested <50% <25% <50% detected and notified <50%
Source: WHO 2015b.
Note: A blank cell indicates that no data are available. TB = tuberculosis; MDR TB = multidrug-resistant TB; HIV = human immunodeﬁciency virus; ART = antiretroviral treatment; 
IPT = isoniazid preventive therapy; WHO = World Health Organization.
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economic development in Asian countries. Three WHO 
regions—the Americas, South-East Asia, and Western 
Pacific—reduced prevalence 50 percent by 2013, but the 
other three regions have not yet achieved that goal. 
In 2014, the WHO Africa region had the highest inci-
dence rates (about 280 cases per 100,000 population) 
and 28 percent of the estimated number of cases globally. 
Asia had 58 percent of total cases. China and India 
alone accounted for more than one in three (35 percent) 
of the world’s new TB cases in 2013. Approximately 
78 percent of total TB deaths and 73 percent of TB 
deaths among HIV-negative people occurred in the 
Africa and South-East Asia regions. 
The spatial and temporal variation in TB incidence in 
Africa is strongly correlated with the prevalence of HIV/
AIDS infection (Corbett and others 2003). Globally, an 
estimated 11 percent of all new adult TB cases were 
infected with HIV/AIDS in 2015. In the WHO Africa 
region, the percentage of incident TB cases with HIV/AIDS 
varied from 8 percent in Eritrea to 77 percent in Swaziland. 
Many of the gains in TB control globally are stalling, 
with TB incidence no longer falling in some East Asian 
settings, notably Hong Kong SAR, China; Japan; the 
Republic of Korea; and Singapore. Part of the explanation 
could be that more cases are arising by reactivation from 
a previously infected aging human population (Vynnycky 
and others 2008; Wu and others 2010). Additionally, 
immigration from high-incidence countries is part of the 
reason why the decline of TB in North America and 
Western Europe has plateaued. Immigrants infected in 
their country of origin contribute, in varying degrees, to 
further transmission and outbreaks in the country where 
they have come to live or work (Verver and others 2005).
Global Response 
Following its declaration in 1993 that tuberculosis was a 
global health emergency, the WHO launched the DOTS 
strategy in 1994 (WHO 1994). Prior to DOTS, there were 
at least five recommended regimens for treatment of 
TB, with varying effectiveness, serious adverse effects, and 
varying costs (Murray, Styblo, and Rouillon 1990). DOTS 
aimed to create a single common best-practice strategy that 
would be applicable to all countries and would include not 
just observing treatment but also securing political com-
mitments as well as adequate and sustained financing:
• Ensure early case detection and diagnosis through 
quality-assured bacteriology 
• Provide standardized treatment with supervision and 
patient support 
• Ensure effective drug supply and management 
• Monitor and evaluate performance and impact.
Emerging drug resistance compelled the WHO 
to introduce DOTS-plus in 1998, with two additional 
requirements: (1) the capacity to perform drug-sensitivity 
testing (DST) and (2) the ability to ensure access to 
second-line drugs (Stop TB Working Group on DOTS-
Plus for MDR-TB 2003). 
DOTS expanded further in 2014 to reflect six pro-
grammatic actions critical to an effective global TB control 
strategy (box 11.1). Thus, the history of TB response 
reflects attempts to tackle ever more fundamental causes of 
TB by addressing health system drivers of the epidemic. 
Major organizational initiatives have sought to inten-
sify the fight against TB: the TB Alliance in 2000; the Green 
Light Committee at the WHO in 2000; the Stop TB 
Initiative in 2001; the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria (Global Fund), which was 
created as a major funder of country programs in 2002; 
UNITAID in 2006; and the Stop TB Partnership in 
2008, which was created to coordinate, together with the 
WHO, the many provider, advocacy, and donor groups 
engaged in fighting TB. The Stop TB Partnership has 1,200 
partners in 100 countries. Further, the Global Laboratory 
Initiative was established in 2007 to strengthen laboratory 
capacity in LMICs. 
Increased attention and initiatives have been coupled 
with significant increases in international and domestic 
funding for TB. Funding for TB prevention, diagnosis, 
and treatment reached US$6.6 billion in 2016, almost 
double the level in 2006 (WHO 2015b). Overall about 
84 percent (US$5.5 billion) of reported TB funding 
was derived from domestic sources; nevertheless, low- 
income countries (LICs) have benefited from Global 
Fund financing, which accounts for about 67 percent of 
total TB funding for these countries. In 2016, most TB 
Box 11.1
WHO DOTS Strategy, 2014
• Pursue high-quality DOTS expansion and 
enhancement 
• Address TB and HIV/AIDS co-infection, 
MDR TB, and the needs of poor and vulner-
able populations
• Contribute to health system strengthening 
based on primary health care 
• Engage all care providers
• Empower people with TB and communities 
through partnership. 
Source: WHO 2014b.
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funding (US$ 4.9 billion) was spent on drug-susceptible 
TB, with MDR TB receiving about US$1.7 billion. 
The WHO estimates that the gap in funding to achieve 
the SDG for TB is on the order of US$2 billion per year 
(WHO 2015a, 2016a).
Evolving Targets 
The initial DOTS targets aimed to achieve a global tuber-
culosis detection rate of 70 percent and a treatment 
success rate of 85 percent. In 2000, the UN Millennium 
Declaration (UN General Assembly 2000), which estab-
lished the MDGs, set in motion worldwide concerted 
efforts to alleviate poverty and improve global health. 
Astonishingly, the MDG goals did not specifically men-
tion tuberculosis, which was then causing more than 
9 million new cases and 1.5 million deaths annually. 
However, MDG 6, which aimed to halt and begin to 
reverse HIV/AIDS, malaria, and “other infectious dis-
eases,” provided sufficient language for international 
targets to be established for TB control. 
The Global Plan to Stop TB 2001–15 of the Stop TB 
Partnership established two targets in addition to the 
general goal in MDG 6, for a total of three targets often 
referred to in the TB literature:
• Halt and reverse the global growth in TB incidence 
• Decrease TB prevalence 50 percent from 1990 base-
line levels by 2015 
• Decrease TB mortality 50 percent from 1990 baseline 
levels by 2015.
The current UN Sustainable Development Goals 
seek to reduce tuberculosis deaths 95 percent and 
reduce the TB incidence rate 90 percent by 2035, effec-
tively eliminating the disease. These are ambitious 
goals, and experts have outlined milestones in five-
year increments to track progress and hold governing 
bodies accountable. With evidence that transmission 
and treatment failures in many countries continue at 
high levels, other metrics, including case detection 
and treatment success rates, are important indicators 
of progress. 
Dye and others (2013) modeled what would be 
required to eliminate TB as a public health problem 
(less than 1 case per 100,000 population) by 2015. 
A projection of the decline in incidence at current rates 
(around 1 percent annually) indicates that MDG goals 
would not be met for more than 50 years. An updated 
model requires that incidence decrease 10 percent 
in 2020 and 17 percent a year thereafter (figure 11.3). 
Figure 11.3 Projected Acceleration in the Decline of Global Tuberculosis Incidence Rates to Target Levels, 2015–35 
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However, such a “rate of decline has never been 
achieved on any geographical scale for any period 
of time and is not possible globally with the present 
suite of tools and systems for their delivery” (Dye 2013, 
272–73). 
It is difficult to conceive that significant prog-
ress will be realized by 2035 without the develop-
ment and application of new tools and investment 
in health systems for TB, including reinstituting 
active case finding, devising more effective delivery 
strategies, investing in the supply chain and informa-
tion management systems, conducting research and 
development into new diagnostics, and implement-
ing new and more effective treatment regimens and 
vaccines. 
The WHO’s current strategic plan for TB con-
trol, the End TB Strategy (Uplekar and others 2015; 
WHO 2015c, 2016a) is a multifaceted program far 
more extensive than previous iterations. Recognizing 
both the successes of previous programs in reduc-
ing both mortality and prevalence and the failure 
of  present programs to reduce incidence at a rate 
that will enable countries to meet the SDG targets by 
2035, it proposes a broader and more  ambitious pro-
gram based on three pillars (box 11.2). 
These are very ambitious and important goals that, to 
a large extent, will depend on investments in research 
and development of new tools and more effective use of 
the available tools. 
INFECTION AND DISEASE IN INDIVIDUALS 
AND POPULATIONS 
Tuberculosis is an infectious bacterial disease caused 
by Mycobacterium tuberculosis, which is transmitted by 
aerosols and most commonly affects the lungs. Mtb is 
essentially found only in humans, although the related 
pathogenic mycobacteria, M. bovis, causes disease in 
cattle and, before Pasteurization of milk, was the cause 
of scrofula, TB of the lymph nodes. A related pathogen, 
M. leprae, is the cause of leprosy in humans. Because 
there is no animal reservoir for Mtb, the pathogen has 
evolved to persist in people for long periods of time, 
with only a portion of people developing clinical disease 
with lung damage. 
TB is transmitted from person to person via aerosol 
droplets from the throat and lungs of people with 
active respiratory disease. Individuals with pulmonary 
or laryngeal tuberculosis produce airborne droplets 
while coughing, sneezing, or simply speaking (Lin and 
others 2008; Loudon and Spohn 1969; Rodrigo and 
others 1997). Inhaled infectious droplets lodge in the 
lung alveoli and bacilli and are taken up there by 
macrophages. 
Stages of TB Disease and Intervention Points
TB is best understood not as a single clinical entity 
but as a spectrum, which generally correlates with the 
Box 11.2
WHO End TB Strategy 
Integrated, patient-centered care and prevention 
• Early diagnosis of tuberculosis, including uni-
versal drug-susceptibility testing and systematic 
screening of contacts and high-risk groups 
• Treatment of all people with tuberculosis, includ-
ing drug- resistant tuberculosis, and patient 
support 
• Collaborative tuberculosis and HIV/AIDS activi-
ties and management of comorbidities 
• Preventive treatment of persons at high risk and 
vaccination against tuberculosis.
Bold policies and supportive systems 
• Political commitment with adequate resources 
for tuberculosis care and prevention 
• Engagement of communities, civil society orga-
nizations, and public and private care providers 
• Universal health coverage policy and regulatory 
frameworks for case notification, vital registra-
tion, quality and rational use of medicines, and 
infection control 
• Social protection, poverty alleviation, and actions 
on other determinants of tuberculosis.
Intensified research and innovation 
• Discovery, development, and rapid uptake of new 
tools, interventions, and strategies 
• Research to optimize implementation and impact 
and to promote innovations.
Source: WHO 2015a, 2015c.
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immune responses. A high, but unknown, percentage of 
people infected with Mtb develop latent or persistent 
infection, but only about 10 percent develop disease in a 
lifetime (Chee and others 2005; Hanifa and others 
2009). For immune-compromised individuals, the risk 
is about 8 percent a year (Selwyn and others 1989). A 
portion of highly exposed individuals likely to be 
infected with Mtb fail to develop tuberculin skin tests 
(TSTs) but remain healthy, suggesting that they are pro-
tected by yet-unknown immune mechanisms. Another 
unknown proportion of individuals with tubercle bacilli 
in sputum remain asymptomatic but it must be pre-
sumed capable of transmitting infection (Bates and 
others 2012; Mao and others 2014; Willingham and 
others 2001; Wood and others 2007).
Multiple possible points for interventions exist 
along the care continuum, including preventing infec-
tions, preventing establishment of latency, preventing 
transition from latent TB to active disease (chemopro-
phylaxis), and treating persons with active disease to 
achieve cure, thereby reducing morbidity, mortality, 
and transmission intensity (figure 11.4).
In most healthy people, infection with M. tuberculo-
sis often causes no symptoms, since the person’s immune 
system, through innate and acquired immunity, acts to 
kill or wall off the bacteria. Acquired cell-mediated 
immunity develops two to eight weeks after infection, 
and granulomas—that is, infiltrating macrophages and 
lymphocytes—wall off the infection and limit further 
replication and spread of the organism (Aziz, Ishaq, and 
Akhwand 1985), although this is only partially protective 
(Andrews and others 2012; Bates and others 2007; da 
Silva and others 2014; Lin, Ezzati, and Murray 2007; 
Slama and others 2007). 
There is a widespread belief that infection does not 
confer significant subsequent immunity (Achkar and 
Jenny-Avital 2011; Barry and others 2009), which is 
used to explain why reinfection is not uncommon 
(Luzze and others 2013; Verver and others 2005). 
However, recent reanalysis of many studies reveals that 
latent TB infection does protect against active disease, 
almost certainly by engendering protective innate or 
acquired immune responses, but that this protection is 
only partial (Andrews and others 2012). Molecular fin-
gerprinting techniques can be used to distinguish bacte-
ria obtained during relapses of prior infection from 
reinfection with new strains. The original infecting 
strain can reemerge after apparent cure or ineffective 
treatment and reestablish active disease (relapse) (Khan, 
Minion, and others 2012; Luzze and others 2013). 
Reactivation rates vary from 1 percent to 30 percent a 
year in different populations. Whether latent bacilli 
remain viable for the full life span of all infected people 
is unknown, but the risk of reactivation persists into old 
age (Stead and Dutt 1989). 
The phenomenon of reactivation, often long after 
infection or after treatment, reflects the limitations of 
immune responses in assuring protection and indicates 
the challenge facing the development of effective vac-
cines that can provide long-term protection (Lin and 
others 2014; Lönnroth and others 2010; Selwyn and 
others 1989). Bacille Calmette-Guérin (BCG) is the only 
licensed vaccine available today and has been used for 
more than 90 years with a good safety record, except in 
immunodeficient children. However, its efficacy in pre-
venting TB in adults has varied in different parts of the 
world, while consistently protecting children against the 
most severe forms of disease: disseminated miliary TB 
and TB meningitis (Mangtani and others 2014; Roy and 
others 2014). BCG vaccination is discussed further in the 
section on prevention.
Primary infection in some individuals leads to 
active TB (primary progressive tuberculosis) when the 
host immune response cannot effectively suppress 
the replication of bacilli. The symptoms of active TB 
of the lung are coughing, sometimes with blood in 
sputum; chest pains; weakness; weight loss; fever; and 
night sweats. Clinical tuberculosis is the sum of com-
plex interactions between the pathogen and an indi-
vidual’s immune response that facilitate mycobacterial 
replication and cause illness, including wasting and 
granulomatous inflammation with tissue damage, 
Figure 11.4 The TB Spectrum and Possible Points of Intervention 
Note: TB = tuberculosis; TST = tuberculin skin test. Infection with Mycobacterium tuberculosis 
can lead to subclinical infection, which is cured by innate or acquired immune responses; latent 
infection that persists; chronic or asymptomatic TB in which tubercle bacilli are found in sputum 
of otherwise apparently healthy individuals; and active TB disease. In a small proportion of 
individuals, infection can lead directly to rapidly progressing disease, known as primary 
progressive TB. Miliary TB is widely disseminated, occurring primarily in children and severely 
immunodeﬁcient individuals.
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for example, caseation, vasculitis, and fibrosis (Jagirdar 
and Zagzag 1996; O’Garra and others 2013; Shaler and 
others 2013). The most common clinical manifestation 
of TB is pulmonary disease, and, in the most infectious 
patients, bacilli are visible microscopically on stained 
sputum smears (50–70 percent of pulmonary cases) 
(Huang, Tchetgen, Becerra, Cohen, Galea, and others 
2014; Huang, Tchetgen, Becerra, Cohen, Hughes, and 
others 2014). Extrapulmonary tuberculosis accounts 
for 10–30 percent of disease, but is more common 
among women and children (particularly lymphatic 
tuberculosis) and in people infected with HIV/AIDS 
(Chadha and others 2005; Lowell, Edwards, and Palmer 
1969; MacIntyre and others 1997).
In the absence of other predisposing conditions, 
only 5–10 percent of infected people develop progres-
sive primary disease within five years of infection 
(Chee and others 2005; Hanifa and others 2009; van 
Rie and others 2013). After five years, there is a much 
lower annual risk of developing TB by the reactivation 
of latent infection. However, the risk in HIV-positive 
individuals is on the order of 10 percent a year after 
infection (Selwyn and others 1989). The risk of pro-
gressing to active disease is relatively high in infancy, is 
lower in older children, increases quickly during 
adolescence (earlier in girls), and then increases more 
slowly throughout adulthood (da Silva and others 
2014; Hanifa and others 2009; Isler and others 2013; 
Lienhardt and others 2003). The lifetime risk of devel-
oping TB following infection clearly depends on the 
prevailing transmission rate, but is generally estimated 
to be about 10 percent. 
Latent TB, which exists in an unknown percentage 
of people infected with M. tuberculosis, has significant 
impact on the epidemiology and population dynamics 
of tuberculosis. It represents a huge reservoir of poten-
tial disease and further transmission. Concomitantly, 
long-term latent infection appears to provide partial 
protection against developing disease (Andrews and 
others 2012). 
Following Mtb infection, whether the infection 
remains latent or develops into active disease is thought 
to depend largely on the host’s ability to generate pro-
tective innate and cell-mediated immunity. There is at 
present little evidence that serum antibodies provide 
protection, although recent studies of serum from 
TST-negative highly exposed individuals indicate they 
may have antibodies capable of enabling macrophages 
to kill some bacilli in vitro (Lu and others 2016). 
Human T-cells are highly heterogeneous. From animal 
studies, both CD4 cells and cytotoxic CD8 T-cells are 
important for protection against Mtb infection. CD4+ 
cells are functionally heterogeneous. In the simplest 
case, two antagonistic subclasses of CD4+—Th1 and 
Th2—have been described, each with its own set 
of cytokine mediators. Th1 responses, characterized 
by production of interferon gamma (IFN-γ), are 
 associated with protection, while Th2 responses, 
 characterized predominantly by Th2 cytokines (for 
example, IL-4, IL-10), are associated with antibody, 
inflammatory responses and tissue damage. A unique 
subset of human Th1 cells has recently been described 
that appears strongly to correlate with protection 
against mycobacterial disease. These Th1* cells consti-
tute a unique subset of human CD4+ T-cells expressing 
the chemokine receptors—CCR6, CCR4, and the RORγ 
nuclear transcription factor, which exclusively appears 
to produce IFN-γ to mycobacteria (Sallusto 2016). 
The importance of TB among infectious diseases is 
attributable to the high case fatality rate among untreated 
or improperly treated cases. About two-thirds of 
untreated smear-positive TB cases will die within five to 
eight years; most will die within the first two years 
(Huang, Tchetgen, Becerra, Cohen, Hughes, and others 
2014; Libshitz and others 1997). As illustrated in 
figure 11.4, the rest will remain latent, chronically ill, or 
asymptomatic, or will self-cure. The case fatality rate for 
untreated microscopy smear-negative cases is lower, but 
still on the order of 10–15 percent (Chadha and others 
2005; Khan, Minion, and others 2012; Libshitz and 
others 1997). Even among smear- positive patients 
receiving TB drugs, the case fatality rate can exceed 
10 percent if adherence is low or if rates of HIV/AIDS 
infection and drug resistance are high.
M. tuberculosis Strains 
There is striking evidence that the major strains of 
M. tuberculosis co-evolved with the major migrations 
of humans from Africa to Asia, Europe, and the 
Americas (Gagneux 2012). Many strains of Mtb can be 
revealed by molecular analyses, and the diversity is 
thought to exacerbate drug resistance and to affect the 
effectiveness of interventions to control the disease. 
While early targeted genetic analyses suggested only 
minimal within-species diversity of M. tuberculosis 
(Keane and others 2001; Yokoyama and others 2004), 
genomic studies have revealed much more variation 
(Alhajri and others 2011). Subsequent examination has 
provided increasing understanding of Mtb strains and 
how they spread globally (Talat and others 2010). 
Other investigations aim to discover whether differ-
ences between or within (according to Cegielski, Arab, 
and Cornoni-Huntley 2012) strains modify the ability 
of the pathogen to infect hosts or are associated with 
differences in the natural history of disease (Alhajri and 
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others 2011; Wilkinson and others 2000). The number 
and scope of such studies is still limited, but a recent 
study has associated differences in Mtb strains with the 
probability of transmission of disease among house-
hold exposures in Brazil (Lopez and others 2003). 
Evidence is accumulating that strain lineages vary in 
strength and mechanism of host-immune stimulation 
after infection (Baker and others 2012), within-host 
competitive ability (Boelaert and others 2007), rates of 
acquiring mutations (Bellamy and others 1998; Ford 
and others 2013) and drug resistance (Borrell and 
Gagneux 2011), and the specific mutations acquired 
(Fenner and others 2012), each of which may affect the 
within-host course of infection, disease, and response 
to therapy (Gagneux 2012). In general, the fitness of 
pathogens diminishes as mutations accumulate. A vari-
ety of evidence indicates that MDR TB strains are het-
erogeneous in their transmissibility in animal models 
and human populations (Grandjean and others 2015; 
Lee, Radmonski, and others 2015). It is likely that com-
promised transmissibility can change if compensatory 
mutations arise that reestablish fitness. A particular 
concern is the enhanced transmissibility of the Beijing 
strain with antibiotic resistance (Ford and others 2013; 
Hanekom and others 2007). Mathematical modeling 
similarly indicates that strain diversity may affect the 
emergence of drug resistance (Basu and Galvani 2008) 
and interventions (Cohen and others 2008; Colijn and 
others 2009), but improved projections will require 
additional data, especially from whole-genome 
sequencing and long-term monitoring of strain types 
within human populations. 
TB and HIV/AIDS Co-Infection 
The extent to which HIV/AIDS is fueling TB transmis-
sion (in addition to provoking reactivation) remains 
poorly understood. One analysis suggested that 1–2 
percent of all transmission events were from HIV-
positive, smear-positive TB cases in 2000 (Corbett and 
others 2003). The co-infection of TB and HIV/AIDS is 
geographically heterogeneously distributed. In countries 
in Eastern Europe and Southern Africa, as many as 75 
percent of all TB patients are HIV-positive; in others, 
such as China and India, only a small fraction of TB 
cases are HIV-positive (Dye 2015). 
The fraction of TB infections attributable to persons 
co-infected with HIV/AIDS depends on the prevalence 
of HIV/AIDS as well as on the infectiousness of HIV/
AIDS-associated Mtb compared with that of TB cases 
not affected by HIV/AIDS. This fraction is influenced by 
biological factors (for example, the probability of 
smear-positive pulmonary disease) and how rapidly 
individuals are diagnosed and receive effective treatment. 
The duration of HIV/AIDS-associated TB appears to be 
shorter than the duration of HIV-negative TB (Corbett 
and others 2004) or about the same (Wood and others 
2007), depending on the setting. 
Clearly, HIV/AIDS infection exerts a multifaceted 
suppression of the innate and acquired T-cell responses. 
In a sense, TB is often a sentinel for HIV/AIDS infection 
in high HIV/AIDS-endemic areas. Even prior to signifi-
cant CD4+ T-cell depletion, individuals with latent TB 
can progress to active disease. Not only does HIV/AIDS 
infection suppress immune responses to Mtb, but the 
stimulation of T-cells by antigens of Mtb may contribute 
to T-cell activation, leading to the increased production 
of HIV/AIDS and acceleration of the disease process. 
Clinically, the prevalence of extrapulmonary TB and 
disseminated TB are both increased in HIV-positive 
patients. Low CD4 cell counts are associated with an 
increased frequency of extrapulmonary TB, positive 
mycobacterial blood cultures, and atypical chest radio-
graphic findings, reflecting an inability of the impaired 
immune response to contain infection. The rise in TB 
incidence attributable to HIV/AIDS appears to have 
peaked in most countries, as HIV/AIDS incidence has 
declined (Dye 2015).
Effect of TB on the Distribution of Other Diseases
TB affects the presence and nature of other diseases, 
possibly conferring protective effects. Microbial infec-
tions have the potential to influence the balance 
between CD4+ T-cell functional subsets by stimulating 
innate immune responses and by altering cytokine pro-
files, with positive or negative consequences for health 
(Sallusto 2016). Mtb infection may also protect against 
asthma, possibly by shifting the innate and acquired 
Th2 response to a Th1 subset that reduces the inflam-
matory response. One study of Japanese children found 
that strong tuberculin responses following BCG immu-
nization were associated with less asthma, rhinocon-
junctivitis, and eczema in later childhood (Shirakawa 
and others 1997). A study of South African children 
found an inverse association between M. tuberculosis 
infection and atopic rhinitis (Obihara and others 
2005). Comparisons among countries have found that 
asthma tends to be more common where TB is less 
common (Shirtcliffe, Weatherall, and Beasley 2002; von 
Mutius and others 2000). 
Interactions between other infections have also been 
investigated. Vigorous Th2 responses are seen in pro-
tective immune reactions to helminth infections, and 
helminths can shift the balance of immune responses 
to enhance allergic responses and thus compromise 
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Th1 immune responses to BCG and M. tuberculosis 
(Hopkin 2000). Conversely, a mycobacterial-based 
 vaccine could potentially be constructed to prevent 
allergic responses and reduce asthma. Mtb infection 
may protect against leprosy, as does BCG (Karonga 
Prevention Trial Group 1996), and natural TB trans-
mission may have contributed to the decline of leprosy 
in Europe (Lietman, Porco, and Blower 1997). 
There is no information at present on whether the 
human microbiome affects responses to mycobacteria, 
but this is an area of research worthy of investigation. 
While the synergistic and antagonistic interactions 
between bacterial, viral, and parasitic infections are 
complex and unresolved, these examples raise the gen-
eral likelihood that mycobacteria influence, and are 
influenced by, the presence of other infections. 
Risk Factors for TB
Risk factors influence the probability of infection, dis-
ease, or outcome and operate on many scales (physio-
logical, genetic, environmental, and behavioral). Once 
an individual has been exposed to a person with infec-
tious pulmonary TB, his or her risk of developing sub-
clinical TB infection depends on factors that influence 
either the ability of the person infected to transmit the 
disease or the susceptibility of the person exposed to 
infection and disease. Infected persons who are acid-fast 
bacillus smear- or culture-positive (Riley and Moodie 
1974; Ross and Willison 1971; Tornee and others 2005), 
who have cavitary disease (destructive lesions in the 
lung where the bacilli multiply to high levels; Rodrigo 
and others 1997) or frequent cough (Loudon and Spohn 
1969), or who have delayed treatment (Aziz, Ishaq, and 
Akhwand 1985; Lin and others 2008) are major trans-
mitters of TB infection. 
Risk factors relevant to the exposed host most often 
reflect the social and environmental determinants of 
heavy exposure and include living in densely popu-
lated spaces (Chadha and others 2005; Lowell, Edwards, 
and Palmer 1969; MacIntyre and others 1997), being 
incarcerated (Chadha and others 2005; Chee and oth-
ers 2005), and working in occupations such as health 
care that involve frequent social or direct contact with 
TB patients (Hanifa and others 2009; Isler and others 
2013; van Rie and others 2013). Most studies suggest 
that, among similarly exposed contacts, the risk of TB 
infection does not vary much by host attributes. 
However, some recent studies report that genetic loci 
are associated with differential risk of infection among 
household contacts exposed to an infectious case (da 
Silva and others 2014; Lienhardt and others 2003), 
while evidence indicates that smoking increases the 
risk of TB (Bates and others 2007; Lin, Ezzati, and 
Murray 2007; Slama and others 2007).
In contrast to infection, disease progression is known 
to be highly dependent on host risk factors, the most 
important of which include HIV/AIDS co-infection 
(Selwyn and others 1989), low body mass index 
(Lönnroth and others 2010), exposure to tobacco 
(WHO 2015d) and biomass fuels (indoor air pollution; 
Bates and others 2007; Lin, Ezzati, and Murray 2007; 
Lin and others 2014; Slama and others 2007), diabetes 
mellitus (Jeon and Murray 2008), and heavy alcohol use 
(Lönnroth and others 2008; Rehm and others 2009; 
WHO 2014a). Host-specific risk factors also affect TB 
outcomes, including the risks of failing therapy, relaps-
ing after treatment, and dying a TB-related death. In 
addition to HIV/AIDS, smoking and diabetes are recog-
nized biological risk factors for poor treatment out-
comes (Kim and others 2014), and some studies have 
implicated other comorbidities such as iron overload 
(Yokoyama and others 2004), renal dysfunction (Keane 
and others 2001), and hematological malignancies 
(Keane and others 2001). 
Abundant evidence indicates that undernutrition 
is associated with TB in LMICs. In national surveys 
in India, the population-attributable risk of TB in 
undernourished adults and adolescents was two-fold 
or greater and greatest in rural areas (Bhargava and 
others 2014).
Table 11.2 lists the risk factors for TB progression and 
summarizes the relative risks for selected determinants 
for which meta-analyses have been conducted. Although 
HIV/AIDS is a much stronger risk factor for disease pro-
gression than other exposures, the relatively frequent 
occurrence of other determinants means that they 
explain a higher proportion of global TB cases than does 
HIV/AIDS. Table 11.3 estimates the most common 
Table 11.2 Key Risk Factors for Tuberculosis from 
Meta-Analyses of Randomized Controlled Trials
Key risk factor Odds ratio
Cigarette smoking 2.01–2.66
Indoor air pollution 1.4
Low body mass index 2.45a
Alcohol use (daily or alcohol use disorder) 2.94
Diabetes mellitus 3.11
Source: International Institute for Population Sciences and Macro International 2007.
Note: Human immunodeﬁciency virus/acquired immune deﬁciency syndrome 
(HIV/AIDS) does not appear in the table because once it was clear that HIV/AIDS 
was a major risk factor for TB, it became unethical to do a prospective study that 
did not offer HIV-positive patients isoniazid.
a. Odds of tuberculosis for body mass index of 18.5 compared to 25.
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attributable risk factors in different economic strata in 
India using data from the Indian National Family Health 
Survey (International Institute for Population Sciences 
and Macro International 2007). These data show that 
multiple risk factors often converge in individuals living 
in poverty, further amplifying their risk of disease. 
HIV/AIDS is associated with only about 11 percent of 
TB patients worldwide. Other risk factors, such as diabetes 
mellitus and smoking, occur more widely. The population- 
attributable fraction is the proportional reduction in 
population disease or mortality that would occur if expo-
sure to a risk factor were reduced to an alternative ideal 
exposure scenario, for example, no smoking. A global 
estimate of population- attributable factors for TB is given 
in table 11.4. It is not possible to estimate accurately the 
number of people with each of the risk factors because 
the data on background risk are uncertain and risks 
 overlap. Nevertheless, the greater numbers of smokers and 
rapidly expanding number of people with diabetes melli-
tus allow us to infer that the proportion of all cases due to 
malnutrition and diabetes is five times higher and the pro-
portion due to smoking is eight times greater than the 
proportion due to HIV/AIDS.
Risk factors also vary by socioeconomic status, as 
illustrated for India. While infection with Mtb is a risk 
for people of any economic stratum, the data from India 
indicate that some known risk factors for TB are greatest 
in the lowest socioeconomic group, a finding likely to be 
true for most populations. 
Other less common comorbidities also modify the risk 
of disease. Persons are more likely to progress to active 
tuberculosis if they suffer from silicosis (Corbett and 
others 2000; Snider 1978), kidney disease (Mitwalli 1991), 
or solid (Libshitz and others 1997) and hematological 
(Khan and others 2005) malignancies; have undergone 
gastrectomy or ileojejunal bypass surgery (Choi and 
others 2015; Kim and others 2014; Yokoyama and others 
2004); or have received the tumor necrosis factor alpha 
(TNF-α) inhibitor infliximab for the treatment of rheu-
matoid arthritis (Keane and others 2001). While these 
exposures are rare, some dramatically increase the risk of 
TB; older forms of weight-loss surgery, for example, can 
profoundly increase risk. To date, although several case 
reports document TB among patients undergoing gastric 
bypass, no systematic epidemiologic studies have been 
conducted on this risk factor (Alhajri and others 2011).
Table 11.4 Global Prevalence, Relative Risk, and Attributable Fraction for Incident Tuberculosis
Key risk factor Global prevalence Relative risk Attributable fraction (%) References
HIV/AIDS 0.008 8.3 5.5 WHO 2009a 
Undernourishment 0.11 2.1 10.7 Lönnroth and others 2010
Diabetes mellitus 0.085 3.0 14.5 Jeon and Murray 2008
Heavy alcohol use 0.075 2.9 12.5 Lönnroth and others 2008
Cigarette smoking 0.21 2.6 25.1 Lin, Ezzati, and Murray 2007; 
Slama and others 2007 
Indoor air pollution 0.41 1.5 17.0 Lin, Ezzati, and Murray 2007
Note: Relative risk estimates the magnitude of an association between exposure and disease on the basis of the incidence of disease in the exposed group relative to the 
unexposed group. Attributable risk is the absolute difference in incidence between an exposed and unexposed group that quantiﬁes the risk of disease in the exposed group 
attributable to the exposure by removing the risk that would have occurred due to other causes. 
Table 11.3 Attributable Fraction of Key Risk Factors for Tuberculosis Disease Progression in India, 
by Socioeconomic Strata
Key risk factor
Population-Attributable Fraction (%)
Lowest 
socioeconomic stratum
Middle 
socioeconomic stratum
Highest 
socioeconomic stratum
Cigarette smoking 16 10 6
Indoor air pollution 29 25 6
Low body mass index 34 27 20
Alcohol use, daily 4 2 1
HIV/AIDS seroprevalence 9 10 6
Source: Oxlade and Murray 2012.
Note: HIV/AIDS = human immunodeﬁciency virus/acquired immune deﬁciency syndrome.
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In addition to low body mass index, several micronu-
trient deficiencies have been associated with TB 
 progression. In vitro studies suggest a role for vitamin D 
in host susceptibility to disease and, in one clinical study 
conducted in Pakistan, 25-hydroxy-vitamin D—25(OH)
D—levels less than 9 nanograms per milliliter increased 
the risk of progression to active disease fivefold (Talat 
and others 2010). Vitamin A deficiency was found to be 
associated with a 2.8 increased risk of TB in the United 
States, although this finding was not statistically signifi-
cant (Cegielski, Arab, and Cornoni-Huntley 2012), and 
reciprocal seasonal variation in vitamin D levels in South 
Africa correlate with TB notifications (Martineau and 
 others 2011). 
Nutritional factors may also interact with genetic 
polymorphisms to increase TB risk. Polymorphisms in 
the 25(OH)D receptor have been associated with TB 
risk, and several studies have demonstrated a gene- 
 environment interaction between 25(OH)D levels and 
25(OH)D receptor mutations (Wilkinson and others 
2000); there is considerable evidence that 25(OH)D3 is 
essential for human macrophages to kill Mtb in vitro 
(Fabri and others 2011; Liu and others 2007). Vitamin 
D is produced in the skin by exposure to ultraviolet 
light, and seasonal variation in vitamin D has been cor-
related with the number of TB cases (Wilkinson and 
others 2000). This finding and the role of the skin pig-
ment melanin to absorb ultraviolet light may explain 
the increased susceptibility of dark-skinned individuals 
to TB infection and more severe disease (Martineau and 
others 2011; Modlin and Bloom 2013). But correlation 
does not imply causation, and there is a critical need for 
well-designed clinical trials to ascertain the importance 
of these factors.
Much recent work has focused on identifying the 
genetic determinants of TB progression (Abel and oth-
ers 2014). Twin studies strongly support the hypothesis 
that genetic factors play a role in TB susceptibility, and 
multiple loci have been implicated through candidate 
gene studies (Snider 1978). Some of these are rare vari-
ants that lead to alterations in the interferon-γ pathway 
required to develop acquired immunity to mycobacteria. 
Multiple defects in this  pathway result in Mendelian 
susceptibility to mycobacterial diseases, which predis-
poses individuals not only to disseminated infections 
with nontuberculous mycobacteria, but also to tuber-
culosis (Bustamante and others 2014; Mitwalli 1991). 
Other studies have implicated candidate genes that 
affect innate immune responses (Png and others 2012). 
Several genome-wide association studies have also 
been reported, as reviewed in Naranbhai (2016). 
Some have identified alleles, which occur in “gene-free” 
regions of the human genome, but these have not been 
consistently validated in separate populations. A locus 
on chromosome 11 has been associated with suscepti-
bility in multiple populations (Chimusa and others 
2014; Thye and others 2012). Of particular interest is a 
locus on chromosome 5 that encodes a component 
of interleukin 12 (IL-12) required for differentiating 
T-cells, which appears to confer resistance in highly 
susceptible HIV-positive populations in East Africa 
and for which there is evidence of positive selection 
(Sobota and others 2016).
TB DIAGNOSIS AND SCREENING
In simplest terms, the DOTS strategy for TB control 
has been to test individuals who seek care at a health 
facility for clinical symptoms of TB and to provide 
appropriate drug treatment for a period of 6–24 
months. With timely diagnosis and correct treatment, 
almost all people with drug-sensitive TB can be cured, 
and even a short duration of treatment reduces the 
bacillary load and likelihood of transmission. 
Nevertheless, worldwide, the TB case detection rate 
remains low: in 2012, about 66 percent (5.7 million) of 
the estimated 10.4  mil lion people who developed TB 
were newly diagnosed cases, with an estimated 3  million 
to 4 million cases remaining undiagnosed or unknown 
to health systems. Case detection in children is of par-
ticular concern: an estimated 1 million children devel-
oped tuberculosis in 2010, with about 32,000 children 
contracting multidrug-resistant TB disease (Seddon 
and others 2015). 
In most countries, the most common diagnostic 
test is microscopic scanning of acid-fast stained bacilli 
in sputum smears—a technique dating to the 1880s. 
It is convenient but insensitive, diagnosing only 
about half of all TB cases in adults (Frieden 2004) 
and fewer in children (Detjen and others 2015) and 
HIV-positive individuals (Harries 1997). Diagnostic 
certainty is obtained when the organism is demon-
strated in a laboratory after clinical evaluation of 
symptoms (usually cough) compatible with tubercu-
losis. In the absence of diagnostic laboratory tests, 
clinicians need to review clinical information and 
decide whether to initiate treatment for tuberculosis, 
weighing the risks of leaving possible TB untreated 
against adverse drug reactions and the social and 
financial costs of committing to months of therapy 
(WHO 2007). Often treatment, appropriate or not, is 
instituted before it is clear whether the patient has TB 
and whether the infection is drug-susceptible or 
drug-resistant. 
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Diagnosis of MDR and XDR TB 
Diagnosis and treatment of MDR TB, in particular, has 
largely faltered worldwide. Only 30 of 107 countries are 
treating 75 percent or more of patients with MDR TB, 
with countries experiencing high levels of loss to 
follow- up (WHO 2013a). Of the estimated 450,000 
people who devel oped MDR TB in 2012, only 94,000 
(20.9 percent) were detected, and just 77,000 were 
started on second-line treatment. MDR and XDR TB 
also represent a threat to health care personnel and 
health infrastructure. Unknown numbers of nurses and 
physicians have acquired MDR and XDR TB, and in 
2014, there were an estimated 210,000 deaths from 
MDR TB (WHO 2015b).
The diagnosis of drug-resistant TB and its treat-
ment are complex, requiring laboratory capability for 
drug-sensitivity testing and between 9 and 20 months 
of daily administration of drugs that are both more 
toxic and less efficacious than the drugs used to treat 
drug-sensitive TB (Nathanson and others 2010). 
Inadequate human resources, poor access to laboratory 
services, and low capacity to do drug-susceptibility 
testing and analysis partly account for low case detec-
tion for MDR TB (Shin and others 2008). Health sys-
tem approaches that favor hospital-based management 
of MDR TB frequently have limited access to service 
delivery, and scale-up of new diagnostic tools and 
treatment regimens is often weak in health systems 
where MDR TB dominates (Keshavjee and Farmer 
2010; Nardell and Dharmadhikari 2010). 
Several economies—including Estonia; Hong Kong 
SAR, China; Latvia; and Singapore—that have strength-
ened their health systems by improving access to diag-
nosis and primary care treatment have halted the rise 
in MDR TB incidence (Cohen and others 2014; Cuevas 
and others 2011; Dye 2009). Strong laboratory capacity, 
which has enabled rapid and definitive determination 
of drug sensitivity, strong supply chain management 
systems, and successful scale-up of effective treatment 
regimens have contributed to this success (Gandhi and 
others 2010). In this context, it is technically difficult 
for countries to diagnose patterns of drug resistance. 
For this reason, the WHO created the TB Supranational 
Reference Laboratory Network of 24 quality-control 
laboratories, which are located in every continent and 
able to carry out sophisticated testing for drug resis-
tance (WHO 2015a).
Recent Advances in TB Diagnostics 
Tuberculosis diagnostics have advanced steadily over the 
past decade (see box 11.3). As a result, between 2007 and 
2012, the WHO issued 10 new policy  statements on TB 
diagnosis covering an array of approaches (Lawn 2015).
Box 11.3
New Strategies for TB Diagnosis
• Use of light-emitting diode (LED) microscopy as 
an alternative to conventional Ziehl-Neelsen light 
microscopy, which has been the mainstay of TB 
diagnosis for decades (Cuevas and others 2011)
• Use of nucleic acid amplification tests (NAATs) 
for diagnosis of active TB, including manual 
technologies such as loop-mediated isothermal 
amplification as well as automated technologies 
such as Xpert MTB/RIF (Pai, Kalantri, and Dheda 
2006)
• Use of nucleic acid amplification technology 
approaches for rapid screening for drug resis-
tance, for example, based on line probe assays 
(Pai, Kalantri, and Dheda 2006)
• Use of liquid culture systems as a more rapid and 
sensitive alternative to conventional solid culture 
(Palacios and others 1999).
Other avenues for developing new TB diagnostics 
hold promise: 
• Urine-based diagnostics for detecting M. tuberculo-
sis antigen, for example, assays to detect lipoarabino-
mannan, especially in HIV-positive patients (Green 
and others 2009; Nakiyingi and others 2014)
• Immunochromatographic tests for rapid confirma-
tion of Mtb in culture (Hasegawa and others 2002)
• Exhaled air mass spectrometry for volatiles and 
chemical analysis (Phillips and others 2007).
250 Major Infectious Diseases
Among the new diagnostic options that have 
emerged in recent years, the Xpert MTB/RIF test has 
received the most attention. Xpert MTB/RIF is an 
automated deoxyribonucleic acid (DNA) amplification 
test that provides rapid and sensitive detection of TB 
and rifampicin resistance. It uses a cartridge-based 
system that integrates sample processing and real-time 
polymerase chain reactions, accommodates use by rel-
atively unskilled health care workers, and provides 
results in less than two hours. The system is expensive, 
costing about US$17,000 per unit, and the tests, cur-
rently subsidized, cost about US$10. The ability to 
diagnose TB and identify MDR TB from sputum in less 
than two hours is a major step forward in linking diag-
nosis to rapid initiation of treatment. However, Xpert 
MTB/RIF is currently not a technology for point-of-care 
diagnosis. In December 2010, the WHO recommended 
that the device be used for initial diagnosis in patients 
suspected of having MDR TB or HIV/AIDS-associated 
TB disease. Subsequently, some countries, including 
China, India, and South Africa, have purchased Xpert 
equipment at reduced prices and taken advantage of 
volume pricing to purchase test cartridges. 
The Xpert system is a significant advance in acceler-
ating the diagnosis of TB, particularly MDR TB, and will 
likely be a valuable new tool for major hospital and TB 
diagnostic laboratories, despite being dependent on a 
sophisticated and expensive device and relatively expen-
sive costs for each sample tested. However, a multicenter 
trial in four African countries failed to demonstrate 
lower TB-related morbidity (Theron and others 2014). 
A new device model being developed, the GeneXpert 
Omni, which is portable and battery operated, has the 
potential to become a point-of-care diagnostic test in 
many more sites and is to be released later in 2017.
Since shortening the time between diagnosis and ini-
tiation of appropriate treatment is a major factor in 
reducing transmission, technologies that allow diagnosis 
and drug-sensitivity testing at the point of care are ideal. 
Some innovative research is under way to achieve that 
goal, but point-of-care testing remains a formidable 
challenge. Considering the sheer number of patients 
queued in busy outpatient departments, it is unlikely 
that cough screening and sputum testing can be 
 effectively implemented in many of the highest-risk 
ambulatory settings—or in all resource-limited settings. 
Even the DNA amplification methods lack the sensitivity 
to detect many patients with early disease. Potentially 
infectious TB cases will be missed, delays in diagnosis 
will occur, and patients with XDR TB will likely not 
respond promptly to current therapy. Traditional meth-
ods of control will be necessary for the foreseeable future 
(WHO 2009a). 
A recently developed molecular approach examin-
ing gene expression of peripheral blood cells rather 
than sputum has the potential to identify the subset 
of healthy individuals with latent TB who are likely 
to progress to active disease (Zak and others 2016). 
Rather than detecting components of the pathogen, 
this novel method measures gene expression signa-
tures in peripheral white blood cells that are elevated 
in healthy individuals with latent infection prior to 
their progression to active TB. In a panel of 16 gene 
probes in three separate cohorts in different coun-
tries, it was possible to predict persons who pro-
gressed to active disease six months to one year 
before any symptoms could be detected clinically. At 
the one-year point prior to diagnosis, the specificity 
of the test was around 61 percent; in HIV-positive 
individuals, it was significantly higher, at around 
80 percent. The molecular exploration of host 
responses offers new possibilities for diagnosing 
infection and defining the gene signatures of persons 
who do not progress to active disease, potentially 
enabling understanding of the genes required for 
resistance to disease. In a similar approach, gene 
expression in the whole blood of patients with either 
latent tuberculosis or other diseases versus patients 
with active tuberculosis was compared using a vali-
dated multicohort analytical framework. The diag-
nostic capacity of a three-gene set was found to be 
88–90 percent in active and latent TB in samples 
from children and adults in 10 countries (Sweeney 
and others 2016). Such molecular host signatures 
could potentially serve as biomarkers for defining 
determinants of protection against infection or dis-
ease in future studies and vaccine trials. 
TB TREATMENT
Treatment aims to cure the disease process, rapidly 
stop transmission, and prevent relapse (WHO 2006). 
Current treatment of tuberculosis requires multiple 
antibiotics, guided by predicted or demonstrated anti-
biotic susceptibility and taken for many months. 
Context-specific treatment guidelines are usually 
developed by local health authorities with guidelines 
and oversight from the WHO. Clinical trials in the 
twentieth century established current first-line drug 
regimens (Fox, Ellard, and Mitchison 1999; Mitchison 
2004). Treatment success rates of 85 percent or more 
for new drug-sensitive cases are regularly reported to 
the WHO from a wide variety of clinical settings 
(WHO 2012a, 2015b). 
Treatment effectiveness has been eroded, however, by 
the evolution and transmission of multidrug- resistant 
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tuberculosis. Treatment for MDR TB, which is defined as 
resistance to isoniazid and rifampicin (the two most 
effective TB drugs) is longer and requires more expen-
sive and more toxic drugs. For most patients with MDR 
TB, the current regimens recommended by the WHO 
last 18–24 months, and treatment success rates are much 
lower, around 60 percent. The WHO now conditionally 
recommends using seven drugs to reduce the time of 
treatment to nine months for uncomplicated pulmonary 
disease (WHO 2016b). New drug combinations, for 
example, including bedaquiline or delaminid, which are 
thought to act on new molecular targets, are being intro-
duced, but an ideal combination is likely several years 
away (Villemagne and others 2012; Zumla, Nahid, and 
Cole 2013). 
Patients who are effectively treated for tuberculo-
sis usually show clinical response within 8–12 weeks, 
both subjectively (reduced cough, fatigue, fevers, and 
sweats; increased appetite) and objectively (sputum 
smear or culture conversion from positive to nega-
tive; weight gain) (WHO 2010). Failure to respond to 
treatment is typically due to poor drug quality, 
underdosing or malabsorption, nonadherence, drug 
resistance (which may broaden while on treatment), 
paradoxical reactions or immune reconstitution 
inflammatory syndrome (IRIS), adverse drug effects, 
or another disease process (bronchiectasis, malig-
nancy, pneumoconiosis, autoimmune disease, or 
organ failure). 
One of the embarrassing deficits in the field of TB 
control is the ambiguous definition of “cure.” In the 
twenty-first century, it should be shocking that accu-
rate biomarkers for treatment response, or in fact cure, 
are essentially nonexistent, as is the ability to predict 
relapses after treatment (Walzl and others 2008). 
Within clinical trials, cure is defined as no relapse after 
one year after completing therapy. In LMICs the gen-
eral criterion of cure for individual patients is two 
negative sputum smears a month apart (WHO 2014b). 
Yet sputum smears are not sufficiently sensitive or pre-
cise to be certain that there is true sterilization of the 
infection. Bacterial culture, though more sensitive, is 
also more time-consuming and less frequently used in 
resource-poor countries (Phillips and others 2016). 
There are no microbiological or molecular biomarkers 
to establish whether an individual’s infection has been 
sterilized by treatment. Recurrence can be due either 
to reactivation of a previously treated strain or to rein-
fection with a new strain. Reinfection in previously 
treated patients may be as common as relapse and can 
be distinguished from relapse by comparing mycobac-
terial DNA sequences from both the original isolate 
and the recurrence (Marx and others 2014). 
Treatment Regimens
Effective tuberculosis treatment needs to overcome the 
organism’s ability to persist in diverse microenviron-
ments under extreme conditions, including immuno-
logical attack, prolonged antibiotic exposure, and 
nutrient and oxygen depletion (Islam, Richards, and 
Ojha 2012; Shaler and others 2013). Standardized treat-
ment regimens and fixed-dose combination medica-
tions simplify good clinical care in resource-limited 
settings. Table 11.5 presents current treatment regi-
mens, with an intensive phase followed by a continua-
tion phase (Chakraborty and others 2013; Donald and 
McIlleron 2009; Shi and others 2011; WHO 2010, 
2013b, 2016a, 2016b). 
First-Line Treatment of Drug-Susceptible TB
Rifampicin and isoniazid are the most potent drugs for 
susceptible TB and are taken throughout the course of 
first-line treatment (Donald and McIlleron 2009; 
WHO 2010). Pyrazinamide synergistically reinforces 
the sterilizing activity of rifampicin and, when added 
to the first two months of treatment, reduces the dura-
tion of treatment to six months (Fox, Ellard, and 
Mitchison 1999; Hong Kong Chest Service and British 
Medical Research Council 1979). Ethambutol is added 
to the regimen for two months to reduce on-treatment 
development of drug resistance (WHO 2010) and is 
continued for the full duration of therapy in settings 
with high background prevalence of isoniazid resis-
tance. As effective as standard treatment has been, 
resistance to isoniazid, rifampicin, and pyrazinamine is 
increasing in many countries, indicating that new reg-
imens will need to be increasingly incorporated into 
TB treatment.
Second-Line Treatment of MDR TB
The treatment of drug-resistant TB is evolving, and 
recommendations are changing rapidly. Four factors 
make it difficult to arrive at clear, generalizable recom-
mendations. First, individual strains vary in their sus-
ceptibility, and customized regimens might be more 
appropriate, when possible. Second, testing susceptibil-
ity to pyrazinamide and second- and third-line agents is 
neither widely available nor consistently reliable. Third, 
many agents have limited availability due to their cost or 
limited production. Finally, few comparative studies are 
available to provide data on which to make optimal 
treatment decisions.
While drug-resistant disease is curable, the cure 
rate in several studies is lower than for drug-sensitive 
disease. In some studies of MDR TB, only 54 to 70 
percent of patients achieve treatment completion or 
cure (Ahuja and others 2012; Bassili and others 2013; 
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James and others 2011; Loveday and others 2012; 
Nathanson and others 2010). Treatment requires 
new drugs, with regimens containing anywhere from 
three to seven drugs that have not been previously 
employed (Mitnick and others 2008). In general, these 
second- and third-line agents are less potent and must 
be administered for a more extended period of time, 
ranging from 9 to 24 months. They are also more dif-
ficult to administer, as most regimens contain agents 
such as kanamycin and amikacin that must be admin-
istered by injection. These drugs are far more toxic 
than first-line agents, causing a range of drug-specific 
side effects. Nevertheless, it has been possible to 
achieve MDR TB cure rates of 60–80 percent irrespec-
tive of HIV/AIDS status in settings with severe 
resource constraints and patients with advanced dis-
ease (Meressa and others 2015; WHO 2016a). 
Key strategies that have contributed to successful 
treatment include intensive management of adverse 
effects, nutritional supplementation, adherence inter-
ventions, and collaboration between the public health 
service and nongovernmental organizations (NGOs). 
These approaches should be routinely incorporated into 
programs wherever possible. 
Generally, MDR TB has substantial human, eco-
nomic, and social consequences (Rouzier and others 
2010). The cost of treating MDR TB using conventional 
regimens ranges from US$2,500 to US$10,000, com-
pared with US$100–US$1,000 for drug-susceptible TB 
cases (Floyd and others 2013), placing substantial costs 
Table 11.5 Tuberculosis Treatment Regimens Currently Recommended by the WHO 
Type of case and phase Length of regimen (months) Drug used
New tuberculosis case
Intensive phase 2 Rifampicin, isoniazid, pyrazinamide, ethambutol
Continuation phase 4 Rifampicin, isoniazid (low risk of isoniazid resistance) or rifampicin, 
isoniazid, ethambutol (high riska of isoniazid resistance)
Previously treated tuberculosis case (relapse or default)b
Intensive phase 2 Rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin
Continuation phase 1 Rifampicin, isoniazid, pyrazinamide, ethambutol
5 Rifampicin, isoniazid, ethambutol
Previously treated tuberculosis case (treatment failure)c
Intensive phase 8 MDR TB regimen (see below)
Continuation phase 12 MDR TB regimen (see below)
MDR TB cases
2010 guideline 20 Kanamycin (or amikacin), moxifloxacind (ethionamide, cycloserine 
(or terizidone), pyrazinamide
Intensive phase 8 Bedaquiline or delamanid, where sensitivity following the initial 
regimen cannot be assured (up to six months)
Continuation phase 12 Moxifloxacin,d ethionamide, cycloserine, pyrazinamide
2016 short regimen (conditional 
recommendation)
Intensive phase 4–6 Kanamycin, moxifloxacin,d prothionamide, clofazimine, pyrazinamide, 
high-dose isoniazid, ethambutol
Continuation phase 5 Moxifloxacin,d clofazimine, ethambutol, and pyrazinamide 
Note: MDR TB = multidrug-resistant tuberculosis deﬁned as resistance to isoniazid and rifampicin; WHO = World Health Organization. 
a. Using local epidemiological data.
b. Low risk of MDR TB using local epidemiological data. The WHO recommends treatment guided by drug-susceptibility testing, especially rapid molecular tests, 
and suggests that standard ﬁrst-line treatment be used if there is no evidence of drug resistance to isoniazid and rifampicin.
c. Deﬁned as smear positive after ﬁve months of ﬁrst-line treatment, relapse or default after second or subsequent course of treatment, or active tuberculosis after contact 
with an MDR TB case.
d. Or high-dose levoﬂoxacin or gatiﬂoxacin.
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on high-burden countries. For example, in South Africa, 
although MDR TB and XDR TB represent less than 3 
percent of all TB cases detected, they consume an esti-
mated 35 percent of the national health budget allocated 
to tuberculosis control (Pooran and others 2013). In 
some countries, the costs to treat MDR TB are estimated 
to exceed the total budget for TB control. 
In May 2016, the WHO issued a conditional recom-
mendation on use of the shorter MDR TB regimen, 
which would shorten the duration of treatment (to 9–12 
months), increase adherence and retention in care, and 
lower costs (about US$1,000 in drug costs per patient) 
(WHO 2016a). Routine analysis of mutations conferring 
resistance to isoniazid may further inform the choice of 
MDR TB treatment: isolates with mutations in the pro-
moter region of the inhA gene are susceptible to high-
dose isoniazid but resistant to ethionamide, while those 
with katG mutations are resistant to high-dose isoniazid 
but sensitive to ethionamide (WHO 2016a). 
Ongoing clinical studies are beginning to form the 
evidential basis for the WHO guidelines given in 
table 11.5, and are discussed in more detail in the section 
titled “Research and Development.” In this rapidly 
changing area, encouraging data suggest that higher cure 
rates are possible, perhaps with shorter courses using 
newer agents (see the review by Zumla, Nahid, and Cole 
2013). Bedaquiline and delamanid, two newly approved 
drugs, both lead to more rapid clearance of organisms 
and higher cure rates for MDR TB when administered 
with an optimized regimen. Similarly, the oxazolidinone 
antibiotic linezolid, which is used largely to treat Gram-
positive infections, accelerates clearance and increases 
cure. Clofazimine, a riminophenazine dye used to treat 
leprosy, is now recommended for the shortened MDR 
TB regimen. These new treatments may cause significant 
side effects. Clofazamine may cause skin discoloration. 
For unclear reasons, bedaquiline therapy has been asso-
ciated with a higher death rate, while linezolid produces 
a range of dose-limiting toxicities, including neuropathy 
and myelosuppression. 
Treatment in Specific Situations
Regimens for treating tuberculosis in children are iden-
tical to those for adults. Correct dosing by weight is 
essential, and the most appropriate formulation of com-
bination medications receives ongoing advocacy (WHO 
2013c). 
Tuberculosis in pregnancy can be treated with iso-
niazid, rifampicin, pyrazinamide, and ethambutol. 
Streptomycin, amikacin, and kanamycin may cause 
fetal ototoxicity and should not be used if possible 
(Donald 2016). The safety of other drugs used to treat 
MDR TB has not been well studied in pregnancy. 
Treatment should be individualized, with expert review. 
Contraceptive advice during MDR TB treatment is 
essential. 
Glucocorticoids may limit the inflammatory damage 
associated with tuberculosis (Critchley and others 
2013). Evidence supports the use of glucocorticoids 
for tuberculous meningitis (Prasad and Singh 2008). 
Additionally, surgery may be necessary to improve the 
chance of cure by removing localized disease (Marrone 
and others 2013) and to decompress vital structures 
that are compromised by the tuberculous cavities.
A particularly devastating form of TB, tuberculous 
meningitis, has a rapid onset and is frequently fatal. 
Current treatments are less effective for TB meningitis, 
and higher doses of drugs may be needed to reach ther-
apeutic levels in the central nervous system (Donald 
2016).
Drug Toxicities and Interactions
Prompt detection and effective management of 
adverse drug effects is essential to the integrity of a 
treatment program. TB antibiotics, like other medica-
tions, may interfere with drug metabolism and excre-
tion. Rifampicin potently induces expression of 
hepatic cytochrome P450 enzymes (McIlleron and 
others 2007), substantially reducing levels of several 
clinically important drugs including HIV/AIDS pro-
tease inhibitors, warfarin, phenytoin, carbamazepine, 
and estrogen-containing contraceptives. Antiretroviral 
drugs nevirapine and efavirenz interact with rifampi-
cin; however, only the nevirapine interaction is clini-
cally significant, and current recommendations are to 
use efavirenz with rifampicin. The newer drugs, 
bedaquiline and delamanid, which in small studies 
seem to be effective against MDR- or XDR-TB, 
increase the QT interval with a risk of arythmia, and 
linezolid has serious effects on bone marrow and neu-
rologic function. Clinically significant interactions 
should be checked regularly online.1 
Antiretroviral Therapy
In 2014, there were 10.4 million new cases of TB, of 
which 1.2 million (11 percent) were among people living 
with HIV/AIDS. Over the past 30 years, antiretroviral 
therapy for HIV/AIDS infection has improved to the 
point where effective therapy is widely available in 
LMICs, with strikingly improved mortality in patients 
co-infected with HIV/AIDS and tuberculosis (Khan, 
Minion, and others 2012). 
Early initiation of ART reduces mortality risk in 
HIV-positive patients co-infected with tuberculosis and 
is therefore recommended, irrespective of CD4 count 
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(WHO 2013a). To reduce mortality risk, it should be 
commenced within two weeks of TB treatment.2 The 
goal of ART is to achieve long-term viral load suppres-
sion assessed with regular viral load measurements. 
Cotrimoxazole prophylaxis for Pneumocystis pneumo-
nia, toxoplasmosis, bacterial sepsis, and malaria reduces 
mortality in patients co-infected with TB and HIV/
AIDS and should be given until the CD4 count recovers 
to above 200 cells per microliter after at least six months 
of ART. 
One significant adverse effect of combined treat-
ment is the development of IRIS, which is character-
ized by persisting or recurring fevers and a worsening 
of the focal tuberculous process (in profoundly 
immune-suppressed patients with CD4 count below 
50 cells per microliter) starting combination ART 
shortly after commencing tuberculosis treatment 
(Meintjes and others 2008; Meintjes and others 2010). 
IRIS can usually be controlled with steroids and non-
steroid anti- inflammatory agents. 
Antidiabetic Treatment
Diabetes is a significant risk factor for tuberculosis 
but has received less attention than HIV/AIDS in LMICs. 
This will likely change given the increasing life expec-
tancy and prevalence of obesity and type 2 diabetes 
globally. All patients with tuberculosis should be screened 
for diabetes (Faurholt-Jepsen and others 2012; WHO 
2011a). Diabetic patients should have their glucose con-
trol assessed regularly while on TB treatment as part of 
integrated clinical care, and treatment should be opti-
mized with oral antidiabetic agents and insulins. 
Surgery
With treatment outcomes for multidrug-resistant 
tuberculosis patients achieving only about 50 percent 
success, surgery, once a major tool in the pre- antibiotic 
era, has reemerged as an adjuvant therapeutic strategy. 
A systematic review and meta-analysis to assess the 
evidence for the effect of surgery as an adjunct to che-
motherapy found that there was little substantial data 
on which to base recommendations, but there appeared 
to be some enhancement of successful outcomes from 
surgery on adults treated for MDR TB (Harris and 
others 2016).
Palliative Care
Tuberculosis remains a leading cause of death in LMICs. 
Suffering and the process of dying are important clinical 
consequences of advanced tuberculosis that should be 
detected and communicated by an experienced clinician 
who can initiate effective palliative treatment (Connor 
and others 2012; Smart 2010). Terminally ill patients 
may decide to improve their quality of life by discontin-
uing tuberculosis treatment. Physical discomfort, psy-
chological distress, and unresolved end-of-life social 
issues can all potentially be addressed by trained com-
munity health workers (CHWs) once the need has been 
identified. These structures need ongoing local support 
and advocacy (Harding and others 2012).
The Cascade of Care and Completion of Treatment
The DOTS strategy to control tuberculosis promotes 
standardized treatment, with supervision and patient 
support, which may include direct observation of ther-
apy, where a health care worker personally observes the 
patient taking the medication (WHO 2013b). The scien-
tific evidence on the effectiveness of DOT compared to 
self-administered therapy is mixed. Despite the galva-
nizing impact of the DOTS strategy in mobilizing sup-
port and treatment activities, a systematic comparison 
of the effectiveness of DOT relative to self-medication in 
11 random control trials failed to establish its unique 
effectiveness in ensuring either compliance or cure 
(Karumbi and Garner 2015).
DOTS has been associated with reduced prevalence 
of drug resistance in the United States (Moonan and 
others 2011; Pasipanodya and Gumbo 2013); other 
HICs; and many LMICs, such as Cambodia, China, and 
Ethiopia (WHO 2014b, 2015b). However, in highly 
endemic countries, especially those  burdened with HIV/
AIDS, even where adequate diagnosis and effective treat-
ment are provided, the strategy has not dropped inci-
dence or transmission as much as needed. As discussed 
in the section on research and development, additional 
strategies will be needed where the forces of infection, 
environment, and HIV/AIDS are driving the infection 
rate, despite effective treatment of incident cases 
(Middelkoop and others 2015).
Some countries have experimented with involving 
community members to make treatment supervision 
more acceptable to individual patients (Datiko and 
Lindtjørn 2009), but the operational issues are substan-
tial, and a meta-analysis after DOTS implementation 
that included community members in China found that 
52 percent of patients still took self- administered ther-
apy (Hou and others 2012). Nonadherent patients need 
to be identified early and offered practical interventions 
to assist their return into care (Toczek and others 2013; 
Yin and others 2012), including hospitalization for 
supervised treatment and physical rehabilitation. Clinic 
staff who know the patient and community are in the 
best position to decide which patients need the intense 
adherence support implicit in DOTS. 
 Tuberculosis 255
It is important to emphasize that early case detec-
tion, whether by passive or active case finding, is a 
necessary but not sufficient condition for effective 
control of TB. A recent analysis of the cascade of care 
of TB in India reveals the challenges of ensuring treat-
ment completion (Subbaraman and others 2016). In 
this important study of about 2 million cases of con-
ventional TB evaluated through the Revised National 
Tuberculosis Control Program, the authors created a 
framework and followed the cascade of care from the 
number of prevalent cases to those reaching TB diag-
nostic centers, those diagnosed with TB, those regis-
tered for treatment, those who completed treatment, 
and finally those with recurrence-free survival at one 
year. The results indicated for conventional TB that 
45 percent completed treatment and 39 percent were 
disease free after one year. Of patients diagnosed with 
MDR TB, only 14 percent completed treatment and 
11 percent remained disease free at one year. These 
striking results clearly indicate the critical need for 
support of treatment to enable greater treatment com-
pletion in India and most LMICs. 
TB PREVENTION 
There are three obvious strategies for preventing TB: 
vaccination, infection control, and chemoprophylaxis or 
isoniazid preventive therapy (IPT). Arguably, the most 
useful but perhaps least appreciated preventive interven-
tion is simply the early diagnosis and rapid initiation of 
effective treatment of TB cases, thus reducing the infec-
tious burden and reducing transmission. TB is unusual 
among infectious diseases, in that appropriate (and 
effective) treatment of the individual patient may be the 
most effective public health intervention to protect the 
population. 
Vaccination: Natural and Acquired Immunity 
BCG Vaccine
The most widely used vaccine in the world is BCG, 
which is given to about 100 million children annually. 
Isolated in 1908, following attenuation through 431 pas-
sages of a virulent M. bovis isolated from a human TB 
case, BCG was found to be protective to some extent in 
multiple animal models of TB. In its first human trial in 
1921, it was found to protect a child heavily exposed in a 
household at high risk. 
BCG has several advantages: it can be given at birth or 
at any time after birth; a single inoculation produces 
long-lasting skin test positivity to tuberculin; it is rela-
tively stable; it produces a scar useful for epidemiological 
surveillance of access to immunization; and it is 
inexpensive. 
Considerable evidence indicates that giving BCG to 
young children is effective at preventing tuberculous 
meningitis and disseminated (miliary) TB (Mangtani 
and others 2014; Rodrigues, Diwan, and Wheeler 1993). 
Random control trials and case control studies have 
shown consistently high protective efficacy of BCG 
against serious childhood forms of disease (73 percent), 
meningitis, and miliary TB (77 percent). The most com-
plete analysis of the effect of BCG vaccine suggests that 
giving BCG to children born in 2002 prevented about 
29,000 cases of childhood meningitis and 11,500 cases of 
miliary TB during the first five years of life or one case 
of meningitis for every 3,400 vaccinated children and 
one case of miliary TB for every 9,300 vaccinated chil-
dren (Trunz, Fine, and Dye 2006). A recent report indi-
cates that deferring BCG immunization to six weeks 
after birth generates stronger and longer-lasting specific 
Th1 cellular immune responses (Kagina and others 
2009; Lutwama and others 2014). In some countries, 
children were repeatedly vaccinated over time, and there 
is some evidence from Taiwan, China, that multiple vac-
cinations may increase protection (Chan and others 
2013). A worrisome drawback, however, is the incidence 
of disseminated BCG infection in HIV-positive children 
(Hesseling and others 2007). 
Successful vaccines ideally prevent both infection 
and disease among persons exposed to the pathogen. 
While it is generally believed that BCG protects against 
disease rather than infection, recent findings, using 
Interferon-Gamma Release Assays (IGRAs) that can dis-
tinguish Mtb infection from BCG vaccination, suggest 
that BCG may protect to varying degrees against infec-
tion as well (Eisenhut and others 2009; Mangtani and 
others 2014; Soysal and others 2005). 
The cost-effectiveness of BCG was estimated in 2006 
to be between US$40 and US$170 per disability-adjusted 
life year (DALY), US$8,000 and US$11,000 per life saved, 
or US$5,000 and US$8,000 per case averted (Dye 2006), 
making it a very cost-effective intervention. 
Despite positive evidence regarding the impact of 
BCG on children, BCG remains the most controversial 
of all currently used vaccines, because its protective 
efficacy has varied widely in different parts of the 
world, from 77 percent protection in adolescents in the 
United Kingdom (Sutherland and Springett 1987) to 
0 percent protection in all age groups in South India 
(Bloom 1994; Mangtani and others 2014). Because 
young children represent only a minor contributor to 
TB transmission, BCG immunization of infants has 
only a relatively small impact on transmission within 
populations (Knight and others 2014). This finding is 
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borne out by outcomes in parts of Europe and North 
America that did not use BCG, where TB declined at 
rates that were not measurably different from those in 
regions that used the vaccine (Styblo 1991). In a recent 
analysis using South African data, Dye (2013) found 
that BCG vaccination would reduce TB in HIV-negative 
individuals by about 17 percent, to which would be 
added the value of preventing transmission to HIV-
positive individuals. He estimated that revaccination 
with BCG would be highly cost-effective at all combi-
nations of cost (US$1–US$10 per child) and efficacy 
(10–80 percent).
BCG immunization has also been shown to have 
extremely variable protective efficacy against adult TB in 
randomized trials and observational studies (Bloom and 
Fine 1994; Fine 1995; Mangtani and others 2014). 
Explanations for the variation remain unclear. 
Suggestions include the fact that BCG lacks more than 
100 genes of Mtb, including some putative protective 
antigens; the genetic make-up of different human pop-
ulations; the variable persistence of different BCG 
strains or preparations; and the interference by atypical 
mycobacteria in the environment. It was shown many 
years ago that guinea pigs immunized with different 
species of environmental atypical mycobacteria showed 
different degrees of protection against Mtb. Some, such 
as M. kansasii, were as effective as BCG in animals 
(Palmer and Long 1966). It is often forgotten that M. 
microti, a murine mycobacterium, was as effective as 
BCG in the British Medical Research Council human 
vaccine trials (Bloom and Fine 1994; Hart and Sutherland 
1977). This suggests that, if exposure to environmental 
mycobacteria in a population provides some degree of 
protection, the effects of BCG observed in that popula-
tion will be comparably less than in a naïve population. 
This could explain the large differences in BCG efficacy 
in populations living in different geographic locations 
(Weir and others 2006), where children in tropical lati-
tudes show less protection (Mangtani and others 2014). 
For example, in the South India trial area, two-thirds of 
the individuals were positive to an M. avium purified 
protein derivative skin test by age 9 years and 97 percent 
were positive by ages 15–19 years (Tuberculosis 
Prevention Trial 1979). Understanding the degree of 
environmental exposure to nontuberculous mycobacte-
ria will be important in planning and evaluating any 
new vaccines against TB.
A Rationale for Vaccines: Latent Infection 
Can Prevent Reinfection
It is widely believed that a protective vaccine is unlikely 
to be developed against TB because natural infection 
with Mtb is ineffective at preventing reinfection. However, 
there is a remarkable amount of epidemiologic evidence 
that, in fact, Mtb latent infection does indeed provide 
significant protection against reinfection by engendering 
protective immune responses that likely  persist (reviewed 
by Andrews and others 2012). Early experiments of 
Heimbeck (1938) in Norwegian nurses and Sutherland, 
Svandova, and Radhakrishna (1982) found that, among 
healthy young individuals, being  TST-positive provided 
up to 80 percent protection against reinfection (ranging 
from 45 to 81 percent in multiple studies) compared to 
being TST-negative. In a more recent study from South 
Africa where it was possible to measure infections in the 
apparently uninfected group and to observe cases of 
tuberculosis directly, the estimated immunological pro-
tection conferred by latent TB infection was 79 percent 
(Andrews and others 2012). These results encourage the 
view that new vaccines with better efficacy than BCG 
could provide relatively high levels of protection, if the 
protective immune responses generated are sustained 
over time, as is the case of latent TB. 
Innate Immune Responses
The body’s immune response is critical in protecting 
against infection and disease, through both innate 
and acquired immunity. This is perhaps best exempli-
fied by the fact that, although only 10 percent of per-
sons infected with TB develop disease in their lifetime, 
immune-compromised individuals have a risk of 
almost 10 percent per year (Selwyn and others 1989). 
Immunodeficient individuals, such as persons infected 
with HIV/AIDS (Gandhi and others 2006) or receiv-
ing anti-TNF immunotherapy for autoimmune dis-
eases (Wolfe and others 2004), have a markedly 
increased incidence of TB. In immune-compromised 
HIV-positive patients in KwaZulu-Natal, the mean 
time from diagnosis to death from XDR or drug- 
 resistant TB was an astonishing 16 days (Gandhi and 
others 2006). And the increased prevalence of drug- 
resistant TB in immune-compromised individuals is 
consistent with the view that the effectiveness of anti-
biotics depends to some extent on the antimicrobial 
immune response. It is intriguing that a population of 
healthy contacts exists in high-burden countries, who 
almost certainly have been exposed repeatedly to 
infection yet remain TST-negative, IGRA-negative, 
and apparently healthy. This suggests that mecha-
nisms of innate immunity may have the ability to kill 
the relatively small numbers of infecting tubercle 
bacilli early after respiratory infection even before 
they can grow to numbers able to sensitize and 
expand T-cells able to respond to TB antigens. These 
mechanisms are currently not understood, and greater 
research is needed.
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Preventive Therapy 
There are two approaches to preventive therapy. For 
HIV-positive individuals at high risk for many oppor-
tunistic infections, cotrimoxazole is recommended 
routinely, and in high-burden countries between 50 
and 87 percent of HIV-positive patients are receiving 
this preventive therapy (WHO 2015b).
The major approach to prevent development of TB 
in persons at high risk, particularly household contacts 
and HIV-positive individuals, is to screen them with a 
TST and, ideally, to offer persons found to be HIV-
positive chemoprophylaxis, most commonly IPT, for a 
latent infection (Rangaka and others 2015). In perhaps 
the most dramatic studies, a community- based trial of 
IPT among BCG-unvaccinated Alaska Eskimos, a com-
munity with a high risk of infection, produced a 
60 percent decline in TB incidence that lasted more 
than two decades in treated households (Comstock, 
Baum, and Snider 1979). Overall in an analysis of ran-
domized controlled trials, preventive therapy has clear 
benefits. In 2011, the WHO began recommending that 
HIV-positive individuals free of symptoms suggestive of 
tuberculosis receive treatment with IPT for at least six 
months (WHO 2011a). The risk of clinically active TB 
disease is reduced 60 percent in immunocompetent, 
HIV-negative individuals (Smieja and others 2000) and 
32–62 percent in HIV-positive adults who are treated 
with preventive therapy lasting 3 to 12 months (Akolo 
and others 2010). Since these guidelines came into 
force, the number of HIV-positive people receiving IPT 
has increased sharply, rising to approximately 933,000 
in 2014 (WHO 2015b). The high risk of TB among 
persons co-infected with M. tuberculosis and HIV/AIDS 
motivates those encouraging wider use of preventive 
therapy, especially in Africa (Stop TB Partnership 2011), 
but questions have been raised about the methods of 
screening to ensure that the persons most likely to ben-
efit receive this treatment (Lawn and others 2012) and 
that the persons with subclinical TB are not inadver-
tently treated with isoniazid monotherapy that could 
lead to resistance. Studies among child contacts of 
active cases have demonstrated that giving isoniazid 
daily for 12 months provides 30–60 percent protection 
against active TB (Ayieko and others 2014). Recent 
work suggests that isoniazid can be continued for lon-
ger than six months in HIV-positive adults with mini-
mal adverse effects and longer protection (den Boon 
and others 2016).
At a population level, a randomized trial in high- 
incidence urban communities in Brazil found that TB 
incidence was 15 percent lower in intervention than 
in nonintervention communities after five years 
(Cavalcante and others 2010). Yet IPT is not widely 
used. Of the highest-burden countries, only Brazil 
and South Africa have policies to scale up the use of 
IPT. Even with the resources available in the United 
States, the implementation of contact tracing and IPT 
has fallen short of recommendations (Lee and others 
2006). In trials of IPT in high-burden countries, pro-
tection of TST-positive adults infected with HIV/
AIDS averaged about 60 percent, but the effects were 
lost soon after the IPT treatment ended, and there was 
little or no impact on mortality (Churchyard and 
 others 2012; Samandari and others 2011). By contrast, 
IPT was shown to reduce both TB incidence and mor-
tality among HIV-positive children (Zar and others 
2007). A randomized controlled trial, the Temprano 
study, compared early versus later treatment with 
ART and early versus later treatment with IPT and 
various combinations in 2,050 HIV-positive individ-
uals with high CD4+ counts in Côte d’Ivoire. The 
results showed that six months of IPT resulted in a 44 
percent lower risk of severe HIV/AIDS-related illness 
and a 35 percent lower risk of death from any cause 
than the risks with deferred initiation of ART and no 
IPT and that the combination reduced TB by 73 
percent (Temprano ARNS Study Group 2015). Use of 
IPT for six months reduced the incidence of TB in 
Brazil not only for the duration of treatment but over 
a seven-year follow-up (Golub and others 2015). The 
strong inference from this work is that the combina-
tion of early initiation of both ART and IPT in HIV-
positive individuals, now adopted by the WHO, 
should become the norm in HIV/AIDS and TB 
control. 
Real challenges are associated with the use of IPT: 
active disease must be excluded, where practical by 
radiography, before isoniazid is taken alone, and adher-
ence to six or more months of daily treatment tends to 
be poor among healthy people. Even in the United 
States, fewer than 50 percent of individuals who initi-
ated IPT completed six months of treatment (Hirsch-
Moverman and others 2015). Adverse effects include a 
risk of hepatitis, especially in persons co-infected with 
HIV/AIDS (Ayles and Muyoyeta 2006), if IPT is admin-
istered for long periods of time. In the United States, 
adverse effects are on the order of 1 percent but rise to 
4 percent if IPT is given with rifapentine (Getahun and 
others 2015). A recent cluster randomized trial of mass 
screening and IPT was carried out for tuberculosis con-
trol among gold miners in multiple mines in Thibela in 
South Africa, a community known to be at high risk for 
TB. Miners were given IPT for 9 months, and the effect 
on prevention of disease was followed for 12 months. 
Despite the positive effect of isoniazid in preventing 
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tuberculosis during the period of treatment, IPT had 
no significant sustained impact on TB control in South 
African gold mines (Churchyard and others 2014). 
Most discouraging, the results of a systematic review 
and meta-analysis of the cascade of care in latent TB 
indicated that completion of preventive treatment was 
only 19 percent (Alsdurf and others 2016).
It remains unclear, other than in the case of HIV-
positive individuals and child household contacts, how 
feasible and cost-effective IPT scale-up would be in 
high-burden countries. It has been a challenge for health 
systems in LMICs, which are finding it difficult to pro-
vide treatment for diagnosed TB patients and to main-
tain IPT for healthy contacts. A recent approach to 
shortening preventive therapy derives from studies of a 
combination of long-acting rifapentine plus isoniazid, 
which reduced the time of treatment from nine to three 
months and was better tolerated, if more expensive 
(Sterling and others 2011).
The critical question of the best preventive therapy 
with which to combat MDR TB remains unsettled. The 
significant adverse effects of MDR TB regimens are a 
serious trade-off against prevention of the 10 percent of 
cases likely to result from preventive treatment, and no 
optimal regimen using newer drugs has been estab-
lished (Moore 2016). The alternative is registering all 
such contacts, monitoring them carefully, and institut-
ing treatment at the earliest sign of disease.
It may not be altogether fanciful to imagine, with 
advances in research, that more effective drug regimens 
for latent infection could have a profound effect on reduc-
ing the global burden of TB. It is unknown what propor-
tion of the one-third of people on the planet exhibiting 
positive TST retain viable tubercle bacilli capable of reac-
tivating and transmitting disease. But, if a practical drug 
regimen could sterilize the infection in all of these indi-
viduals, this enormous reservoir of the pathogen could be 
eliminated in a short period of time. Rather than passively 
detecting patients with disease, screening populations for 
persons who were infected as determined by tuberculin 
positivity and applying the hoped-for effective mycobac-
tericidal regimen, the great burden of latent TB could 
conceivably be reduced or eliminated. This approach 
should be considered in future research.
Impact of Effective Treatment on Transmission
Of the interventions available to control transmission, it 
has long been taught that effective treatment ranks 
highest. Treatment can be applied only to known or 
suspected cases, and, to be effective, requires knowledge 
of drug resistance. It has traditionally been thought that, 
for drug-susceptible TB, at least two weeks of effective 
treatment are required to reduce the risk of transmis-
sion substantially, regardless of sputum smear status 
(Rouillon, Perdrizet, and Parrot 1976). For drug- 
resistant TB, however, the two-week rule appeared to 
have failed as a policy during the outbreaks in New York 
City and Miami in the 1980s and 1990s, when patients 
with unsuspected drug resistance on conventional four-
drug therapy transmitted their infection after isolation 
ended (Coronado and others 1993). Therefore, current 
guidelines generally recommend isolating MDR TB 
patients until smear or culture conversion. 
The rate at which treatment renders tuberculosis 
cases noninfectious was recently reexamined, employ-
ing the classic model of transmission from humans to 
guinea pigs, wherein TB transmission was established 
by passing exhaust air from the ward past a panel of 
guinea pigs highly susceptible to TB (Dharmadhikari 
and others 2014). The study suggested that, like drug-
susceptible TB, MDR TB transmission also responds 
rapidly to effective treatment, well before sputum smear 
or culture conversion (Dharmadhikari and others 
2014). In a series of five exposure studies where mostly 
smear-positive, coughing patients with confirmed MDR 
TB were admitted and promptly started on therapy, 
transmission to guinea pigs appears to have occurred 
predominantly from patients with unsuspected XDR 
TB who were not responsive to effective treatment. 
Infection Control of TB Transmission in 
Congregate Settings
Transmission and reinfection, especially of drug- resistant 
strains, is a key driver of the global TB epidemic (Wood, 
Lawn, Caldwell, and others 2011; Wood, Lawn, Johnstone-
Robertson, and others 2011). The benefit of isoniazid 
prophylaxis in high-risk HIV-positive populations, for 
example, has been rapidly reversed by ongoing transmis-
sion and reinfection soon after isoniazid is stopped 
(Samandari and others 2011). Likewise, the challenge in 
high-transmission settings is to provide greater protec-
tion against reinfection than is currently provided by 
BCG immunization at birth as well as subsequent natural 
exposure to Mtb and environmental mycobacteria 
(Tameris and others 2013). 
Transmission control was not specifically mentioned 
in the original Global Plan to Stop TB 2006–15, but the 
mostly hospital-based outbreak of XDR TB in 2006 dra-
matically called attention to the problem (Gandhi and 
others 2006). Since then, control efforts have centered on 
health care facilities, although it is widely understood 
that transmission also occurs in homes, schools, 
churches, shelters, refugee camps, and correctional facil-
ities, among other congregate settings (WHO 2009b). 
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Still, because they specifically bring together infectious 
and vulnerable persons, health care facilities dominate 
the list of environments that amplify transmission at the 
population level. 
Hospitals as Epicenters of Transmission
One key epicenter of transmission is hospitals where TB 
patients reside. Because hospital exposure is better doc-
umented than many other congregate interactions, there 
is a likely bias toward indicting hospitals, but it is also 
likely that hospital transmission is underestimated, for 
example, by not counting infecting strains for which 
DNA fingerprints are not available. 
The significant reduction of the TB epidemic in New 
York City from 3,800 cases in the 1980s to 577 in 2015 
indicates that multifaceted efforts are needed in large 
urban multicultural environments with large numbers 
of visitors, migrants, and homeless people and increas-
ing rates of HIV/AIDS.3 Clearly DOT was helpful in 
ensuring compliance in a portion of TB patients, but 
perhaps more significant was the major effort to insti-
tute infection control in hospitals, prisons, shelters, and 
congregate housing facilities (Frieden and others 1995).
Using network analysis, Gandhi and others (2013) 
concluded that most strain-specific XDR TB 
transmission in KwaZulu-Natal occurred in hospitals 
due to prolonged stay, congregate settings, and delayed 
recognition of drug resistance. Transmission patterns 
are similar as far away as Tomsk Oblast, Siberia. A retro-
spective study of the causes of drug resistance in the 
Tomsk Oblast showed a greater than sixfold higher risk 
among treatment-adherent patients hospitalized for 
drug-susceptible TB than among patients not hospital-
ized (Gelmanova and others 2007). Anyone familiar 
with treatment practices common to Eastern Europe 
will understand why this might occur. Although Tomsk 
predominantly uses ambulatory treatment for new TB 
cases, hospitalized patients are admitted to poorly venti-
lated, multibed rooms, tightly sealed against the cold. 
Drug susceptibility is normally only tested when patients 
fail to respond to first-line treatment, usually following 
months of ineffective treatment. Drug susceptibility 
testing by conventional methods requires additional 
months. During this prolonged period of ineffective 
treatment, there is ample opportunity for transmission 
and reinfection. This scenario is not unique to Tomsk, as 
delays in drug-susceptibility testing occur in most TB 
programs where laboratory services are inadequate. 
Treatment failure is the usual indication for drug- 
 susceptibility testing, and molecular methods are only 
slowly reducing the time required for results on first-line 
and, much less often, second-line drugs. However, 
despite hospital transmission, ambulatory treatment is 
highly effective, and Tomsk is among the few high- 
burden places in the world where MDR TB rates may be 
declining (WHO 2010).
Principles of TB Transmission Control 
Since the 1985–92 resurgence of TB in the United States 
and several European settings, where institutional trans-
mission played an important role, a three-tiered hierar-
chical approach has been adopted, based on a paradigm 
used in industry: administrative controls, engineering 
(or environmental) controls, and personal protection 
(respirators). Administrative controls entail the rapid 
diagnosis of symptomatic, potentially infectious cases 
and drug resistance and the prompt initiation of effec-
tive therapy. This has recently been promoted under the 
acronym, FAST (Find cases Actively by cough surveil-
lance, Separate temporarily, and Treat effectively), as a 
way to communicate the key components and facilitate 
adoption. Environmental controls have focused on nat-
ural and mechanical ventilation and on the evolving 
technology of sustainable ultraviolet germicidal (UVGI) 
air disinfection. Personal respiratory protection is the 
last tier of protection, assuming incomplete protection 
from administrative and engineering controls. Ironically, 
although the last tier of protection, respirators are often 
the only protection available to health care workers, can-
not be worn continuously, and are unlikely to be worn 
when treating a patient with unsuspected TB. 
Measures of the Efficacy of TB Transmission Control 
Measuring the efficacy of transmission control interven-
tions has been elusive. Among process indicators are 
questions regarding whether windows are open or respi-
rators are available, although these factors may be tied 
too loosely to exposure to be useful. However, to the 
extent that undiagnosed TB patients and undiagnosed 
drug resistance are key exposure factors, process indica-
tors tied to unprotected exposure time can be measured 
and reported. Institutions can document, for example, 
the percentage of admissions that are screened for cough 
and had sputum sent to a lab; the turnaround time from 
submission until results are obtained; and the time from 
admission until the onset of effective treatment based on 
drug-sensitivity testing. Such measures should become 
routine in hospitals with access to rapid diagnostic tests. 
Few studies have been conducted not only of the effi-
cacy of TB infection control methods, but also of their 
cost. Apart from the great difficulty of measuring the 
efficacy of interventions to prevent transmission, isolat-
ing the costs of infection control activities can be chal-
lenging, as many infection control interventions are 
integral to hospital functions more generally. Assuming 
the presence of unsuspected, untreated patients in the 
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hospital, ventilation is a key intervention, and natural 
ventilation ranks high among recommendations in suit-
able climates. The added cost of designing and con-
structing a naturally ventilated patient waiting area is 
difficult to separate from the routine capital costs of 
hospitals. Some insights can be gleaned from unpub-
lished data from a high-risk setting in Vladimir, Russia, a 
training center of excellence in TB control (box 11.4). 
Cost-Effective Air Disinfection 
Natural ventilation alone does not provide adequate 
ventilation for airborne infection control in many set-
tings. However, mechanical ventilation systems are 
often prohibitively expensive and often fail due to lack 
of maintenance. Room air cleaners (with filters, UVGI, 
or both) are often sold to hospital administrators as a 
simple, inexpensive fix, but they rarely move enough 
air to achieve the 12 or more equivalent air changes per 
hour recommended to control airborne infections. 
Reentrapment and recirculation of the same air through 
the device (short-circuiting) also lead to low rates of 
effective clean air delivery. 
As noted in the Vladimir study, upper-room germi-
cidal UVGI (with room air-mixing fans) is among the 
most effective and least expensive ways to achieve 
high-volume air disinfection. Hospital studies have 
shown 70–80 percent efficacy. But like mechanical venti-
lation and room air cleaners, caution is required. Although 
they are under development, international standards and 
guidelines for safe and effective application and mainte-
nance are not widely available. No agency currently 
regulates this small industry, and few experts are qualified 
to plan installations. Still, as back-up technology for 
natural ventilation, they are a logical choice. Low-velocity 
ceiling fans are recommended to assure essential room air 
mixing. With the development of LED (light-emitting 
diode) UVGI, the prospect of solar- powered systems with 
battery back-up may make upper-room germicidal UVGI 
more sustainable in the near future.
Masks and Respirators 
Assuming incomplete efficacy of both source control 
and engineering or environmental control strategies, the 
last-tier intervention is respiratory protection—that is, 
use of a device designed to exclude infectious droplet 
nuclei from inhaled air. 
Masks and respirators are easily confused. Surgical 
masks are designed to protect the environment by 
blocking the aerosolization of some portion of exhaled 
respiratory droplets and droplet nuclei, but they do 
not adequately protect the wearer and have a limited 
role in TB transmission control when worn short-term 
by patients. MDR TB patients wearing masks were 
53 percent less likely to infect guinea pigs breathing 
exhaust air from the ward (Dharmadhikari and others 
2012). Recently, using the same transmission model in 
South Africa, Mphaphlele and others (2015) tested the 
efficacy of several control interventions in preventing 
transmission from patients in hospital rooms to 
guinea pigs. The study confirmed the previous report 
and showed 70–80 percent efficacy of upper-room 
UVGI air disinfection. 
Box 11.4
Real Costs of Infection Control in Vladimir Oblast TB Dispensary, Russia
Costs for high-level infection control are difficult 
to obtain. The TB Dispensary, with assistance from 
the Centers for Disease Control and Prevention, 
has over the past decade painstakingly introduced 
and studied the impact of a variety of conven-
tional and novel TB infection control interven-
tions in Vladimir Oblast, an area with high rates 
of TB and drug resistance. For the entire Vladimir 
region (population 1.5 million), accurate esti-
mates of annual cost are US$350 for health care 
worker training; US$12,000 for ventilation system 
maintenance; US$10,000 for respirators; US$300 
for respirator fit testing; and US$3,000 for health 
care worker screening. For the multistory hos-
pital, with floor area of 17,000 cubic meters, the 
capital cost of a new, high-capacity ventilation 
system with negative-pressure isolation rooms 
was US$345,000, and the cost of maintenance 
was US$4,425 per year. Of three ventilation sys-
tems studied, the upper-room UVGI system was 
the least expensive intervention, at US$14 per 
equivalent-room air change, more than nine times 
more cost-effective than expensive mechanical 
systems per equivalent- room air change.
 Tuberculosis 261
In contrast, respirators are designed to protect the 
wearer. Properly fitted, certified N-95 (or equivalent) 
respirators can be 85–90 percent protective. However, 
as an intervention, respiratory protection often fails 
either because the face seal leaks due to improper fit or 
adjustment or, more important, because the masks are 
not worn consistently. The cost of respirator programs 
is easily assessed, but their effectiveness is not. 
Lessons for Household Transmission
Since TB is transmitted largely by aerosol droplets, 
transmission is affected by the built household environ-
ment. One study from South Africa found evidence that 
transmission of infection was greater, as determined by 
DNA fingerprinting of the strains, in modern-built 
brick housing with windows than in older shacks 
(Wood and others 2010). The reason may be that resi-
dents in modern housing kept windows closed in an 
effort to maintain cleanliness, whereas shacks simply 
had more ventilation. Another study measured the 
effects of increasing natural ventilation in traditional 
housing and demonstrated that natural ventilation was 
facilitated by opening doors and windows and extrapo-
lated that such a change could potentially reduce the 
risk of household transmission by 80 percent (Lygizos 
and others 2013). 
TURNING THE TIDE AGAINST TB
Despite the progress made in TB control over the past 
two decades, serious gaps persist. Although TB can be 
treated and cured, it is still one of the deadliest infectious 
diseases in the world today.
Three key elements are needed to achieve effective 
TB control and to meet the Sustainable Development 
Goals: (1) early and accurate diagnosis and drug- 
 sensitivity testing, (2) patient access to and completion 
of effective treatment, and (3) prevention of progression 
from latent infection to disease. Obviously, these catego-
ries are not distinct; each affects and is related to the 
others, and all face both technical and system challenges. 
Without greater effectiveness of these key elements, it 
will not be possible to bend the curve and dramatically 
reduce transmission and incidence rates in all countries. 
Turning the tide against TB therefore requires investing 
in new technologies—diagnostics, treatment regimens, 
and vaccines—and tackling the system and strategic 
challenges that influence the degree to which technolog-
ical advances reach the people who need them and 
translate into better heath. 
Earlier Diagnosis: Toward Active Case Finding
Limitations of Passive Case Finding
Even with modern technology, effective case detection in 
resource-poor communities with weak health systems 
has been difficult to introduce (Kranzer and others 2010; 
Kranzer and others 2013). The principal paradigm for 
diagnosing cases of TB is passive case finding, which 
depends on the TB-infected individual seeking medical 
care. But passive case finding faces many challenges. TB 
is most prevalent in marginalized communities that are 
less visible to conventional health systems. Patients are 
typically poor, from disadvantaged groups, prone to 
other diseases such as HIV/AIDS and diabetes that 
increase their vulnerability to TB, and often migrants. 
Even when symptoms are present, in many countries, up 
to a third of TB patients either fail to seek treatment or 
do so from traditional healers before seeking medical 
treatment, leading to more severe illness, delayed treat-
ment, and increased transmission (Brouwer and others 
1998; Sreeramareddy and others 2014).
TB control is premised fundamentally on the assump-
tion that, if active TB cases are identified and treated, 
transmission will be diminished and ultimately inter-
rupted. The issue of unsuspected cases is, however, a 
serious problem that has received very little attention. 
Traditional guidelines tend to focus on known or sus-
pected cases with classic symptoms and active disease. 
However, some forms of TB, such as asymptomatic and 
chronic tuberculosis, do not present with clinical symp-
toms for months or years and can transmit infection 
over extended periods of time. 
Evidence strongly indicates that the problem of 
unsuspected or asymptomatic cases of TB and unsus-
pected cases of drug resistance is significant, contribut-
ing to the one-third of TB patients being “unknown to 
the health system.” These patients are capable of trans-
mitting disease but not ill enough to seek care or to be 
detected by passive case finding. In a teaching hospital in 
Lusaka, Zambia, for example, 900 newly admitted 
patients (70.6 percent HIV-positive) who were able to 
produce sputum without induction were screened. 
Testing by fluorescent microscopy and automated liquid 
culture detected TB in 22 percent of patients, of which 
13.4 percent were unsuspected (Bates and others 2012). 
This number included 18 MDR TB cases, 5 of which 
were unsuspected. In the same hospital, 94 patients with 
cough, who were admitted primarily for obstetric or 
gynecological indications (73.4 percent HIV-positive), 
had sputum processed in the same way; in addition, 
Xpert MTB/RIF was used for rapid diagnosis (Friedich 
and others 2013). TB was diagnosed in 28 percent of the 
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94 sputum specimens, of which the Xpert device detected 
80.8 percent compared to 50 percent by standard smear 
microscopy. Results of this kind are not new: similar 
results were reported more than a decade ago in a low-
HIV/AIDS setting in Lima, Peru, where 250 of 349 con-
secutive new admissions to a female general medical 
ward were screened for TB by sputum smear, culture, 
and radiographs. Of these, 16 percent had culture- 
proven TB, one-third of which were unsuspected, 
including 6 unsuspected MDR cases (Willingham and 
others 2001).
The DOTS strategy in high-burden countries, even 
when implemented more effectively, will simply not 
be sufficient to overcome the challenge of unsus-
pected cases or drug resistance. In a groundbreaking 
population-based active case finding survey of HIV/
AIDS and TB in Sub-Saharan Africa, where the popula-
tion has a 23 percent prevalence of HIV/AIDS infection, 
Wood and others (2007) found that, despite a highly 
effective DOTS TB control program with high rates of 
compliance, 63 percent of adult cases with pulmonary 
TB were not known to the health system. Among HIV-
negative individuals, passive case finding identified 
67 percent of prevalent smear-positive cases, the target 
recognized for adequate DOTS implementation. But 
among individuals with HIV/AIDS infection, passive 
case finding identified only 33 percent of those with 
smear-positive TB. 
Similar findings were obtained in a large survey of 
47,000 individuals in Cambodia, in which 12 percent of 
individuals were examined clinically and sputa were 
tested by smear and by culture. Only one-third of TB 
cases were detected by sputum smears. Importantly, 44 
percent of the sputum-positive cases and 23 percent of 
the smear-negative culture-positive cases exhibited none 
of the signs of clinical tuberculosis (Mao and others 
2014). A surprising demographic finding was that peo-
ple over age 50 years accounted for more than half of all 
detected infections, a trend evident in other Asian 
countries.
Clearly, in many parts of the world where the burden 
of TB is low and control programs have been effective, 
the need for active case finding is not great, and cost- 
effectiveness would argue against recommending it. 
However, in high-burden communities, passive case 
finding fails to detect early and asymptomatic cases, 
leaving a third of TB patients not known to the health 
system.
Active Case Finding: What Does the Evidence Show?
Active case finding—mass screening and surveillance—
almost certainly contributed to the rapid decline of TB 
in European countries and the Americas (5–8 percent 
a year) following World War II—that is, prior to the 
introduction of antibiotics (Dye 2015; Golub and others 
2005). In 1974, the WHO recommended discontinuing 
active case finding with radiography, since it was no lon-
ger necessary or cost-effective in populations with low 
prevalence of TB and good access to high-quality health 
care, particularly in HICs. The WHO reiterated this 
policy in 2014, again finding that it would not be cost- 
effective, and recommended that indiscriminate mass 
screening be avoided (WHO 2013c). However, it did 
recommend systematic screening for active TB in 
 geographically defined subpopulations with extremely 
high levels of undetected TB (1 percent prevalence or 
higher). Regrettably, this WHO recommendation has 
not been sufficiently emphasized to stimulate countries 
and donors to initiate and support active case finding in 
high-burden countries or to have an impact on trans-
mission in those countries.
One strategy for active case finding has been to use 
X-radiography, particularly mobile X-ray units, to detect 
lung lesions with computer-assisted detection in people 
who are relatively asymptomatic (Melendez and others 
2016; Philipsen and others 2015). This strategy is able to 
detect many more patients with infection than is possi-
ble through passive case finding, screening for coughs, or 
self-reporting. In South Africa, for example, the only 
period in which incidence of TB cases declined occurred 
between 1950 and 1975, when X-ray surveillance cap-
tured about 10 percent of the population annually 
(R. Wood, personal communication). While in Europe 
and North America TB control programs dramatically 
reduced the annual risk of infection in successive cohorts 
(Cauthen, Pio, and ten Dam 2002), such a decline has 
not occurred in countries with high prevalence of TB 
and HIV/AIDS (Kritzinger and others 2009). 
In recent studies in Kenya, abnormal chest radiography 
had high sensitivity (94 percent) and reasonable specific-
ity (73 percent) for detecting tuberculosis (van’t Hoog and 
others 2012). Radiography represents a potentially valu-
able population-based screen to determine which individ-
uals should have their sputum tested by culture or by an 
Xpert device for definitive diagnosis. With rapid technical 
developments, computerized reading of X-radiograms 
could allow high-throughput screening of larger num-
bers of individuals in a cost-effective way (see box 11.5). 
This is particularly true when combined with clinical 
symptoms, where it was found that a sensitivity of 
95 percent and negative predictive value of 98 percent 
could be achieved. (Melendez and others 2016).
Active Case Finding in Targeted Regions
In many LMICs, patients with TB often seek care from 
one or more traditional providers before seeking 
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medically appropriate care (Satyanarayana and others 
2011). Even symptomatic surveillance for classic signs of 
TB—cough, fever, and weight loss—fails to detect a sub-
stantial number of cases, especially in persons who are 
HIV-positive (Corbett and others 2010). 
In cluster randomized trials in Brazil, intensified case 
finding had a significant impact on reducing TB 
(Cavalcante and others 2010). The WHO commissioned 
several studies on the effectiveness and acceptability of 
active case finding or systematic screening of active TB 
(WHO 2013d). The studies reported that active case 
finding was highly acceptable to populations in Sub-
Saharan Africa. 
In a recent review of undiagnosed TB that would not 
be found by passive case finding, Yuen and others (2015) 
found that it is precisely in high-risk populations, as well 
as in persons infected with HIV/AIDS, where intensive 
case finding and early initiation of treatment or preven-
tive therapy would likely have the greatest impact for the 
fewest resources. 
In another study in South Africa (Shapiro and oth-
ers 2012), a group of 2,800 individuals in households 
with a detected TB index case were enrolled to deter-
mine community prevalence of undetected TB and 
HIV/AIDS. Field teams screened participants for TB 
symptoms, collected sputum specimens for smear 
microscopy and culture, and provided HIV/AIDS 
counseling and testing. They found that 6,075 per 
100,000 of the household contacts were sputum- 
positive compared with 477 residents of random house-
holds without an index case. This finding demonstrated 
the value of screening contacts of index cases in a 
high-burden area and cautioned against random 
screening of total populations. Of the 169 previously 
unidentified cases with TB detected by culture, only 
6 percent were found to be sputum-positive, and 
only 11 percent were symptomatic; the remaining 
89 percent would not have been diagnosed with passive 
case finding. 
However, the evidence is mixed. In a large, complex 
community randomized trial, the Zamstar study (Ayles 
and others 2013), 64,000 individuals in Zambia and the 
Western Cape, South Africa, were surveyed for TB 
symptoms, sputa were taken for identifying individuals 
with disease, and one arm employed enhanced house-
hold active case finding with counseling. Clearly, screen-
ing households with index cases revealed a greater 
number of TB cases. The adjusted ratio for prevalence 
and the adjusted ratio for incidence did not differ sig-
nificantly for the enhanced case finding versus usual 
practice or for the household versus nonhousehold 
groups. The study identified no evidence that enhanced 
case finding had an effect on the burden of tuberculosis 
at the community level. However, despite not reaching 
Box 11.5
Undetected Cases in Hospitals: The Case of FAST
TB infection control needs to focus on prompt 
screening of admitted patients with chronic cough. 
This concept has been formulated into a transmis-
sion control strategy called FAST (Find cases Actively 
by cough surveillance, Separate temporarily, and 
Treat effectively). 
Several pilot FAST projects have begun around the 
world, including in Bangladesh and Russia. In a TB 
hospital in Veronesh, Russia, of almost 1,000 
patients hospitalized with suspected pulmonary 
TB, 93.5 percent were tested by Xpert MTB/RIF 
within two days of admission. Of these, 407 were 
positive, and 161 were rifampin-resistant, of whom 
159 received MDR TB treatment within three work-
ing days of receiving the result. Under normal oper-
ating conditions, treatment failure would have been 
identified months after admission, and drug- 
 susceptibility testing would have taken several more 
months, during which time, other patients and staff 
would have been exposed. FAST, in other words, 
was a dramatic improvement from the status quo. 
Similar results are being obtained in a pilot study at 
the National Institute of Diseases of the Chest 
Hospital (NIDCH), a 680-bed facility in Dhaka, 
Bangladesh. Because respiratory symptoms are com-
mon in patients admitted to NIDCH, a decision was 
made to conduct universal sputum sampling. Of the 
TB cases identified, 13 percent were unsuspected 
and an additional 1.3 percent were infected with 
MDR TB. Diagnoses were available within one to 
two days of collection, and treatment was initiated 
within one day of a confirmed diagnosis.
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statistical significance, the findings suggested that the 
household intervention did reduce the burden of tuber-
culosis in these communities.
A meta-analysis of controlled studies found that 
screening increased the number of cases found in the 
short term and tended to find cases earlier and with less 
severe disease (Kranzer and others 2013). Treatment 
outcomes among people identified through screening 
were similar to outcomes among people identified 
through passive case finding. Once again, this analysis 
confirmed that, in many settings, more than half of the 
prevalent TB cases remain undiagnosed.
A recent transmission modeling study of TB in 
South Africa suggested that the current DOTS approach 
of passive case finding is unlikely to permit the country 
to reach the WHO targets for 2050. The model predicts 
that interventions such as active case finding, with early 
initiation of treatment and reduction of pretreatment 
loss to follow-up, could have a large impact (Knight and 
others 2015). Thus, defining the high-burden target 
populations where active case finding is likely to be most 
effective is an important analysis to be undertaken.
Although most official data on TB incidence and 
prevalence are estimated for entire countries, a recent 
innovative epidemiological approach asked whether 
high-burden regions within countries—TB hot spots—
might lend themselves to targeted control efforts. Such 
hot spots have been identified in a few countries, such as 
Moldova, and it will be of interest to learn whether tar-
geted control efforts can improve their effectiveness at 
lower cost than the usual countrywide programs 
(Dowdy and others 2012; Jenkins and others 2013; 
Manjourides and others 2012; Zelner and others 2016). 
These population experiments for TB control need to be 
supported and evaluated.
We therefore recommend identifying countries and 
high-risk populations that are not responding effectively 
to the standard DOTS strategy and designing targeted 
active case finding interventions that could have a 
greater impact on earlier case detection and successful 
treatment. 
Initiating active case finding interventions in 
high-burden countries will clearly require external 
financial assistance. Nevertheless, given the limitations 
of current tools and increasing threat of MDR TB, active 
case finding may be the best strategy for reducing inci-
dence and prevalence in the long run in high-burden 
areas. And although active case finding is more expen-
sive than passive case finding, added costs will be more 
than offset by the diagnostic and treatment costs 
averted—that is, TB transmitted in the hospital and in 
the community by unsuspected cases, especially MDR 
TB cases. The questions of how much screening, in what 
places, and at what cost need to be answered if we are to 
avert each additional case of drug-susceptible or MDR 
TB. If interrupting transmission and reducing incidence 
more rapidly is the goal, the evidence suggests that active 
case finding targeted to high-burden areas can make a 
difference. 
Community-Based, Integrated Delivery of TB Care
Service delivery—from screening and diagnosing 
patients to administering treatment and monitoring 
progress—is a key challenge in TB control, as with other 
health care services (Farmer 2013; Kim, Farmer, and 
Porter 2013). 
Dominance (and Costs) of Hospital-Based Care 
The costs of health service delivery are the largest cost of 
tuberculosis control. While the mean costs of diagnostics 
and tests do not vary significantly across income groups, 
the costs of drugs and hospitalization do (Laurence, 
Griffiths, and Vassall 2015), particularly the costs of 
treatment (WHO 2013b, 2014b, 2016a). For example, 
the costs per patient of drug-sensitive TB treatment were 
US$14,659 in HICs, US$840 in upper-middle-income 
countries, US$273 in lower-middle-income countries, 
and US$258 in LICs, with strong positive correlation 
with income (Laurence, Griffiths, and Vassall 2015). 
However, the mean costs of treating drug-susceptible TB 
were highly variable in countries at the same income 
level (Floyd and others 2013; Laurence, Griffiths, and 
Vassall 2015).
Hospitalization accounts for an average of 74 percent 
of all drug-susceptible TB costs (although this varies 
widely between individual studies) and 64 percent of all 
MDR TB costs. Conversely, mean costs of outpatient 
treatment were 12 times less than hospitalization costs, 
accounting for 6 percent of total costs. In one study, in 
the LMIC group, India consistently had the lowest costs 
for hospitalization and Ukraine had the highest costs for 
hospitalization and outpatient care (Laurence, Griffiths, 
and Vassall 2015). In Ukraine, high hospitalization costs, 
where patients also incurred costs, led to treatment 
default (Vassall and others 2009). In 2013, in countries 
with a high burden of TB and MDR TB (excluding 
China and Russia), almost 38 percent of funding (US$919 
million) was allocated to hospital inpatient and hospital 
outpatient care of drug-susceptible TB (WHO 2013b). 
In addition, in 2013 Russia spent US$1.6 billion on TB 
control, most of which went toward hospital- based TB 
care (Atun, Samyshkin, and others 2006). However, 
funding allocated to neglected high-transmission 
areas, such as prisons, remains woefully low (Lee and 
others 2012).
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Efficient and effective delivery of health services for 
TB is critical for improving TB outcomes globally. Yet, 
the delivery of TB services is inefficient and ineffective 
due to the high reliance on hospital services and the 
vertical delivery of DOTS (Atun, Samyshkin, and 
 others 2006; Atun, Weil, and others 2010; Samb and 
 others 2009). For example, from 2008 to 2010 in most of 
the world’s 22 high- burden countries, the average cost of 
treating a patient with drug-susceptible TB was US$100–
US$500. However, the average costs varied from US$100 
to US$10,000 when Russia (a hospital-based service 
delivery model) was included (Floyd and others 2013). 
In 2014, in most of the 22 high-burden countries for 
drug-susceptible TB, the WHO estimated that the share 
of hospital inpatient and outpatient costs ranged from 
30 to 60 percent, with durations of stay ranging from 5 
to 56 days (WHO 2014b). In the 22 high-burden TB 
countries, the costs of hospital inpatient and outpatient 
care for managing drug-susceptible TB as a proportion 
of the national TB program budget were 1–10 percent in 
the Democratic Republic of Congo, Ethiopia, Tanzania, 
Thailand, and Uganda; 11–20 percent in Bangladesh, 
Kenya, Myanmar, and Pakistan; and in excess of 40 
percent in India (46 percent), Mozambique (51.8 
percent), and Vietnam (74.2 percent) (WHO 2013b). 
While the WHO report did not have data for China and 
Russia, earlier studies suggested that, in Russia, where 
drug-susceptible TB is treated predominantly in hospi-
tals, patients are kept under observation long after treat-
ment completion; as a result, hospital inpatient costs 
account for around 60 percent of the total costs of treat-
ment (Atun, Samyshkin, and others 2006). It is difficult 
to understand why China has shifted most TB care from 
outpatient to hospital-based care. 
In South Africa, which has the second-highest number 
of confirmed cases of MDR TB (WHO 2011b) and the 
highest number of confirmed cases of XDR TB, MDR TB 
accounts for only 3.5 percent of the TB disease burden, 
but absorbs almost half of the US$218 million national 
TB program budget (WHO 2011c). Patients with MDR 
TB are hospitalized from the initiation of treatment until 
culture conversion, and the cost per patient of treating 
MDR TB was US$17,164, more than 40 times the cost of 
treating drug-susceptible TB (Schnippel and others 
2013), which was estimated to be US$314–US$392 for 
community-based treatment (Sinanovic and others 
2003). Around 95 percent of these costs were hospitaliza-
tion costs (Schnippel and others 2013). More recent 
studies in South Africa have put the cost of inpatient 
treatment of MDR TB at US$6,772 (compared with 
treatment of drug-susceptible TB at US$256), with esti-
mates suggesting that 45 percent of total costs are hospi-
talization costs (Pooran and others 2013). 
The cost situation in South Africa is similar to that 
observed in countries where drug-susceptible and MDR 
TB are treated as inpatient care, such as Estonia 
(US$10,880) and Russia (Tomsk region, US$14,657). 
These high costs contrast with the lower costs recorded 
in countries where MDR TB is managed in outpatient 
clinics and at home—for example, Peru (US$2,423) and 
the Philippines (US$3,613). In Estonia and Russia, hos-
pital costs accounted for 43 and 52 percent, respectively, 
of the total cost of treating an MDR TB patient 
(Fitzpatrick and Floyd 2012). Estimates suggest that the 
global average cost per patient of treating MDR TB is 
US$13,259 (5th–95th percentiles US$2,797–US$42,040) 
using an outpatient model and US$34,599 (5th–95th 
percentiles US$6,959–US$109,154) using an inpatient 
model (Fitzpatrick and Floyd 2012).
High hospital costs crowd out funding for cost- 
 effective interventions, such as those aimed at addressing 
the social determinants of health, as well as new diagnos-
tics and medicines that could be delivered in the com-
munity or in primary care settings. 
Worldwide, there is substantial variation in the cost of 
treating patients using DOTS. Among the 22 high- burden 
countries, the cost per successfully treated patient varies 
from less than US$100 to more than US$10,000 for a 
standardized treatment. Even in countries with similar 
per capita income levels, the cost per successfully treated 
patient varies 50-fold (Floyd and others 2013). According 
to recent cost-effectiveness studies, the cost of treating 
one MDR TB case ranges from nearly US$15,000 in a 
hospital-based program in Tomsk, Siberia, to US$2,400 
in a community-based  program in Lima, Peru (Fitzpatrick 
and Floyd 2012). 
The failure to prioritize MDR TB adequately or to 
achieve adequate cure rates is a major problem exempli-
fied by the situation in two large countries. In India, the 
MDR TB cure rate is about 11 percent (Subbaraman and 
others 2016). In China, only about 5 percent of MDR 
patients are being treated, and the policy is formulated 
entirely around hospital-based treatment, with high 
relapse rates after discharge (Zhao and others 2012).
Efficiency and Effectiveness of Community-Based 
TB Treatment
A great deal of evidence points to the effectiveness of 
transitioning hospital-based TB care to primary health 
care settings (Edginton 1999) and to community-based 
models (Ayles and others 2013; Binagwaho 2013; 
Cavalcante and others 2007; Cavalcante and others 
2010; Corbett and others 2010; Islam and others 2002; 
Shapiro and others 2012), even for management of 
MDR TB (Fitzpatrick and Floyd 2012; Furin and others 
2011; Heller and others 2010; Luyirika and others 2012; 
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Mitnick and others 2003; Mukherjee and others 2002; 
Nathanson and others 2006; Seung and others 2009; 
Smart 2010). In addition to clinical effectiveness and 
improved outcomes, community-based models appear 
to be more acceptable to patients (Horter and others 
2014).
A recent community-based model for providing TB 
treatment was developed in Bangladesh by BRAC, the 
world’s largest NGO (Islam and others 2002; Islam and 
others 2011). Individuals diagnosed with tuberculosis 
are given free treatment but asked to provide a small 
bond, equivalent to about US$3.25, to assure that they 
will complete treatment. Upon successful completion of 
treatment, the funds are returned. The treatment cost 
per patient was US$312 in 2010. For patients unable to 
afford the bond, the community acts as underwriter, 
which establishes a social incentive to complete treat-
ment. Program cure rates are up to 92 percent, which is 
comparable to a government-run program, yet the costs 
of the community-based program are half those of a 
public program (Islam and others 2002).
Several countries transitioning from hospital-based 
services to primary health care or community settings 
have improved quality and outcomes of TB care—for 
example, Haiti (Farmer and others 1991), Latvia 
(Leimane and Leimans 2006), Moldova (Soltan and oth-
ers 2008), Romania (Marica and others 2009), and 
Zambia (Miti and others 2003). Ethiopia has introduced 
the use of health extension workers to scale up access to 
primary health care services, including TB services, with 
improved compliance and treatment outcomes (Bilal 
and others 2011; Datiko and Lindtjørn 2009, 2010), and 
employed village outreach programs in rural settings 
(Shargie, Mørkve, and Lindtjørn 2006). Similarly, India 
has engaged urban community volunteers to supervise 
DOTS (Singh and others 2004). South Africa and 
Tanzania have used CHWs to expand access to TB ser-
vices (Sinanovic and others 2015; Wandwalo and others 
2004), and Rwanda has achieved effective community- 
based treatment (Binagwaho and others 2014). In addi-
tion to community-based care, a public-private mix with 
NGOs has been used in India, South Africa, and beyond 
to expand access to TB services and improve outcomes 
(Lal and others 2011; Pantoja, Floyd, and others 2009; 
Sinanovic and Kumaranayake 2006; Wells, Uplekar, and 
Pai 2015).
In the case of drug-susceptible TB, early indications are 
that outpatient treatment in the community is not poorer 
than hospitalized care (Bassili and others 2013; Loveday 
and others 2012). Although current guidelines recom-
mend isolating MDR TB patients until smear or culture 
conversion, community-based treatment of drug-resistant 
TB is growing in acceptance due to its cost-effectiveness 
and a shortage of long-term hospital beds—for example, 
in South Africa (Brust and others 2012). 
The benefits of transitioning facility-based services 
to community-based care are substantial. In six studies, 
where outcomes between community-based and health 
facility–based TB care were similar, the costs of 
community-based care were 33 to 70 percent lower 
(figure 11.5). In the four countries where the treatment 
outcomes in community-based TB care and health 
facility-based TB care were better, costs were 32 to 
77 percent lower. 
Community-based DOTS in Tanzania reduced costs 
35 percent: from US$203 per patient treated at a health 
center to US$128 per patient treated in the community, 
with almost identical treatment outcomes. This program 
reduced costs by lowering the number of visits to the 
clinic (Wandwalo, Robberstad, and Morkve 2005). In 
Malawi and Kenya, moving to a community-based 
model reduced costs even more: 67 and 77 percent, 
respectively (Floyd and others 2003; Nganda and others 
2003) (table 11.6).
Figure 11.5 Cost-Effectiveness of Community-Based Interventions 
Compared to Health Facility–Based Interventions for Tuberculosis 
Treatment in Select Countries
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Human Resource Challenges to Community- 
Based Care
Despite the evidence, many countries have not transi-
tioned to community-based models of service delivery 
for TB. Barriers to adoption of innovative models of 
care delivery are often related to health system gover-
nance, organization, and financing, in particular (exter-
nal and domestic) financing flows that reinforce vertical 
programing; provider payment systems that allocate 
large proportions of the budget to structures and inputs 
(hospitals and hospital activities), rather than health 
outcomes; and a health workforce that lacks suitable 
skills (in particular, trained CHWs who underpin 
community- based service delivery). A general reluc-
tance to adopt innovations may also impinge the move 
to community- based models, including public-private 
partnerships, which in several countries have helped to 
improve outcomes while lowering costs (Atun, de Jongh, 
and others 2010; Atun, Lazarus, and others 2010; Atun, 
McKee, and others 2005; Atun and others 2012; Howitt 
and others 2012; Khan, Khowaja, and others 2012). 
Both active case finding and community-based TB 
delivery models require a competent, motivated health 
workforce, both at health facilities and in communities. 
Following patient diagnosis, treatment must be adhered 
to, and factors that drive patient adherence to medica-
tion are complex and relate both to patients’ willingness 
and ability to seek health care and their experiences 
within the health system (Munro and others 2007; 
Podewils and others 2013). Clinic staff with limited 
resources need to provide accurate information to their 
patients and make it easy for patients to access and take 
good-quality treatment consistently until cured. 
Inadequate human resource capacity remains an 
important health system barrier for TB control 
(Figueroa-Munoz and others 2005; Harries and others 
2005), especially for MDR TB, which requires longer and 
more complex interventions than drug-susceptible TB 
(Keshavjee and Farmer 2010). Several factors, such as 
weak planning, absolute shortage of health staff, limited 
training, inadequate skills, lack of incentives to motivate 
and retain staff, and inappropriate distribution of the 
available health workforce, have contributed to the 
human resource crisis confronting global efforts to con-
tain TB (Awofeso, Schelokova, and Dalhatu 2008; Buchan 
and Dal Poz 2002; Caminero 2003). 
While community-based TB treatment certainly 
requires initial investments, including training, supervi-
sion, and management of CHWs, the initial investment 
is generally offset in the long run by savings accrued 
from community-based treatment rather than hospital 
care (Wandwalo, Robberstad, and Morkve 2005).
Private Sector Challenges
Some high-burden countries, such as India, have health 
care systems in which private sector rather than public 
sector care predominates. In India, about 75 percent of 
health care is provided by the private sector, most often 
based on OOP payments (Pai, Daftary, and Satyanarayana 
2016). A high proportion of providers in many countries 
Table 11.6 Costs and Effectiveness Comparing Community-Based Tuberculosis Care to Health Facility–Based 
Tuberculosis Care
Study Study country
Community cost 
(2012 US$)
Health facility 
cost (2012 US$)
% difference in 
cost per patient
Effectiveness of 
community-based care vs. 
health facility–based care
Islam and others 2002 Bangladesh 172.80 259.20 33 Similar
Wandwalo, Robberstad, 
and Morkve 2005
Tanzania 216.10 331.90 35 Similar
Dick and Henchie 1998 South Africa 1,296.10 2,073.10 37 Similar
Moalosi and others 2003 Botswana 5,135.90 8,543.40 40 Similar
Datiko and Lindtjørn 2010 Ethiopia 138.00 332.70 59 Similar
Pichenda and others 2012 Cambodia 639.30 2,131.10 70 Similar
Khan, Khowaja, and 
others 2012 
Pakistan 320.83 471.16 32 Higher
Okello and others 2003 Uganda 796.52 1,405.63 43 Higher
Nganda and others 2003 Kenya 752.65 2,250.51 67 Higher
Floyd and others 2003 Malawi 1,040.94 4,477.99 77 Higher
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are not medically trained, and appropriate care is often 
not provided (Udwadia, Pinto, and Uplekar 2010). 
Patients with TB often seek care initially from private 
providers and may consult three to five providers before 
receiving a correct diagnosis of TB, which delays the 
average time to initiate treatment to 60–66 days 
(Satyanarayana and others 2011; Sreeramareddy and 
others 2014). 
In studies using surrogate patients presenting to 
physicians with cardinal TB symptoms, correct diag-
nosis by physicians may be as low as a third (Das and 
others 2015), and surveying physicians for how they 
would treat a new patient diagnosed with TB revealed 
that no more than a third recommended the WHO 
standard treatment protocol. In this context, private 
practitioners often do not register TB patients in the 
health system; without notifications, it is difficult for 
state and national TB programs to conduct planning 
and to improve control of TB. Such countries need to 
improve the communication between private provid-
ers and the health system. Innovative approaches in 
India and Pakistan have included the creation of 
public- private mixes using interface organizations and 
information technology to improve treatment of TB 
(Khan, Minion, and others 2012; Wells, Uplekar, and 
Pai 2015).
From Vertical to Targeted, Integrated Delivery
Another challenge for TB service delivery is the domi-
nance of vertically organized and financed TB programs, 
supported by external institutions (Katz and others 
2010), which circumvent and fail to strengthen weak 
health systems in LMICs in an effort to deliver accessible 
and quality TB services (Atun, Weil, and others 2010; 
Car and others 2012; Coker, Atun, and McKee 2004; 
Coker and others 2005; Samb and others 2009; Shigayeva 
and others 2010; Wood and others 2010). 
Integrated service delivery has been shown to be 
beneficial. By 2008, TB services were being delivered at 
the primary health care level in 20 of the 22 high- 
 burden countries and 83 percent of 173 countries 
reported making progress in TB control (WHO 2013b). 
However, these services were not effectively integrated 
with other disease control programs as part of compre-
hensive primary health care. In Cambodia, hospital- 
based DOTS care was the norm until stronger primary 
health care enabled the introduction of integrated 
community-based TB services. Similarly, the National 
Rural Health Mission in India has expanded integrated 
service delivery, including rapid scale-up of child 
health, TB, and combined TB and HIV/AIDS services. 
Thailand extended access to primary health care–based 
TB services as part of universal health coverage. 
In Vietnam, tuberculosis control services, which were 
historically operated through a vertical network, are 
now embedded in general health services (Atun, Weil, 
and others 2010). Integration between care delivery 
domains—for example, civilian and prison health care 
(Shin and others 2006)—has also been shown to 
improve patient outcomes.
Vertical delivery of TB services is especially ineffi-
cient in the context of concurrent tuberculosis and 
HIV/AIDS epidemics (Drobniewski and others 2004). 
As noted, the burden of TB and HIV/AIDS co-infection 
is substantial, most acutely in Sub-Saharan Africa, and 
there is a demonstrable need to integrate TB and HIV/
AIDS services (Corbett and others 2006; Creswell and 
others 2011; DeLuca, Chaisson, and Martinson 2009; 
Perumal, Padayatchi, and Stiefvater 2009; Sylla and 
others 2007). Emerging evidence indicates the benefits 
of integrating TB control with HIV/AIDS control 
(Gandhi and others 2009; Gasana and others 2008; 
Harris and others 2008; Huerga and others 2010; Jack 
and others 2004; Legido-Quigley and others 2013; Miti 
and others 2003; Pevzner and others 2011; Phiri and 
others 2011; Uwinkindi and others 2014; Uyei and oth-
ers 2011; Walton and others 2004; Zachariah and others 
2003) and other targeted programs (Howard and 
El-Sadr 2010; Zwarenstein and others 2011) in the 
primary health care setting. Integration improves 
outcomes—for example, through concurrent screening 
or through provision of cotrimoxazole during routine 
TB care or isoniazid during routine HIV/AIDS care and 
at voluntary counseling and testing centers (Uyei and 
others 2011). 
Treatment for both tuberculosis and HIV/AIDS 
should be integrated at the clinic as a standardized 
package of care, with adherence support and HIV/AIDS 
drug-resistance testing. It is essential that all HIV-
positive individuals be tested for TB. In 2004, the WHO 
introduced integrated activities to improve  prevention, 
diagnosis, and treatment of TB in people living with 
HIV/AIDS (box 11.6), but the achievements have been 
mixed. Creating positive synergies through effective 
integration of TB control with HIV/AIDS and other 
targeted programs has been arduous (Ansa and others 
2012; Atun and Cooker 2008; Atun, Lazarus, and 
others 2010; Marais and others 2010; Okot-Chono 
and others 2009; Uwimana, Hausler, and Zarowsky 
2012; Uwimana and Jackson 2013). Integration must 
be site- and service-specific. 
While integrating diagnostic and laboratory services 
makes great sense, integrating patients with undiag-
nosed TB in health care clinics and hospitals without 
the benefit of proper infection control measures poses 
serious risks to persons with HIV/AIDS. Moreover, 
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an anticipated consequence of integrating HIV/AIDS 
and TB care is the exposure of immune-compromised 
HIV-positive patients to undiagnosed TB, making it 
essential to control infection and separate patients. 
Effective TB control will require health systems to 
interact with sectors that address the social determinants 
of health. However, it has been argued that the program-
matic and biomedical focus fostered by DOTS may have, 
in some instances, hindered multisectoral collaboration 
and effective coverage of vulnerable communities (Ayles 
and others 2009; den Boon and others 2007; Gler, 
Podewils, and others 2012; van’t Hoog and others 2011; 
Wood and others 2007); geographically concentrated 
groups (de Vries and others 2014); groups at risk, such 
as women, children, and adolescents (Ettehad and oth-
ers 2012; Isaakidis and others 2013; Marais and others 
2010; Moyo and others 2014; Sheriff and others 2010); 
and disenfranchised populations (Corbett and others 
2009), for example, persons imprisoned in penitentiary 
facilities (O’Grady, Hoelscher, and others 2011; O’Grady, 
Maeurer, and others 2011).
Stronger Supply Chains
A robust and well-functioning supply chain is a complex 
but essential component of any country’s health system. 
An uninterrupted supply of high-quality drugs is imper-
ative to treat TB effectively and to prevent transmission of 
the disease or its escalation to drug-resistant strains. Weak 
systems of supply chain management, with inadequate 
demand forecasting, ineffective drug procurement, long 
procurement cycles, poor-quality drugs, and delays in the 
delivery of diagnostics and medicines, have led to treat-
ment interruptions, exacerbating drug-susceptible and 
MDR TB epidemics (Mathew and others 2006; van der 
Werf and others 2012; Victor and others 2007). The lack 
of availability or poor quality of TB drugs in public clinics 
run by national TB programs or in private facilities leads 
to patients missing doses, creating increased risks for 
relapse and the emergence of drug-resistant forms of the 
disease. 
Stock-outs of TB medicines have many causes. While 
some stock-outs are related to poor planning, distribu-
tion bottlenecks, and poor demand visibility, there are 
global shortages for some drugs. The problem of global 
shortages affects many antimicrobials, especially generic 
injectable agents. Very often, given the small number of 
manufacturers, when one manufacturer experiences 
problems related to quality or manufacturing, global 
shortages can arise. 
Global Supply Chain
The global supply chain of TB medicines, from the man-
ufacturer to the patient, can be divided into two distinct 
segments: the upstream supply chain (global supply 
chain) and the in-country supply chain (figure 11.6). 
The global, or upstream, segment consists of the pro-
cesses related to global demand forecasting, procure-
ment, and financing. The in-country segment includes 
the quantification of needs by national TB programs, 
Box 11.6
WHO-Recommended Collaborative TB and HIV/AIDS Activities 
In 2004, the WHO recommended a set of collab-
orative activities to improve prevention, diag-
nosis, and treatment of TB in people living 
with HIV/AIDS (WHO 2004). These recom-
mendations were updated in 2010 and 2011 
(WHO 2012b). Collaborative activities include 
the following:
1. Establish and strengthen coordination mech-
anisms for delivering integrated TB and HIV/
AIDS services.
2. Test TB patients for HIV/AIDS.
3. Provide ART and cotrimoxazole preventive ther-
apy to TB patients living with HIV/AIDS.
4. Provide HIV/AIDS prevention services for TB 
patients.
5. Intensify TB case finding among people living 
with HIV/AIDS.
6. Offer isoniazid preventive treatment to people 
living with HIV/AIDS who do not have active TB.
7. Control the spread of TB infection in health care 
and congregate settings.
8. Use Xpert MTB/RIF as the primary test for diag-
nosing TB in people living with HIV/AIDS who 
have signs and symptoms of TB.
270 Major Infectious Diseases
procurement by ministries of health, warehousing, dis-
tribution, and information collection about patients 
regarding treatment and future needs. 
The upstream supply chain for TB medicines is 
fraught with market shortcomings. All commonly used 
TB drugs are off-patent, holding little interest for large 
pharmaceutical companies. As a consequence, there are 
few producers for most drugs. In particular, timely pro-
vision of life-saving second-line medicines for MDR TB 
has been woefully inadequate, with estimates suggesting 
that less than 0.5 percent of the MDR TB cases in 2002–
09 were treated with drugs of known quality (Keshavjee 
and Farmer 2012). Stock-outs of TB medicines are fre-
quent in LICs, and shortages exist even in HICs, where 
standard isoniazid has not been available for more than 
a year.
Apart from the lack of manufacturer interest in these 
low-demand, limited-profit-potential medicines, the 
lack of procurement coordination across low- and 
high-demand countries further fragments the small 
market. Lack of proper quantification at the country 
level translates into a lack of robust global forecasts for 
TB medicines. The upstream supply chain for the donor-
funded portion of the TB market currently operates 
through a pooled procurement mechanism operated by 
the Global Drug Facility. The Global Drug Facility 
attempts to coordinate the orders from multiple coun-
tries, especially lower-demand countries. For MDR TB 
medicines, it also runs a strategic rotating stockpile to 
reduce stock-outs and volatility in orders to the manu-
facturer. However, the global supply chain is far from 
optimal and requires significant strengthening of its 
technical capacity to manage a small market with highly 
uncertain demand and a fragile supply base (Institute of 
Medicine 2013).
It is important to examine how the global supply 
chain for TB medicines has evolved over time. The Green 
Light Committee was developed in the 2000s to approve 
programs that deliver MDR TB treatment and provide 
access to low-cost second-line drugs. However, the Green 
Light Committee approved a small number of MDR TB 
treatments, creating long delays in receiving approvals 
and drugs, limited demand for second-line drugs, and 
constrained supply, with few producers providing medi-
cines that met stringent regulatory approval. 
In a typical healthy pharmaceutical supply chain, 
some upstream steps such as active pharmaceutical 
ingredient (API) manufacturing, formulation, and pack-
aging are carried out before the buyer places an order. 
These forecast-driven steps lead to the finished product 
or the API manufacturer holding some inventory, which 
reduces the time required to fulfill a confirmed order. 
In the TB medicines supply chain, however, many of 
these processes are order driven as opposed to forecast 
driven. Manufacturers hold little, if any, finished product 
inventory and little, if any, API inventory. All steps in the 
upstream supply chain start only after a confirmed order 
is placed. And the order stream from the pooled pur-
chaser is lumpy, meaning that it occurs in large quanti-
ties at certain times of the year. These problems lead to 
suboptimal holding of inventory, poor planning of batch 
size, subscale manufacturing of the finished product, 
higher costs, and excessively long lead times. These issues 
constrain national TB programs, which are unable to 
plan much in advance due to uncertain financing and 
delayed disbursement and thus face further delays in 
receiving supplies after they place an order. Together, 
these factors contribute to stock-outs of TB medicines at 
the national level. 
Possible mechanisms to address these problems include 
the creation of an accurate global demand forecast system, 
the development of supply-contracting structures that 
provide limited-volume guarantees to manufacturers, and 
a buffer inventory or stockpile to smooth demand. Their 
applicability and cost-effectiveness depend on careful 
analysis of the nature of demand uncertainty, supply lead 
times, and ability of global program staff to operate these 
mechanisms. 
Some of these mechanisms are now starting to be 
used by the Global Drug Facility (Arinaminpathy and 
others 2015), but they require adequate technical 
resourcing. Also, while Global Drug Facility purchasing 
may lead to greater coordination and pooling of orders 
from many LICs, a significant portion of the TB burden 
is in middle-income countries, which do not pro-
cure through the Global Drug Facility. Overcoming the 
excessive fragmentation in the global TB drug market, 
especially for low-demand drugs for MDR TB, requires 
not only robust technical solutions but also strong 
political will.
In-Country Supply Chains
In HICs, while the nature of health care provision and 
financing varies considerably, medicines are distributed 
primarily by private sector agencies. In LICs, and in many 
Figure 11.6 A Simplified Supply Chain from Manufacturer to Patient
Source: Yadav 2010.
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of the TB-endemic countries, in particular, medicines are 
distributed to health facilities primarily through a central 
medical store, regional or district stores, or a transport 
fleet owned by the government or a central medical store. 
Global donor–funded or national government–funded 
TB drugs also flow primarily through this government- 
run distribution system (figure 11.7). 
A multitiered distribution structure wherein TB med-
icines are stored at multiple levels (national, regional, 
district) before reaching TB clinics is common in most 
countries. The distribution system maps directly to the 
administrative structure of the health system, for ease of 
administration and governance, as opposed to technical 
or operational imperatives (Yadav 2010). 
Successfully managing a multitiered distribution 
system for TB medicines is an information-intensive 
operation. Data on stock levels at each stage, past 
consumption, and future requisitioning need to flow 
through different levels of the system. Such data are 
recorded on store ledgers, stock control cards, and requi-
sition forms at the district and health facility levels but 
rarely get reported to higher levels of the distribution 
system. The lack of consumption data prohibits better 
overall supply planning. There is a critical need for a 
simple and robust logistics management information 
system to record and report these data systematically.
Staff need to be well trained to forecast need and 
place orders, yet staff at health facilities often have inad-
equate capacity to estimate the quantity of medicines 
needed, resulting in under- or over-ordering. One solu-
tion is to deploy trained staff from district or regional 
delivery teams to visit health facilities, check the stock 
they have used, help them to estimate how much is 
needed for the next period, and replenish that quantity 
Figure 11.7 Flow of Medicines through the Public, Private, and NGO Sector in Low- and Middle-Income Countries
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from the supply they carry with them. Zimbabwe has 
implemented such a system, called Delivery Team Top 
Up (Yadav, Tata, and Babaley 2011). In a large-scale ran-
domized pilot study in Zambia, relatively simple changes 
to the information and product flow system significantly 
improved the availability of essential drugs (Vledder and 
others 2015). HIV/AIDS medicine programs in multiple 
countries have also experimented with different variants 
of the distribution, requisitioning, and information flow 
model. Such innovation has been lacking for the distri-
bution of TB medicines.
With the recent explosion of inexpensive informa-
tion technology such as mobile phones, new options 
have become available for collecting and using infor-
mation about clinic-level consumption. However, tech-
nology will not fix all of the problems in the distribution 
system.
Apart from lack of information, another crucial 
cause of poor supply chain performance relates to the 
lack of incentives (Yadav, Stapleton, and Van Wassenhove 
2013): public sector supply chains often lack the ability 
to reward good performance or to remove incompetent 
workers. Better mechanisms are needed to align incen-
tives and motivate the supply chain workforce (Spisak 
and others 2016), but greater accountability in the dis-
tribution system for TB drugs requires richer informa-
tion about stock and consumption data. These models 
have not yet been leveraged to their fullest, but they 
have the potential to be the backbone of planning in the 
supply system.
Having a healthy and robust supply chain for TB 
medicines in the private sector is as important as 
improving the publicly run supply chain. Significant 
proportions of TB patients in high-burden countries 
such as China and India seek TB treatment in private 
clinics or obtain medicines in private pharmacies (Wells, 
Uplekar, and Pai 2015); in some countries, public- 
private models rely on the availability and quality of 
drugs in the private sector. While countries such as 
Brazil and China have created social insurance pro-
grams to help patients to cover the cost of private sector 
services, in most countries patients themselves pay out 
of pocket for private sector treatment for TB. 
TB medicines in the private sector are distributed 
through a network of importers, wholesalers, sub- 
wholesalers, pharmacies, and drug stores. Compared to 
private sector pharmaceutical supply chains in HICs, 
private sector supply chains in most TB-endemic coun-
tries are excessively fragmented, with myriad small 
wholesalers and distributors; intermediaries between 
the manufacturer and the patient; and poor information 
technology and communication systems, which result 
in poor coordination across the distribution channel. 
Fragmentation of the supply chain makes it difficult 
to achieve scale economies and to improve or verify 
quality, especially given the severe resource constraints 
of regulatory authorities. 
In some countries where medicine wholesaling is 
highly fragmented, consolidation of wholesaling and dis-
tribution in the supply chain is being driven by policy 
measures such as better enforcement of distribution prac-
tices and stricter reporting requirements. For instance, 
when a nationwide Good Supply Practice enforcement 
campaign was launched in China in 2004, the number 
of pharmaceutical wholesalers dropped from 16,000 to 
7,445 (Yadav 2015). 
Better Information Management and New 
Technologies 
The lack of reliable and timely information impedes the 
organization of TB control and effective discharge by 
ministries of health of their stewardship function. In 
2009, only 4 of the 22 high-burden countries had well-
functioning vital registration systems that appropriately 
coded causes of death (Glaziou and others 2011).
Challenges
As both an infectious and chronic disease, TB presents 
a range of challenges for collecting and managing 
information. First, there is the challenge of case finding 
and surveillance. Once patients are identified, diagnosis 
requires sputum smear and, ideally, culture and drug-
sensitivity testing, a challenge in low-income settings 
where good laboratory facilities are rare. Sputum 
smears can be collected in small clinics, but culture 
and DST is a specialized process. New diagnostic tech-
niques, particularly GeneXpert, have improved the 
situation significantly, avoiding the need for sputum 
smear or culture in initial diagnostic work-up in sites 
that have the machines. However, many clinics have to 
send samples to other sites with machines, and any 
patient found positive for Mtb requires follow-up 
testing to assess their response to treatment. Patients 
found resistant to rifampicin require follow-up drug- 
sensitivity testing to permit individualized therapy 
(Lessem and others 2015). It is therefore critical to 
capture lab data from all locations and sources, includ-
ing GeneXpert. Newer, portable models in development 
(GeneXpert Omni) with potential for point-of-care 
diagnosis have the ability to transfer results in real time 
by short message service or through the Internet. Even 
in countries with sophisticated health care systems, like 
South Africa, there are enormous problems getting 
the data on a sputum sample to the appropriate clinic, 
physician, and patient.
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Once patients have been diagnosed successfully, they 
need to be tracked in a longitudinal record that captures 
data on demographics, clinical condition, current and 
previous medication, lab results, complications, and 
treatment response and outcomes. For first-line TB 
treatment with DOTS, the record is typically a paper 
register in the clinic. This usually supplements other 
registers, including primary care visits and maternal 
health. While well-designed paper registers can be effec-
tive, they are typically challenging for busy staff to keep 
up to date and accurate and lead to much duplication of 
data. This problem becomes much more severe with 
large numbers of patients and mobile populations. 
Drug-resistant TB is a particular challenge due to the 
complexity of recording treatment and clinical data and 
the long treatment times.
E-health systems are playing an increasingly impor-
tant role in the management of TB and are especially 
important for drug-resistant TB in LMICs. Labrique and 
others (2013) describe 12 key functions of m-health 
(and e-health tools more generally). All of these are rele-
vant to TB care:
 1. Client education and behavior change communica-
tion (short message service reminders to take medi-
cation or attend appointments)
 2. Sensors and point-of-care diagnostics (attachments 
for microscopy)
 3. Registries and vital events tracking (community case 
finding and registration) 
 4. Data collection and reporting (research data collec-
tion; Fraser and others 2012)
 5. Electronic health (medical) records 
 6. Electronic decision support (information, protocols, 
algorithms, checklists) 
 7. Provider-to-provider communication (telemedicine 
consultations) 
 8. Provider work planning and scheduling (to help 
community health workers to manage their patients)
 9. Provider training and education (Web-based 
resources and video on mobile phone memory cards)
10. Human resource management (tracking activities, 
patient contacts, and location of community health 
workers)
11. Supply chain management 
12. Financial transactions and incentives.
New Technologies to Improve TB Information 
Management
Several recent e-health applications have addressed case 
finding. An m-health application was developed to assist 
nonclinical CHWs to screen patients in general medical 
clinics in Karachi, Pakistan (Theron and others 2015). 
Staff used the built-in interactive questionnaire to iden-
tify symptoms and signs of TB in patients who were 
coughing for two weeks or more. In the intervention area 
overall, notification of TB cases to the national TB pro-
gram increased from 1,569 to 3,140 cases between 2010 
and 2011. Increasingly, CHWs in rural communities 
in LMICs are using m-health applications to find 
unknown patients with TB and other diseases (Were and 
others 2009).
Some groups have developed Web-based electronic 
medical record (EMR) systems for managing drug- 
resistant TB (Fraser and others 2013). EMRs were one of 
the first e-health applications for managing TB. Partners 
In Health developed and deployed a Web-based medical 
record for managing MDR TB in Peru in 2001, with 
tools to allow clinicians to view trends in lab data and 
changes in medications as well as to create reports for the 
national TB program and funders (Fraser and others 
2002). The system was also used to collect core data for 
subsequent research studies after additional data collec-
tion and cleaning. Image data of chest X-rays captured 
with a digital camera were included for most patients, 
and psychiatric records were added later. The system was 
extensively evaluated to determine its performance and 
potential impact on quality of data and delivery of care 
(Fraser and others 2006). 
From 2000 onward, Peru scaled up the individualized 
treatment of drug-resistant TB, including upgrading 
laboratory facilities at local, district, and national levels. 
Two e-health systems were implemented as part of Peru’s 
system. The first was an early m-health application to 
assist staff in collecting smear and culture data from 98 
small clinics in northern Lima. The system reduced the 
median processing time for cultures from 23 days to 
8 days and for smears from 25 days to 12 days and signifi-
cantly reduced the number of errors. The intervention 
reduced the number of work-hours necessary to process 
results by 70 percent and was preferred by all users. 
Blaya and others (2007) evaluated a Web-based labo-
ratory management and reporting system, eChasqui, also 
in Lima, in a large random control trial of 1,671 patients 
in 44 clinics, 12 of which were randomized to receive 
initial access to the system. Error rates (mainly missing 
results) fell 87 percent for cultures and 82 percent for 
DSTs. Delays for cultures were reduced from a median of 
8 days to 5 days and for DSTs from a median of 17 days 
to 11 days. In addition, the time to culture conversion fell 
20 percent (Blaya and others 2014). Results similar to 
those seen here in TB patients have been replicated for 
other diseases, particularly HIV/AIDS (Amoroso and 
others 2010; Siedner and others 2015). 
Several EMR systems have been developed to assist in 
the management of MDR TB, including eTB manager, 
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initially developed in Brazil and now deployed in many 
countries (Fraser and others 2013).
In 2008, a new EMR system was developed for MDR 
TB care based on the open-source EMR system 
OpenMRS platform (Mamlin and others 2006). The 
OpenMRS-TB system provided similar functionality to 
Peru’s EMR, but was embedded in a general-purpose 
EMR platform that was also used to support a range 
of clinical care, including HIV/AIDS, primary care, 
maternal health, and oncology. It has been deployed 
in Haiti, Indonesia, Pakistan, and several African 
countries. A version of OpenMRS-TB was created and 
deployed in Peru for a large epidemiological study 
of MDR TB (Fraser and others 2012). A new version of 
OpenMRS-TB is currently under development for clin-
ical and research purposes in a collaboration between 
Partners In Health, Médecins Sans Frontières, and 
ThoughtWorks. OpenMRS has been developed as 
open-source software and also supports open stan-
dards for the coding of medical data. OpenMRS is now 
used to support the care of patients in more than 40 
LMICs (Mohammed-Rajput and others 2011; Seebregts 
and others 2009), with versions to support the manage-
ment of HIV/AIDS, maternal-child health, and, more 
recently, heart disease and primary care. 
The design of OpenMRS offers some advantages for 
the development of research data management tools. 
Due to the focus on safe collection, storage, and man-
agement of clinical data, it includes auditing of data 
changes in the main database tables. This feature allows 
tracking of the history of changes in data items linked 
to the login of the user. OpenMRS is designed around 
a flexible data dictionary, called the concept dictionary, 
which allows new data items to be added without 
changing the underlying structure of the database. The 
dictionary simplifies the translation and maintenance 
of items in additional languages like Spanish and has 
led to the development of a core dictionary mapped to 
coding standards such as ICD-10 and SNOMED-CT 
and shared by most users of the system. A major 
advantage of OpenMRS from a developer’s perspective 
is its modular software architecture, which allows 
software modules, either from the OpenMRS module 
library or newly developed modules, to be plugged into 
the main system, adding functions without changing 
the core system. 
Telemedicine to Support Health Workers 
While clinics can generally manage the DOTS protocols 
for treating drug-sensitive TB, management of drug- 
resistant TB can be complex, especially for patients with 
second-line resistance, including XDR TB. Expertise in 
managing such patients is limited, which is one of the 
reasons why only a minority of patients receive fully 
effective treatment. Telemedicine is a potential strategy 
to support clinicians with limited knowledge of these 
complex treatment protocols. This can be as simple as an 
e-mail question to a specialist for advice on a specific 
patient’s drug regimen and resistance or a video confer-
ence with both clinicians and the patient. Many projects 
use “store and forward telemedicine” typically involving 
e-mailing text and attached images (Della Mea 1999). 
Studies have shown that even modest-specification 
digital cameras can capture images of chest X-rays good 
enough for diagnosis and management of TB (Szot and 
others 2004).
Telemedicine approaches often work well in small- 
scale projects but are difficult to scale up. Individual 
e-mails are not suitable for large numbers of referrals 
due to the difficulty of ensuring that all of the correct 
information is recorded accurately in the referral and the 
resulting assessment is recorded in the patients’ notes. 
A more effective approach is to share data in a secure, 
Web-based EMR system like Peru’s EMR, OpenMRS-TB, 
or eTB manager (Fraser and others 2013), giving the 
remote specialist access to the individual patient’s record. 
The remote specialist can see the full range of clinical 
data, lab results, and often imaging and record an assess-
ment directly in the clinical record. Another challenge 
with scale-up is that clinical expertise is limited and 
cannot be “spread too thin.” A more effective and scal-
able strategy can be to use telemedicine as part of 
training initiatives (Geissbuhler and others 2003), along 
with better clinical guidelines and decision support for 
local staff.
SMS Reminders to Improve Adherence
With the importance of achieving good adherence for 
managing TB and preventing the emergence of drug 
resistance, there is great interest in tools and strategies 
to improve adherence. DOT is the best-established 
approach, but questions have been raised about its scal-
ability and cost. With mobile phones widely available in 
LMICs, m-health may provide tools to support treat-
ment adherence. Most work has focused on improving 
adherence to ART with text messages or interactive voice 
prompts, with evidence of improvements in adherence 
in some random control trials (Lester and others 2010; 
Pop-Eleches and others 2011), but also some negative 
results (Cameroon, India).
Analysis of these studies suggests that messages cus-
tomized to each patient and the ability of patients to 
communicate with actual staff (not just automated 
prompts) improve adherence. To date, these tools have 
not matched the adherence rates of effective DOT, and 
there is evidence of messaging fatigue among patients. 
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Further work is under way to design interventions based 
on established psychological models of behavior change 
accompanied by rigorous evaluation.
Information Technology to Manage Supply Chains 
An additional challenge for managing drug-resistant TB 
has been establishing effective medication supply chains, 
and information systems are increasingly important for 
forecasting requirements, tracking medication shipments, 
and managing inventory at clinics. 
Lack of supply of second-line TB medications is a key 
factor in poor scale-up of treatment. While first-line 
drugs are low cost and generally widely available, second- 
line drugs are mostly used for drug-resistant TB and often 
manufactured to order. Orders have to be placed months 
in advance to ensure continuity of care, and accurate 
forecasting is essential. Information systems can assist in 
multiple steps in this process, including forecasting, 
ordering, tracking shipments, and managing inventory. 
In Peru, the EMR was used to forecast medication 
requirements for treating drug-resistant TB. Combining 
data on the number of patients enrolled, their length of 
time in treatment, recruitment rate, and current regi-
mens resulted in error rates of 3 percent or less for more 
than 1,000 patients in both 2003 and 2004 (Fraser and 
others 2013). A related study looked at forecasting med-
ication for 68 patients in the same cohort and compared 
that to the usual manual methods. In one study, Peru’s 
EMR predicted 99 percent of one year’s needed supply 
of medicines, while more manual methods predicted 
149 percent (Fraser and others 2013). 
New tools are becoming available for managing 
shipments and inventory in LMICs.4 One information 
system for drug-resistant TB, eTB Manager, includes 
inventory management for each clinic linked to require-
ments forecasting (Fraser and others 2013). These tools 
are now available for general use in drug forecasting. 
M-health tools are also being used to track inventory in 
local clinics in East Africa using text messages (SMS 
for Life) and have been shown to reduce stock-outs 
 dramatically for antimalarial drugs (Barrington and 
others 2010). They are also being used for TB medica-
tion. Other systems have been developed to detect coun-
terfeit medication in countries like Nigeria by allowing 
patients to text a unique code printed on the medication 
container to a free number.5 
As noted, the OpenMRS-TB EMR platform supports 
the management of a wide range of diseases and primary 
care. Its use of open standards for storing and exchanging 
data supports interoperability with other e-health sys-
tems, allowing systems with a range of functionality to 
be linked together—for example, EMR systems, labora-
tory information systems, pharmacy systems, m-health 
applications, and national reporting systems, such as the 
District Health Information System (DHIS 2). 
Such e-health architecture approaches are being 
deployed in several LMICs, including Bangladesh, India, 
Kenya, the Philippines, and Rwanda. Many countries 
have now adopted the DHIS 2 to collect, manage, and 
report on health data at the district and national levels. 
The system can take direct feeds of data from systems 
such as OpenMRS and some m-health applications, 
improving the accuracy and timeliness of data. 
Embedding the specialized data collection and analysis 
tools for TB care in broader e-health systems has large 
benefits, such as facilitating case finding through primary 
care visits and lab data, identifying potential risk factors 
like diabetes, maintaining a complete and accurate list of 
medications, and providing effective decision support 
based on the sharing of all key data.
Further evaluation is needed on the performance of 
e-health systems in LMICs as well as the clinical impact 
on TB management. In addition, there are only limited 
data at present on the costs of deploying such systems 
and maintaining good performance and usage levels in 
the long term (Blaya, Fraser, and Holt 2010). There is, 
however, some evidence that effective EMR and labora-
tory information systems can save money in LMICs by 
reducing errors and waste and speeding patient manage-
ment (Driessen and others 2013). It is also very likely to 
be more cost-effective to embed TB management tools in 
existing e-health systems than to run parallel systems.
RESEARCH AND DEVELOPMENT
In addition to requiring new care delivery and health 
system strategies, turning the tide against TB will likely 
require technological advances that could accelerate cure, 
reduce transmission and incidence, and prevent disease. 
Despite the effectiveness of standard drug regimens for 
drug-sensitive TB, resistance is increasing, compliance 
with long treatment times is problematic, and new drugs 
and regimens are needed. 
Current TB therapy has many advantages: the stan-
dard drugs are remarkably safe, with little toxicity even 
in vulnerable populations such as pregnant women and 
children; a complete course is highly effective against 
drug-sensitive disease; and the drugs themselves are 
affordable in the poorest parts of the world. Despite 
these advantages, first-line drugs are ineffective against 
multidrug-resistant strains. And rifampin, perhaps the 
most effective agent in the current first-line therapy, has 
pharmacologic interactions with many other drugs, 
most notably HIV/AIDS protease inhibitors taken by 
many co-infected individuals. 
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The most important limitation of the current regi-
men is the extended time required for effective therapy. 
“Short course” chemotherapy is anything but short; 
failing to complete six months of treatment leads to 
significant rates of relapse. Because patients feel better 
in a matter of weeks, they often have little motivation 
to continue taking their medications. In addition, the 
extended course means that a substantial investment 
is needed to ensure a continuous drug supply. These 
requirements add substantially to the cost of what 
otherwise would be an inexpensive undertaking. This, 
together with the training and logistics necessary 
to ensure adequate DOTS implementation, has led to 
remarkably poor results and continued treatment 
failure, leading to millions of deaths each year. Thus, 
the challenge is to develop not just new drugs, but 
ideally new drug regimens effective in treating drug- 
sensitive and drug-resistant TB and shortening the 
time of treatment.
Better drugs and regimens could have a substantial 
impact. To be most useful, they would have the following 
attributes:
• Rapid activity, shortening the course of therapy 
required for cure
• Safety, allowing use in a wide range of patients with-
out requiring substantial prescreening
• Easy administration, preferably oral, so that health 
professionals are not required
• Limited interactions with other drugs, particularly 
antiretroviral drugs
• Limited cost, making them affordable in the poorest 
parts of the world.
There are two general paths to achieving these goals: 
optimizing the use of currently available medications 
and developing completely new drugs. Phase III clinical 
trials are expensive and will always be rare. It will likely 
be impossible to test each new drug serially.
Given the enormous cost of developing new drugs 
(the average cost of developing a new drug to licensure is 
on the order of US$1 billion or more), the former is the 
most attractive path to making rapid changes to recom-
mended therapy. 
Optimizing the Use of Current Medications
Is it possible to reconfigure the current drug regimen to 
produce better efficacy against a broader range of 
organisms? The evidence so far is mixed. Animal 
studies and human pharmacokinetic observations have 
suggested some modifications of TB drug therapy 
that might produce better results. For example, many 
patients who receive rifampin at recommended doses 
have low serum levels. Increasing the dosage of rifam-
pin or using a different rifamycin might enhance the 
clearance of infection. Several studies are looking at 
altered dosing regimens for rifampin or substitution 
of the long-acting drug rifapentine. As measured by 
a surrogate endpoint— culture conversion at two 
months—rifapentine is no better than rifampin. In 
multiple short-term controlled trials that included flu-
oroquinolones to shorten therapy, the failure rate of 
cures at two to four months was unacceptably high. 
None of those shortened regimens was effective enough 
to offer substantial advantages in treatment (Gillespie 
and others 2014; Jindani and others 2014; Merle and 
others 2014).
The fluoroquinolone trials were phase III studies 
designed to permit U.S. Federal Drug Administration 
(FDA) approval for these regimens, if successful. 
Performing such a trial is an enormous undertaking. The 
current treatment regimen is highly successful in 
some patients, with a less than 5 percent relapse rate 
in most settings. Showing improved efficacy requires an 
enormous number of patients, which is why the fluoro-
quinolone study was designed to show noninferiority, a 
criterion that does not require the same level of evidence. 
Nevertheless, these studies require thousands of patients 
to provide confidence in the results and investments in 
infrastructure in the low-income settings where the trials 
are conducted, making them extremely expensive and 
logistically challenging. 
To mitigate the costs associated with such trials, 
some studies are experimenting with alternative trial 
designs. For example, one study investigated the efficacy 
of the oxazolidinone linezolid. Instead of recruiting 
patients with drug-sensitive disease, these investigators 
studied patients with MDR TB, a group where success 
rates are historically lower (Gler, Skripconoka, and 
others 2012; Lee, Song, and others 2015). They com-
pared regimens that had been individually designed for 
each patient with the same regimen plus linezolid. This 
study showed a faster rate of clearance of bacteria and a 
lower relapse rate in the linezolid-treated patients, sug-
gesting that this drug has properties that might allow 
a shorter regimen, at least in this setting. However, 
linezolid treatment was associated with very high 
levels of toxicity, far higher than could be tolerated by 
patients with drug-sensitive disease. Still, this class 
of compounds shows promise. In another study, dela-
manid (OPC-67683), a nitro-dihydro-imidazooxazole 
derivative, was found to accelerate sputum clearance of 
Mtb by 45 percent in two months, somewhat better than 
standard treatment (30 percent). These studies suggest 
that the priority given to shortening treatment time to 
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sputum conversion may be compromising the need to 
assure cure and prevent treatment failure and relapse.
Finding New Treatments
Producing novel agents is in some ways superior to opti-
mizing the use of current drugs. The length of therapy 
cannot be shortened with current drugs. And because 
antibiotic resistance arises from mutations rather than 
acquisition of broad determinants of resistance, virtually 
all bacteria, including MDR TB strains, should be sensitive 
to completely new classes of antibiotics. These advan-
tages must be balanced, however, against the substantial 
costs involved in developing new drugs. Preclinical devel-
opment costs tens of millions of dollars, while complet-
ing all of the clinical studies necessary for drug approval 
can run into the hundreds of millions. And there are 
substantial risks along the way: only a small minority of 
compounds that enter clinical trials are approved; many 
more fail to make it into clinics. 
Nonetheless, new drug development for TB already 
has achieved some notable successes (Hoagland and oth-
ers 2016). Two new drugs have recently received approval 
for human use for MDR TB under certain conditions. 
Both bedaquiline and delamanid have been approved in 
Europe; bedaquiline also has received FDA approval. 
These agents have interesting and novel mechanisms of 
action. Bedaquiline, a diarylquinoline, inhibits bacterial 
adenosine triphosphate synthesis by directly blocking the 
adenosine triphosphate synthase complex. Delamanid, a 
nitroimidazole, is converted by bacterial enzymes to its 
active form, which may liberate toxic nitric oxide in the 
process. As predicted for drugs with new molecular 
mechanisms, there is little cross-resistance to existing anti-
biotics (although altered activity of an efflux pump 
might decrease the efficacy of both clofazimine and 
bedaquiline). It is not clear how these agents will be used. 
In rather small clinical trials, bedaquiline was effective, 
but patients who received the drug had higher death 
rates, largely after treatment was completed, for unknown 
reasons (Cox and Laessig 2014; Diacon and others 2014; 
Gupta and others 2015). Until more is known, bedaquiline 
use will likely be restricted to persons with drug-resistant 
TB (WHO 2013e). Less is known about delamanid and 
its optimal use at this point.
The path to obtaining approval for bedaquiline and 
delamanid is both interesting and illustrative. Both were 
tested in patients with MDR disease in much the way that 
linezolid was used, adding them to optimized therapies. 
Patients treated with the new drugs cleared infection 
significantly more rapidly and had lower rates of relapse 
when treatment was stopped. The small numbers in 
these trials provided the basis for “conditional” approval 
of both drugs for use in MDR infections. However, final 
approval and an expanded indication for drug-sensitive 
disease will require larger phase III trials. 
Several new regimens are currently undergoing testing 
in clinical trials. Like the fluoroquinolone trials, many of 
these target drug-sensitive TB with the aim of shortening 
the duration of therapy without compromising the rate 
of cure. As of this writing, trials are planned, enrolling 
participants, or under way that will test whether treat-
ment can be shortened to as little as two months using a 
variety of regimens. Of these, a phase III trial testing 
pretomanid/moxifloxacin/pyrazinamide (PaMZ) was 
the farthest along. However, the trial was put on hold due 
to unexpected toxicity, and its future is uncertain.
In addition to drugs that either have already been 
approved or are in late clinical trials, several preclinical 
compounds are undergoing development. These include 
both new members of existing classes, such as oxazolidi-
nones that might have less toxicity than linezolid, and 
completely new classes of compounds. Compounds with 
novel mechanisms of action are particularly attractive. 
Not only are they generally active against drug-resistant 
disease, but they may exploit pathways that could clear 
disease more rapidly. 
However, two issues have arisen with these new 
compounds. First, many compounds with antibacterial 
activity seem to target a very limited number of bacterial 
processes. These often induce cross-resistant mutations. 
Therefore, there is far less diversity than desired. Second, 
and perhaps more concerning, much remains unknown 
about the fundamental biology of infection. A principal 
goal of new drug development is to shorten the course of 
therapy. However, there are no in vitro correlates that 
confidently predict that an early-stage compound will 
result in more effective therapy. This presents a consid-
erable obstacle to the drug development process. And 
differences in the effectiveness of drugs between labora-
tory studies and patients question whether in vitro and 
animal models adequately predict the most effective 
compounds. 
Do standard markers of rapid clearance in clinical 
trials correlate with ultimate treatment success? It is 
likely that some drugs used in TB act more slowly and 
might not be seen to be effective in early bacterial clear-
ance studies and, conversely, that some drugs act rapidly 
but do not sustain their effects and control infection over 
the longer term. Without biomarkers for the state of 
viability and magnitude of the TB bacillus in the host, 
answering these questions will likely require large trials 
(Wallis and Nacy 2013). 
Even in the best of circumstances, serial testing of indi-
vidual drugs in large trials is unlikely ever to be affordable. 
Moreover, these drugs will never be used alone; instead, 
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they will always be used in combination with other drugs. 
And these combinations might be more (or, conceivably, 
less) efficacious than would be predicted for individual 
drugs. Indeed, experiments in animal models suggest that 
some drugs can act synergistically to effect much more 
rapid cure. This has led to the model of testing regimens 
rather than individual drugs. In this model, which 
has been advanced by the TB Alliance, new drugs would 
be tested and approved in combinations. While the 
characteristics of individual drugs might never be deter-
mined (and, in this model, would not necessarily be 
approved as individual agents), this strategy would pro-
vide a much more rapid and practical path to drug 
approval, albeit at the risk of missing information about 
individual agents.
Because of the cost of developing new drugs and 
regimens and the fact that the populations in greatest need 
are in LMICs, an enormous challenge remains: how can 
countries afford new more effective regimens, and how 
can the international community contribute to making 
them available to the populations that need them? 
Pharmaceutical companies have few private sector incen-
tives to invest in TB drug development or, more generally, 
in antibiotic development at present, and some sort of 
public-private mechanisms will need to be developed.
Developing New Vaccines 
In the past two decades, there has been a renewed effort 
to develop vaccines against TB that would provide 
greater protection than BCG. There are at least three 
strategies for contributing to TB control where vaccines 
are being tested in clinical trials. One strategy is to deter-
mine whether vaccines can prevent infection with TB 
(prevention-of-infection trial), in which IGRAs are used 
to detect infection by Mtb. A second is to test whether 
vaccines can prevent recurrence of TB or MDR TB after 
treatment (prevention-of-recurrence trial) or possibly 
be used therapeutically with chemotherapy to accelerate 
cure. Finally, the ultimate goal is large-scale immuniza-
tion for prevention of disease (POD). About 40 vaccine 
candidates are at various stages of preclinical testing, and 
15 vaccine candidates are currently in clinical trials 
(Jiménez-Levi 2012).
Among the candidates in the pipeline (Evans and 
others 2013) are (1) recombinant vaccine candidates 
expressing Mtb antigens in BCG, adenovirus, cytomeg-
alovirus (CMV), or other vectors; (2) genetically attenu-
ated whole-cell Mtb strains, lacking either virulence 
determinants or ability to replicate; (3) and a variety of 
subunit protein antigen candidates with adjuvants that 
would be used as boosters in children or adolescents 
primed with BCG. All of these vaccines are being tested 
in preclinical studies in experimental animals, and some 
are being tested in nonhuman primates. 
The scientific basis for development of any effective 
vaccine includes (1) significant understanding of immu-
nological mechanisms of protection against infection 
or disease; (2) molecular correlates of mechanisms that 
would diminish the need for large, multiyear efficacy 
trials; (3) definition of Mtb antigens that engender those 
protective mechanisms; (4) means of delivering those 
antigens that generate or prime for protective rather 
than pathogenic responses; and (5) animal models that 
are more predictive of protection in humans than cur-
rent models appear to be. None of these criteria has been 
met for any TB vaccine candidate at present. 
Several special considerations are necessary in vaccine 
testing. Since vaccines, in contrast to most drugs, are 
given to healthy children or adults, their safety must 
be the foremost concern. In addition, they need to be 
tested in places with a high TB burden that have labora-
tories capable of analyzing the immune correlates of 
protection; they cannot compromise the ability to test for 
infection with Mtb in IGRAs; and the preexposure to 
environmental mycobacteria in places where they are 
tested cannot compromise detection of protection. 
From animal studies and human Mendelian genetic 
studies, it appears that both CD4+ and CD8+ T-cells and 
IFN-γ, TNF-α, and other cytokines are necessary to pro-
tect against disease (Modlin and Bloom 2013; O’Garra 
and others 2013). The challenge is to learn what responses 
are sufficient for protection. It is unclear how faithful 
small animal models of TB will be to the human 
response to vaccine candidates. There is hope that non-
human primates may be the most predictive model of 
human protection. Human vaccine trials showing at 
least partial protection may be the only way to establish 
those conditions. The first new candidate, MVA85A, 
expressing a major Mtb antigen, 85A, in modified vac-
cinia Ankara vector, was tested in more than 3,000 South 
Africa infants in a well-executed phase IIb trial (Tameris 
and others 2013). The candidate, which was reported to 
induce IFN-γ and engender some protection in four 
animal species, failed to protect children against either 
infection or disease. 
BCG is known to induce Th1 T-cells and a number of 
cytokines—for example, IFN-γ, TNF-α, IL-12—that, 
in animal models and in human Mendelian genetic 
deficiency studies, appear to be necessary for protection 
against TB. However, the immunological factors that are 
sufficient to engender protection are not yet understood 
(Modlin and Bloom 2013). It is very unlikely that 
large-scale trials of new vaccines, such as the South India 
trial, which followed 360,000 people for 15 years and 
failed to show protection in any age group, will soon be 
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undertaken for new candidate vaccines. Thus, there is an 
urgent scientific need to develop molecular “correlates 
of protection” that can be measured in small numbers of 
recipients, that will predict which new vaccine candi-
dates are likely to protect against infection and disease, 
and that will identify which individuals are likely to 
remain susceptible or relapse after treatment. In the 
absence of molecular markers of protection—for 
example, either involved in protecting against infection 
or preventing latent TB from progressing to active 
disease—serious consideration will have to be given to 
the development of a safe, attenuated, but live genetically 
engineered Mtb challenge. This development could be as 
valuable to TB vaccine development as live challenges 
have been in malaria and enteric vaccines. 
Modeling the impact of possible new TB vaccines has 
been enormously valuable. It has shown that, because 
children contribute little to transmission, giving a more 
effective vaccine than BCG only to infants and children 
would have little effect on the epidemic (Knight and 
others 2014). Modeling suggests that, in high- endemic 
countries, vaccinating adolescents, who were the recipient 
population found to be highly protected (about 
80 percent) in the original trials of BCG and M. microti 
in the United Kingdom (Hart and Sutherland 1977; 
Sutherland and Springett 1987), would be more effec-
tive than vaccinating infants. Immunizing or boosting 
adolescents just before they enter the age of highest 
risk would likely have the greatest impact on the 
disease burden. 
Because of the need to immunize large numbers 
of people in a general population to obtain enough statis-
tical power to establish vaccine efficacy, the approach of 
the field is to test smaller numbers of individuals in high- 
burden countries to learn about immunological parame-
ters that may correlate with protection. For example, an 
experimental trial with a small targeted population could 
ascertain whether immunization could prevent reinfec-
tion and relapse (at the end of treatment). Targeting 
vaccines to a group of treated patients would shorten the 
time to learn whether there was an effect on relapse and 
reduce the costs and time required for disease prevention 
trials in large populations. It is remarkable how little 
research has been devoted to combining chemotherapy 
and immunotherapy in TB.
Understanding the Immune Mechanisms Necessary 
and Sufficient for Protection
Current thinking is that a single vaccine given at birth is 
unlikely to provide sufficient protection to prevent dis-
ease in adults, who have the highest risk of developing 
disease. Because the duration and costs of vaccine efficacy 
trials are great, several strategies are being developed to 
gain insights into the critical immune mechanisms neces-
sary for protection in humans. Testing vaccine candidates 
in TST-negative individuals and evaluating their ability 
to prevent infection as measured by IGRAs could be 
accomplished in a shorter time than disease prevention 
trials. As discussed, vaccinating patients at the comple-
tion of drug treatment to prevent relapses or reinfection 
in high-burden areas could provide information in as 
little as one to two years. In all such trials, it will be essen-
tial to study multiple molecular and immunological 
markers to develop correlates of protection. Finally, the 
most promising candidates need to be tested in small 
groups of volunteers to understand which of the different 
mechanisms each candidate engenders, which are likely 
to correlate with protection, and which can be used as 
biomarkers for protection. Here innovative trial designs, 
such as matched-pair randomized trials, could provide 
power and information with much fewer volunteers 
(King and others 2009).
Relevant are the older studies indicating that latent 
TB seems to engender persisting immune responses that 
afford significant protection from disease (Andrews and 
others 2012), when compared with the risks of reinfec-
tion of TB patients who have been cured (Middelkoop 
and others 2015). This raises the concern that, if chemo-
therapy kills most of the Mtb organisms, the susceptibil-
ity of people successfully cured of TB will revert back to 
that of naïve individuals. This suggests that the immu-
nologic value of latency may lie in the persistence of 
the pathogen and microbial antigens. Thus, the duration 
of protective immune responses engendered by new 
vaccines may be critical to protecting against reinfection 
and relapse. These findings reinforce the approach of 
vaccinating or revaccinating individuals who have been 
“cured” by treatment to test whether vaccination will 
reduce the incidence of relapse or reinfection.
Since BCG is the most widely used vaccine in the world, 
particularly in high-burden TB countries, the most likely 
vaccine strategy will be priming with BCG or another 
whole-cell candidate in early childhood and boosting with 
a live attenuated TB vaccine, a vaccine with Mtb antigens 
expressed in a viral vector (such as an adenovirus or CMV), 
or a subunit vaccine containing multiple epitopes plus an 
adjuvant. Particularly exciting are new vaccine platforms 
that offer the possibility of generating long- enduring 
immune responses to Mtb antigens, including recombi-
nant BCG vaccines designed to engender both CD4 and 
CD8 T-cells (Kaufmann and others 2014), attenuated TB 
vaccine (Spertini and others 2015), attenuated recombi-
nant CMV vectors (Hansen and others 2013), and mRNA 
(messenger ribonucleic acid) vaccines (Chahal and others 
2016; Petsch and others 2012). Clearly, vaccine trials 
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comparing multiple candidate vaccines in phases II and III 
are enormously expensive and time-consuming (on the 
order of US$50 million per trial over a period of three to 
five years). This is why there is an urgent need to define 
molecular or immunological correlates of protection that 
would enable the up-selection of the most promising can-
didates from small-scale human studies. 
An alternative being pursued is developing a safe, 
genetically engineered Mtb live challenge strain that 
could persist long enough to enable rapid assessment of 
the effectiveness of a vaccine to induce killing of the 
challenge strain, but totally lacking the potential to cause 
disease. With phase I human studies in a small number 
of individuals, the ability of a vaccine candidate to kill 
the challenge strain would support conducting a small 
number of phase II and phase III clinical trials to test the 
efficacy of a particularly effective vaccine candidate 
against TB infection and disease. Historically, all vaccines 
have been iterative processes with continuous learning 
and improvements. The development of biomarkers of 
protection that would enable identification of the most 
promising candidates for large clinical trials would pro-
foundly accelerate TB vaccine development. 
Effective new vaccines are essential for TB control, yet 
their development, testing, and regulatory approval 
require many years and considerable investment. The 
slow decline in TB incidence globally, especially in 
high-burden countries, even as mortality and prevalence 
are declining, compels us to recognize the serious possi-
bility that tuberculosis may not be controlled without a 
protective vaccine.
FINANCING FOR TB PROGRAMS
The WHO estimates that funding for prevention, diag-
nosis, and treatment of TB reached US$6.6 billion, of 
which US$5.3 billion was for diagnosis and treatment of 
drug-susceptible TB and US$1.8 billion was for MDR 
TB (WHO 2014b). Of those funds, 84 percent derives 
from domestic sources, which vary across countries 
(WHO 2016a). 
In 2014, development assistance allocated US$1.4 
billion to TB (IHME 2015), a drop of 9 percent from 2013, 
two-thirds of which came from the Global Fund. The 
WHO estimates the shortfall in funds necessary to expand 
TB programs at about US$2.0 billion (WHO 2016a). The 
Global Fund is the single largest funder of TB assistance 
globally committing about 55 percent of its funds to HIV/
AIDS, 27 percent to malaria, and 18 percent to TB (IHME 
2015). Yet financing from the Global Fund represents 
about 50 percent of all current development assistance for 
health devoted to TB. The United States does not have a 
separate entity for funding TB as it does for HIV/AIDS 
and malaria, instead channeling half of its US$500 million 
in TB assistance through the Global Fund; the remainder 
is channeled bilaterally. In 2014, the Bill & Melinda Gates 
Foundation provided about 12.6 percent of all develop-
ment assistance for health dedicated to TB. Other govern-
ment donors were the United Kingdom (7.7 percent), 
France (7.0 percent) Germany (5.1 percent), Japan (3.4 
percent), Canada (4.7 percent), and Australia (2.2 percent) 
(IHME 2015). Of these funds, about 78 percent were 
provided through the Global Fund. 
The WHO estimates that the level of funding required 
to enable a comprehensive approach to controlling TB 
would be on the order of US$8.8 billion, two-thirds of 
which would be for diagnosis and treatment of drug-
susceptible TB and 20 percent for drug-resistant TB 
(WHO 2016a). This figure does not include the costs of 
research needed to develop new drugs, vaccines, and 
diagnostics, which the WHO estimates would require an 
additional US$2.0 billion.
Given the magnitude of the TB epidemic, the emer-
gence of MDR and XDR TB, and the need to strengthen 
health systems for TB, a greater level of funding will be 
required to extend current efforts and enable the new 
approaches recommended here to reduce incidence and 
transmission of the disease dramatically (figures 11.8 
and 11.9). A summary of the latest 2015 recommenda-
tions of the Copenhagen Consensus Center, a consor-
tium of international economists, suggested that 
additional investment in TB would represent a good buy 
(Economist 2015). For every US$1 invested, the return 
was estimated to be US$43. Were US$2 billion invested to 
cover the shortfall, the potential economic savings could 
Source: WHO 2015b.
Note: TB = tuberculosis; HIV = human immunodeﬁciency virus; MDR = multidrug-resistant.
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be on the order of US$300 billion (Lundgrun 2015). But 
despite increases in domestic and international financ-
ing, the WHO estimates the current funding gap to be 
US$2.0 billion for extending current measures and an 
additional US$1.3 billion for research and new technolo-
gies. That leaves a funding gap of US$2.7 billion per year 
to assure a full response to the TB epidemic.
ECONOMIC ANALYSES AND 
COST-EFFECTIVENESS 
As the pipeline for new TB diagnostic technologies contin-
ues to expand, health and economic evaluations are needed 
to inform decisions about the most promising options to 
pursue in different settings and patient populations. 
Economic evaluation of new diagnostic approaches can 
seem deceptively simple, but several factors should be con-
sidered if these evaluations are to provide credible and 
useful guidance for policy. These factors pertain both to 
quantifying potential impact and to estimating costs. 
First, it is important to consider the pathway(s) by 
which new diagnostics are expected to lead to improved 
health outcomes. For instance, aspirations for new point-
of-care diagnostics point to the benefits of returning 
rapid test results, which can reduce loss to follow-up by 
eliminating the need for a return visit. Quicker diagnosis 
may increase the rate of initiating treatment, improve 
patient outcomes, and reduce transmission by decreasing 
the period of infectiousness. However, imperfections in 
implementation may cause real-world application to fall 
short of the maximum theoretical potential. 
Moreover, evaluating the impact and cost- effectiveness 
of a new approach requires comparing the new approach 
to the status quo that it will displace. For example, a 
comparative evaluation of a new diagnostic approach 
should specify (1) where the diagnostic will be used (for 
example, only in central facilities such as district hospi-
tals or also in peripheral health centers); (2) the sequence 
of tests and associated responses that will guide decision 
making in different types of individuals or be based on 
particular population-level factors (for example, in indi-
viduals with HIV/AIDS or a history of treatment or in a 
setting with a particular population-level HIV/AIDS 
prevalence); and (3) the current diagnostic approach in 
these settings that constitutes the status quo comparator 
(that is, the extent to which bacterial culture or drug-
sensitivity testing is currently being used).
It is also crucial to estimate the costs associated with 
scale-up and implementation, which are often signifi-
cantly greater than the costs of the commodities per se 
or even the costs including other health care services 
that are consumed at the patient level (for example, the 
opportunity costs of provider time). At the simplest 
level, scaling up new technologies often involves econo-
mies (or costs) of scale that relate to the shape of the 
average cost function in relation to the quantity, which 
reflects different mixtures of fixed and variable costs 
at different scales. At a more complex level, achieving 
population coverage requires paying attention to health 
system capacity, reflecting constraints not only on the 
budget but also on infrastructure and human and other 
resources. The validity of cost-effectiveness estimates 
depends on quantifying the costs of delivering an inter-
vention or strategy in a way that is consistent with the 
benefits ascribed to that intervention or strategy. Many 
published studies fail to meet this requirement. 
With regard to diagnostic approaches, important ques-
tions should be addressed regarding patient pathways to 
care, how a new diagnostic technology or strategy will 
alter the pathways, and where delays or loss to follow-up 
may occur, particularly as these might attenuate the 
expected benefits of a diagnostic. In HIV/AIDS, consider-
able attention has recently been given to the so-called 
“cascade of care,” and similar considerations are highly 
salient to tuberculosis control interventions, including 
those relating to diagnosis (Subbaraman and others 2016). 
Cost-Effectiveness of Using Xpert MTB/RIF
Xpert MTB/RIF represents a significant technological 
advance in accelerating diagnosis of TB and MDR disease 
in many settings. However, it has significant limitations. 
Several studies have examined the cost-effectiveness of 
Xpert MTB/RIF in different LMICs. A cost-effectiveness 
study published in 2011 by Vassall and colleagues (2011) 
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and focusing on India, South Africa, and Uganda 
estimated that Xpert devices used in combination with 
smear would have an incremental cost-effectiveness ratio 
of between US$41 and US$110 compared to conventional 
use of smear plus clinical diagnosis. A 2012 modeling 
study (Abimbola and others 2012) estimated cost- 
effectiveness of Xpert at the regional level in Sub-Saharan 
Africa and found that Xpert would reduce mortality and 
lower overall costs. Another 2012 study focusing on 
screening with Xpert prior to initiating ART in HIV/AIDS 
patients (Andrews and others 2012) found much less 
favorable results, indicating that using Xpert would cost 
US$5,100 per year of life saved compared to the next most 
attractive strategy, which involved smear and culture. 
A third study from 2012 (Menzies and others 2012) exam-
ined the cost-effectiveness of Xpert in five Southern 
African countries and found a cost-effectiveness ratio of 
around US$1,000 per DALY averted. Other studies have 
shown smaller-than-projected benefits of Xpert.
Widely divergent results reflect the many challenges 
of evaluating new diagnostic technologies and point to 
several areas for further investigation, including the 
extent to which frequent empirical treatment would 
reduce the potential benefit of Xpert technology mea-
sured against a counterfactual of diagnosis based strictly 
on the results from smear microscopy. As dramatic 
scale-up of Xpert has been pursued in South Africa and 
other settings, other implementation challenges have 
come to light, including the high overall budgetary 
impact of seeking high coverage of Xpert, the feasibility 
of deploying Xpert at the point of care, inability to link 
Xpert findings to health information systems, and limits 
on the potential benefit of faster diagnosis arising from 
the failure to translate diagnostic improvements into 
faster initiation of treatment (Lawn 2015). 
New technologies that can be used at the point of care 
are needed, and portable devices (for example, GeneXpert 
Omni) are under development that can be used as a 
point-of-care diagnostic test. Nevertheless, expanding 
their capacity for drug-sensitivity testing against the mul-
tiple drugs used in secondary and tertiary drug regimens 
remains a daunting challenge. 
Cost-Effectiveness of Developing New Drugs and 
Regimens 
The public health case for investing in new TB drugs is 
clear (Zumla, Nahid, and Cole 2013), but the substantial 
cost of drug development remains a significant obstacle 
to progress. Even if the efficiency of new drug develop-
ment can be improved, new TB drug development is 
likely to remain a challenging investment decision for 
many years to come. 
The cost-effectiveness and affordability of first-line 
regimens for TB treatment have been long established 
(World Bank 1993), and attention has focused on explor-
ing the most cost-effective way to deliver treatment. 
For countries providing TB treatment through hospitals, 
studies have demonstrated the relative cost- effectiveness 
of ambulatory treatment (Floyd, Wilkinson, and Gilks 
1997; Vassall and others 2002; Vassall and others 2009). 
Economic analysis in other settings has focused on 
delivering care through community structures (Floyd 
and others 2003; Moalosi and others 2003; Nganda and 
others 2003) and ensuring effective cooperation with the 
private sector (Floyd, Arora, and others 2006; Pantoja, 
Floyd, and others 2009; Pantoja, Lönnroth, and others 
2009). Although these studies demonstrate feasible and 
cost-effective approaches to delivering TB treatment, the 
high costs of delivering relatively long antibiotic therapies 
in poorly resourced health systems is a concern, as are the 
high default rates in some settings (Kruk, Schwalbe, and 
Aguiar 2008). These concerns are heightened by evidence 
of the substantial economic and poverty impact of TB 
treatment on patients (and households), with numerous 
studies finding that the multiple health service visits 
required can have a severe impact on the economic 
welfare of TB patients (Barter and others 2012). 
The current approach to the treatment of MDR TB 
presents a particular challenge from an economic per-
spective. Several studies (Floyd and others 2012; Resch 
and others 2006; Suarez and others 2002; Tupasi and 
others 2006) have suggested that the treatment of MDR 
TB is cost-effective. A recent systematic review found that 
the cost per DALY averted was lower than gross domestic 
product per capita in all 14 of the WHO subregions con-
sidered (Fitzpatrick and Floyd 2012). However, the abso-
lute price of second-line drug regimens, even for LICs, 
can run into the thousands of dollars, with a three- or 
fourfold burden on total costs of the health system. For 
example, in South Africa, treating MDR TB costs more 
than half of the total national budget for TB control 
(Schnippel and others 2013), with hospitalized treat-
ment costing more than US$15,000 per person treated 
(Pooran and others 2013; Schnippel and others 2013). 
However, these costs may be substantially reduced 
given the efforts to decentralize MDR TB treatment and 
care. Also potentially cost-effective, the cost of drug- 
susceptibility testing required to confirm a diagnosis of 
MDR TB treatment can also be substantial (Acuna-
Villaorduna and others 2008; Floyd and others 2012), 
and, as highlighted in previous sections, culture- based 
DST provides a substantial practical challenge in settings 
with limited laboratory capacity. Additionally, the eco-
nomic burden of MDR TB on households may be sub-
stantially higher than the costs of first-line treatment 
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and is likely to be catastrophic (Ramma and others 2015; 
survey of MDR TB patient costs in South Africa, unpub-
lished data). 
In light of these challenges, increasing attention is 
being placed on developing low-cost models of MDR TB 
diagnosis and treatment for scale-up—for example, new 
ambulatory models of care (Sinanovic and others 2015; 
Weiss and others 2014). In short, although the current 
approaches to the treatment of both drug-susceptible 
TB and MDR TB are widely accepted to be cost-effective, 
the relatively high cost of treatment for both patients 
and health systems, the cost of DST, the high levels of 
default, and the limited effectiveness of MDR TB treat-
ment in low- and middle-income health systems make a 
strong economic and public health case for investing in 
new TB drugs. 
In recent years, substantial investments have been 
made in clinical trials of new TB drugs and regimens 
(Hoagland and others 2016; Zumla, Nahid, and Cole 
2013). Candidate drugs affect treatment efficacy or effec-
tiveness and cost through different pathways, but the 
broad aim has been to improve one or more of the follow-
ing three dimensions: 
• Shorten the duration of treatment; trialed examples for 
first-line regimens include four-month moxifloxacin- 
based regimens (Gillespie and others 2014; Jindani 
and others 2014) and the Bangladesh regimen and 
bedaquiline-based regimens for MDR TB (Diacon, 
Donald, and others 2012). 
• Increase the efficacy of treatment, particularly for 
MDR TB; trialed examples include delamanid (Gler, 
Skripconoka, and others 2012) and bedaquiline 
(Diacon, Donald, and others 2012). 
• Develop regimens that are effective in both drug- 
susceptible and MDR TB. This will require new drugs 
for which drug resistance does not currently exist in 
most populations. 
In order to justify and support investment, various 
economic and modeling efforts have explored the poten-
tial gains from improving these dimensions of TB treat-
ment in terms of cost-effectiveness, direct effect on 
treatment success, broader impact on transmission, and 
patient and provider costs. In recent years, academic 
interest in both the investment in new drugs and these 
analyses has increased. At the time of writing, consider-
able work is ongoing, with much new work expected on 
the horizon. 
Shortening Treatment Regimens to Reduce Incidence
To date, modeling analyses of TB treatment have focused 
on the population-level health gains from investing in 
shortening treatment regimens. For example, examining 
first-line treatment, both Salomon and others (2006) 
and Abu-Raddad and others (2009) used a transmission 
model calibrated to the South-East Asia region and found 
a substantial impact on incidence due to the introduction 
of shortened regimens. Salomon and others (2006) found 
that a noninferior two-month first-line regimen would 
prevent around 13–21 percent of all new TB cases 
and 19–25 percent of TB deaths, depending on assump-
tions made regarding the scale-up of current regimens 
over an 18-year period. The study suggested that, if the 
cost savings generated by treatment shortening were 
invested in TB case detection, two- or threefold reductions 
in incidence might be possible. Abu-Raddad and others 
(2009) found that a four-month regimen with efficacy 
similar to that of the standard of care would achieve up to 
a 10 percent reduction in incidence over 35 years and a 
two-month regimen with increased efficacy would achieve 
a 23 percent reduction in incidence over the same period 
of time. A more recent effort by Fofana and others 
(2014) suggested a more modest, but still positive, impact, 
estimating a 3 percent reduction in incidence from 
a four-month regimen and a 7 percent reduction from a 
two-month regimen over a 10-year period. 
The analysis of the economic gains from treatment 
shortening has relied primarily on decision analytic 
models of patient cohorts. A study by Owens, Fofana, 
and Dowdy (2013) examined a hypothetical noninferior 
first-line regimen and explored trade-offs between drug 
price, treatment duration, and health system treatment 
costs for a cohort of new TB patients. This study found 
that a novel regimen with a four-month duration costing 
US$1 per day would at worst be highly cost-effective and 
at best be cost saving, depending on the current level of 
treatment costs. 
Ongoing work using an individual-based cohort 
model is exploring these trade-offs in specific country 
settings, using primary cost data from Bangladesh, Brazil, 
South Africa, and Tanzania (Zwerling and others 2016). 
This study found that, at the cost of US$1 per day, a four-
month noninferior first-line TB drug regimen would 
be cost saving in South Africa (reducing costs about 
10 percent) and in Brazil (reducing costs 20 percent), 
highly cost-effective in Tanzania (saving about US$120 
per DALY averted), but not cost-effective in Bangladesh. 
Even if new first-line drugs cost up to US$10 and US$58 
in South Africa and Brazil, respectively, using threshold 
analysis, Trajman and others (2016) found that the new 
TB regimen would be a cost-effective option compared to 
the standard regimen. This threshold price is US$0.97 in 
Bangladesh and US$1.13 in Tanzania (Zwerling and 
others 2016). In all settings, the impact on health would 
be modest and dependent on current default rates; 
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settings with higher health system and TB treatment 
delivery costs would have the highest gain. Unfortunately, 
the initial first-line regimens with potential regimen-
shortening effects coming out of trials in 2014 
(moxifloxacin-based regimens) failed to achieve adequate 
levels of cure, so these gains, at the time of writing, 
remain hypothetical.
Zwerling and others (2016) also drew attention to the 
importance of patient costs, with the largest savings 
achieved through reductions in the economic burden of 
TB treatment on households. Patient cost savings ranged 
from US$175 (South Africa) to US$45 (Bangladesh), 
depending on the setting. 
Improving Therapeutic Efficacy in Patients with 
MDR TB 
Compared to drug-resistant TB treatment regimens, 
much less research has been conducted on the potential 
cost-effectiveness and impact of new MDR TB regimens. 
In the last few years, two new MDR TB drugs (bedaqui-
line and delamanid) have come up for regulatory authority 
and programmatic approval by the WHO. As part of the 
process, an exploratory cost-effectiveness analysis was 
conducted using a decision analytic model of a cohort of 
new MDR TB cases (Vassall 2013). These analyses found 
both drugs to be potentially cost- effective, given their 
impact on efficacy. However, uncertainty around bedaqui-
line’s impact on mortality and, in the case of delamanid, 
the lack of randomization used when assessing long-term 
outcomes, combined with the potential cardiotoxic effects, 
have raised concerns. The DALYs averted varied by 
setting, with countries already having good outcomes 
benefiting less. However, increased efficacy, even without 
treatment shortening, also reduced costs in some cases, as 
the need for MDR TB retreatment and management of 
chronic cases was reduced. The results were less certain for 
LICs; because the potential benefits of increased efficiency 
for transmission were not included, no definitive conclu-
sion could be reached for these settings.
In the case of bedaquiline, the impact on cost- 
effectiveness of a shortened MDR TB regimen was also 
examined, given that the trial results suggested that time 
to sustained sputum conversion may be reduced (Vassall 
2013). Examining a reduction in treatment of two 
months, the cost-effectiveness analysis found cost sav-
ings at current drug prices. However, the extent of cost 
savings depended on the duration of hospitalization 
during treatment. The benefits in terms of DALYS 
averted were less clear due to the trade-off between the 
reduction in default and cure rates. Further trials, with 
an integrated economic analysis, are ongoing that 
test the use of bedaquiline as part of a nine-month MDR 
TB regimen, the STREAM (Standardized Treatment 
Regimen of Anti-Tuberculosis Drugs for Patients with 
Multi-Drug-Resistant Tuberculosis) Trial (Nunn and 
others 2014). In 2016, the WHO recommended the new 
shortened regimen, which offers the promise of both 
lower drug prices and lower health system costs, while 
being as effective as longer-course treatments (WHO 
2016b). Economic analyses are ongoing. 
Developing New Drugs for Treating Drug-Susceptible 
and MDR TB as First-Line Therapies
For the drugs discussed here, most of the work to date 
has explored the economic and health benefits of reduc-
ing the length of treatment and improving efficacy. 
However, new drugs or regimens that hold promise for 
treating both drug-susceptible and rifampicin-resistant 
TB also may have significant benefits. One example is 
PaMZ (Diacon and others 2010; Diacon, Dawson, 
and others 2012), a trial currently on hold. This new 
treatment regimen was assumed to have a dual benefit: a 
shortened first-line treatment for drug-susceptible 
patients (four months) with an efficacy noninferior to 
the current standard treatment and a shortened second- 
line treatment for patients with rifampicin-resistant TB 
(six months) with an efficacy noninferior to first-line 
treatment for drug-susceptible TB patients. In this case, 
introduction of the new regimen could result in substan-
tial cost savings (at least 35 percent reduction) from a 
societal perspective. The mean cost per presumptive TB 
patient was reduced by US$23 (28 percent) for health 
service treatment-related costs and US$42 (42 percent) 
for patient treatment-related costs in South Africa. 
When the introduction of PaMZ in a cohort of only 
rifampicin-resistant patients was modeled, both the 
reduction in costs and the gain in effect were greater. The 
clinical safety and effectiveness of this new regimen 
remains to be determined, but the economic modeling 
can be applied to any new regimen effective for treating 
both drug-resistant and drug-susceptible TB.
This model can be extended to explore the gains from 
a drug with the following optimal characteristics in all 
dimensions:
1. Short duration (two weeks maximum shortening) 
2. High efficacy (95 percent cure rate for drug-susceptible 
TB, 85 percent for rifampicin-resistant TB) 
3. Ability to treat all forms of TB (that is, with no circu-
lating resistance and no need for initial DST)
4. Drug price set at US$5 per day. 
Using the same model, Zwerling and others (2016) 
found that such a drug would be cost saving in a setting 
such as South Africa. Even with a comparatively high 
daily cost compared to current treatment, these authors 
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Table 11.7 Population Impact, Patient Impact, Cost, and Cost-Effectiveness of New Tuberculosis Drugs
Study and 
goal Regimen Setting
Time 
horizon
Impact 
(reduction) Cost Cost-effectiveness
Shortening treatment duration
Salomon and 
others 2006
First-line, 2 month South-East Asia 2012–30: 
18 years
13–21% incidence; 
19–25% mortality 
— —
Abu-Raddad 
and others 
2009
First-line, 4 month, 
noninferior to  
standard
South-East Asia 2015–50: 
35 years
10% incidence — —
First-line, 2 month, 
90% efficacy in drug-
resistant cases
23% incidence 
First-line, 10 days, 
90% efficacy in drug-
resistant cases
27% incidence
Fofana and 
others 2014
First-line, 4 month, 
noninferior to standard
First-line, 2 month, 
noninferior to standard
First-line, 2 weeks, 
noninferior to standard
Global, 
nonspecific
10 years 1.9% incidence; 
3.5% mortality 
4.3% incidence; 
7.5% mortality
6.7% incidence; 
13.1% mortality
— —
table continues next page
estimated a potential reduction of 51 percent of total TB 
diagnostic and treatment costs when modeling a cohort 
of 10,000 presumptive TB patients from a societal 
perspective. This is primarily a gain on the patient side, 
including a reduction in the direct costs of treatment 
and a more rapid return to full productivity. In this high-
HIV/AIDS-prevalence setting, there is a slight increase in 
ART-related costs (from the health service perspective) 
of 4 percent and an increase in DALYs averted of 
6.5 percent, primarily from a reduction in defaults and 
an increase in cure rates for persons with MDR TB. 
In summary, while much of the evidence on the poten-
tial economic and health benefits of investment in new TB 
drugs is based on models, emerging findings suggest that 
reducing the duration, improving the efficacy, and expand-
ing the range of use of TB regimens may have the potential 
for substantial economic and public health gains in most 
settings (table 11.7). In a field with no new drugs for the 
last half century up until the past five years, the biomedical 
and drug development challenges cannot be underesti-
mated, but new drugs are now being trialed, and much 
work refining and validating these nascent predictions is 
expected to emerge in the coming years.
Costs to Patients of TB Treatment 
For diagnosis and many months of treatment for TB, 
out-of-pocket costs can be catastrophic for patients and 
their families. Data on patient costs in LMICs are limited 
and incomplete. In a systematic analysis of 11 publica-
tions on patient costs in eight countries in Africa, 
Ukwaja and others (2012) estimated that mean patient 
prediagnostic costs varied between US$36 and US$196, 
corresponding to 10.4 and 35.0 percent of their annual 
income, respectively. Average patient treatment costs 
ranged between US$3 and US$662, corresponding to 
0.2–30.0 percent of their annual income. Prediagnostic 
household costs accounted for 13–18.8 percent of 
patients’ annual household income, while total house-
hold treatment costs ranged between US$26 and US$662, 
accounting for 2.9–9.3 percent of annual household 
income. Consequently, 18 percent to 61 percent of 
patients received financial assistance from outside their 
household to cope with the cost of TB care. Patient costs 
in South Africa for diagnosis and treatment of MDR TB 
were even more expensive: only 3 percent of patients 
were still employed, and disability grants were the 
primary source of income for 44 percent of patients 
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Table 11.7 Population Impact, Patient Impact, Cost, and Cost-Effectiveness of New Tuberculosis Drugs (continued)
Study and 
goal Regimen Setting
Time 
horizon
Impact 
(reduction) Cost Cost-effectiveness
Owens, 
Fofana, and 
Dowdy 2013
First-line, 4 month, 
noninferior to standard, 
US$1 per day
Global, 
nonspecific
Cohort 
lifetime 
7.9 DALYs averted 
(100 cohort)
Health service 
cost: cost saving to 
US$5,900 (2012)
Highly cost-effective to cost 
saving, depending on current 
treatment costs
First-line, 2 month, 
noninferior to standard, 
US$5 per day
14.6 DALYs averted 
(100 cohort)
Health service 
cost: cost saving to 
US$20,200 (2012)
Cost saving
Trajman and 
others 2016
First-line, 4 month, 
noninferior to standard, 
US$1 per day
South Africa Cohort 
lifetime
Equivalent effect 10% societal cost 
reduction
Cost saving
Brazil 20% societal cost 
reduction
Cost saving
Bangladesh 3.5% cost increase Not cost-effective (ICER: 997)
Tanzania Cost neutral Cost-effective (ICER: 120)
Increasing efficacy for MDR TB treatment
Vassall 2013 Bedaquiline China, Estonia, 
Nepal, Russian 
Federation, Peru, 
Philippines
Cohort 
lifetime
Varied by setting 
from 0.94 to 5.27 
incremental DALYs, 
depending on 
current treatment 
success
Varied by setting from 
US$823 to US$2,930, 
depending on ability 
to reduce retreatment 
costs
Varied from US$202 to 
US$2,042 per DALY averted; 
likely to be cost-effective in all 
settings except low income, 
but ICER highly uncertain, 
depending on assumptions 
regarding trial results
Vassall 2013 Delamanid China, Estonia, 
Nepal, Russian 
Federation, Peru, 
the Philippines
Cohort 
lifetime
Varied by setting 
from 0.94 to 1.65 
incremental DALYs 
depending on 
current treatment 
success
Varied by setting from 
US$757 to US$2,548 
Varied from US$501 to 
US$1,654 per DALY averted; 
likely to be cost-effective in all 
settings except low income, 
but ICER highly uncertain, 
depending on assumptions 
regarding trial results
Developing regimens that are effective in both drug-susceptible and MDR TB
Gomez and 
others 2016 
First- (4 month) and 
second-line (6 month), 
PaMZ, noninferior to 
standard for first-line 
and equivalent to 
first-line treatment of 
drug-sensitive TB for 
MDR patients, less than 
US$1 per day
South Africa Cohort 
lifetime
Equivalent effect 
estimated, 
presumptive 
TB cohort
16% increase in 
DALYs averted, 
MDR cohort
35% societal cost 
reduction
60% societal cost 
reduction
Cost saving
Cost saving
Future developments
Gomez and 
others 2016
Optimal: first- and 
second-line, 2 weeks, 
high efficacy, US$5 per 
day, no extra DST 
South Africa Cohort 
lifetime
6.5% increase in 
DALYs averted
51% societal cost 
reduction; 58.1% 
patient costs reduction; 
56.5% treatment costs 
reduction; no change in 
diagnosis costs 
Cost saving
Note: DALY = disability-adjusted life year; ICER = incremental cost-effectiveness ratio; MDR = multidrug resistant; TB = tuberculosis; PaMZ = pretomanid/moxiﬂoxacin/pyrazinamide; 
DST = drug-sensitivity testing; — = not available.
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(Ramma and others 2015). Many of the patients reported 
having no source of income before (56 percent) and 
during (47 percent) treatment. These costs were likely 
catastrophic for many patients.
Modeling the Impact of New Vaccines
The last decade has seen a significant increase in the level 
of investment in TB vaccine development: more than 
14 TB vaccine candidates have been tested in 50 human 
trials, with funding of more than US$600 million 
(Jiménez-Levi 2012). Despite the significant costs of 
vaccine development (Brennan and Thole 2012), the 
complex task of selecting vaccine candidates must now 
occur. Therefore, there is an effort to determine globally 
acceptable criteria for differentiating and subsequently 
maintaining the most promising candidates in the vac-
cine pipeline (Brennan and Thole 2012). 
Mathematical modeling can be used to differentiate 
candidates on the basis of the potential impact that 
different vaccine characteristics targeted at different pop-
ulation groups may have on the future TB burden. For 
example, modeling the impact of vaccines targeted at 
uninfected infants in South-East Asia has suggested that 
a novel  vaccine introduced in 2015 could avert more than 
40 percent of the TB burden by 2050 (Abu-Raddad and 
others 2009) and that, to have the most rapid impact on 
TB burden, such a vaccine would need to be efficacious in 
both uninfected and latently infected individuals (Dye 
and Williams 2008). Linking such work to the economics 
of TB vaccines has shown that different TB vaccine pro-
files can also be cost-effective (BIO Ventures for Global 
Health 2006; Ditkowsky and Schwartzman 2014; Tseng 
and others 2011). However, uncertainty remains about 
how various vaccine characteristics (efficacy, duration of 
protection) and targeting strategies (age, HIV/AIDS 
status) may combine to maximize impact in countries 
with the largest TB burden. 
The underlying economics of TB vaccines are also 
unclear. For example, depending on the vaccine profile, the 
likely price of both vaccine delivery and dose remains 
uncertain. TB vaccines for infants could be incorporated 
into the standard infant vaccination program (DTP3 
[diphtheria-tetanus-pertussis]), and cost estimates are 
straightforward to generate. However, the economics of 
targeting adolescents and older populations are largely 
unknown, and only recently are these populations being 
considered as a new platform for other vaccines, such as 
human papillomavirus (Sinanovic and others 2009) or 
measles booster. In the future, with these and other poten-
tial vaccines (for example, measles, human papillomavirus, 
or a future HIV/AIDS vaccine) for adolescents and adults, 
the targeting of adolescents via schools is likely to become 
increasingly common, and thus the costs may decrease. 
Due to the pervasiveness of Mtb infection in high-burden 
settings, TB vaccines targeted at adults may be used in 
mass campaigns to prevent disease. There are few prece-
dents for such campaigns, and the levels of coverage that 
could be achievable are open to debate. Similarly, the lack 
of acceptability of frequent mass campaigns could limit 
the potential impact of a TB vaccine for adults. Finally, it is 
possible that vaccines could be targeted to patients being 
treated with TB or MDR TB either to accelerate treatment 
times or to prevent recurrence after drug treatment.
Knight and others (2014) have explored a wide range of 
vaccine profiles to understand what type of vaccine profile, 
targeted at what age group, would have the biggest impact 
on TB incidence in LMICs (Knight and others 2014). 
Vaccine profiles were defined by both efficacy and dura-
tion of protection, with a range from 40 to 80 percent and 
from five years to lifetime, respectively. The vaccine was 
assumed to be introduced in 2024. A comparison was then 
made between targeting infants and targeting adolescents 
or adults in mass campaigns. A new TB vaccine would 
likely be used as a booster to BCG, due to the broad use of 
BCG and its efficacy in infants. The vaccine was assumed 
to prevent active disease in both uninfected and latently 
infected individuals, with 40 percent less efficacy in per-
sons with HIV/AIDS. Vaccine “take” was modeled with an 
exact duration of protection. Each country was modeled 
separately, with calibration methods used to capture both 
uncertainty in natural history parameters and the data on 
TB burden (WHO 2013b). Vaccine coverage was taken 
from similar mass campaigns in each country, such as for 
rubella, and were timed to occur with a frequency of every 
10 years or the duration of protection (whichever was 
shorter) from 2024 onward. Cost-effectiveness was defined 
as cost per DALY averted compared against gross national 
income per capita from a health sector perspective, with 
tiered vaccine pricing by income group.
By estimating the burden of TB in all LMICs for 
which data were available, the model was able to predict 
that a vaccine targeted at adolescents or adults would 
have a far greater impact on TB burden before 2050 than 
one targeted at infants (figure 11.10) (Knight and others 
2014). This is due to the differential burden of disease 
between these two age groups, with infants suffering 
from greater levels of extrapulmonary TB and therefore 
contributing less to transmission (Styblo 1991). This 
conclusion remained valid over the 2024–50 period, 
even when considering lifetime duration of protection. 
Knight and others (2014) reported that vaccines tar-
geted at adolescents or adults with 10-year durations of 
protection and 60 percent efficacy could be cost-effective 
in LICs at US$149 (95 percent range cost saving of 
US$387) per DALY averted at a cost of US$1 per dose. 
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Figure 11.10 Model Calibration and Vaccine Impact in Low-Income Countries
Note: Model calibration (panels a–c) and vaccine impact (panels d–e) in low-income countries. Panels a–c show median (solid dark blue line) and 95% range (blue cloud) of model 
ﬁts to data. (Panel a) Human population size (per 1,000) in low-income countries, 2000–50. (Panel b) Tuberculosis (TB) incidence: cases per 100,000 population per year, 2000–50 
(Panel c) TB mortality: deaths per 100,000 population per year, 2000–50. (Panels d–e) TB incidence (cases per 100,000 population per year), 2000–50, with median model output 
(black line) and vaccine proﬁle impact: characteristics of efﬁcacy (color) and duration of protection (line type) for vaccines targeted at infants (panel d) or at adolescent or adults 
(panel e). A vaccine targeted at infants (panel d) has a smaller impact on TB disease incidence than one targeted at adolescents or adults (panel e). The “waves” within the 
adolescent or adult incidence ﬁgure (panel e) are due to the impact of mass campaigns.
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The same profile targeted at infants would avert only 0.89 
(0.42–1.58) million TB cases while averting 17 (11–24) 
million TB cases in adolescents or adults and would not be 
considered cost-effective at US$1,692 (US$634–US$4,603) 
per DALY averted. In threshold analysis, the price per dose 
at which the vaccine profile would be cost-effective was 
determined. For example, a vaccine with 10-year duration 
of protection and 60 percent efficacy targeted at adoles-
cents or adults could be priced at up to US$20 in 
upper-middle-income countries and still be considered 
cost-effective. This reflects the large number of cases that 
could be averted by targeting the age group in which most 
cases of disease occur and in which most sources of trans-
mission are found. Vaccines with short duration (five 
years) and low efficacy (40 percent) were also found to be 
cost-effective if targeted at adolescents and adults. 
A recent review pointed out that funding for TB vac-
cine development significantly lacks the same support 
provided to other vaccine development efforts 
(Manjelievskaia and others 2016). For example, funding 
to develop an Ebola vaccine ramped up quickly follow-
ing the 2013–14 epidemic in Guinea, Liberia, and Sierra 
Leone, an outbreak that killed approximately 11,310 
persons. The global response to the outbreak was enor-
mous; the U.S. government alone appropriated more 
than US$5.4 billion for the Ebola emergency response in 
2015, of which a large portion was directed to research, 
including developing Ebola vaccines. In comparison, 
funding to develop a TB vaccine received only US$85 
million to US$90 million in 2015 (based on prior years’ 
funding numbers), despite an estimated 29,000 people 
dying of TB per week (based on 2014 mortality esti-
mates) and little sign of meaningful diminution in the 
global spread of Mtb and the continuing spread of MDR 
and XDR TB (Frick, Henry, and Lessem 2016; TAG 2016). 
In conclusion, vaccines have an enormous potential 
to reduce the incidence and prevalence of TB if they are 
targeted at adolescents or adults, suggesting that 
increased investments in candidate vaccines targeting 
this group are warranted. Vaccines are also likely to be 
highly cost-effective, even if only having relatively mod-
est clinical effectiveness. Given the age-dependent period 
of risk, special consideration should be given to develop-
ing candidate vaccines providing long-term protection. 
EXTENDED COST-EFFECTIVENESS ANALYSIS 
OF UNIVERSAL PUBLIC FINANCING OF TB 
TREATMENT 
Tuberculosis causes approximately 28 million active 
infections and 480,000 deaths in India annually (WHO 
2016a). The disease burden is concentrated largely 
within the poorer parts of the population: TB has a four 
times greater incidence among persons in lower socio-
economic groups, and incidence is greater in rural than 
urban areas (Muniyandi and others 2007). Private health 
expenditures also constitute a large majority of India’s 
total health expenditures, and most TB patients consult 
private practitioners for their first visit, resulting in sub-
stantial OOP spending on TB (Satyanarayana and others 
2011; Uplekar and others 1998; Uplekar, Pathania, and 
Raviglione 2001). In India, as in many countries, OOP 
medical costs are a leading cause of impoverishment. 
Kruk, Goldmann, and Galeo (2009) and Sengupta and 
Nundy (2005) found, for example, that about 40 percent 
of Indian households borrowed money or sold assets to 
pay for health care. In light of such findings, the govern-
ment is increasingly assuming responsibility for financ-
ing TB treatment (Jha and Laxminarayan 2009).
Universal public finance (UPF) is when government 
finances an intervention irrespective of who is receiving 
it. For any given health intervention, UPF entails conse-
quences in multiple domains. First, UPF increases inter-
vention uptake. Second, it eliminates the need for private 
expenditures. Finally, it provides financial risk protec-
tion (insurance) by covering catastrophic expenditures 
that would otherwise throw households into poverty. 
This section reports on these three consequences of UPF 
using extended cost-effectiveness analysis (ECEA) find-
ings on DOTs expansion in India (Verguet, Laxminarayan, 
and Jamison 2015). 
Because of the importance of OOP costs, interna-
tional agencies have supported the use of health sector 
policies to attenuate health-related financial risks (WHO 
1999, 2010; World Bank 1993). Despite the attention 
paid to its significant potential as part of broader social 
insurance, UPF in practice covers few interventions in 
most LMICs, with little consensus on what to cover in 
highly resource-constrained environments. In India, 
UPF has typically financed condition-specific programs 
(for example, against leprosy, HIV/AIDS, and cataract 
blindness) or, more recently, secondary and tertiary care 
insurance such as the Rashtriya Swasthya Bima Yojana 
and the Arogyasri (in Andhra Pradesh) programs. These 
insurance programs are thought to provide significant 
financial protection since they defray the high OOP costs 
associated with hospitalizations. 
Currently, about 70 percent of TB cases receive 
DOTS; only about half of these services are obtained for 
free in the public sector. People do not always obtain TB 
treatment at the public hospital level for various reasons, 
including transportation cost and waiting time. Most 
lower-income people prefer to see a private physician 
after working hours than to take a day off work without 
pay to visit a public hospital (Kumar and Kumar 1997). 
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Yet, privately purchased TB treatment is often ineffective 
because private doctors do not necessarily provide the 
standard regimen with proven efficiency (Satyanarayana 
and others 2011; Udwadia, Pinto, and Uplekar 2010; 
Uplekar and Shepard 1991). A potential virtue of UPF is 
to eliminate low-quality treatment in the private sector, 
enabling the uptake of higher-quality treatment and 
increasing technical efficiency. However, this requires a 
well- managed public sector program, something widely 
achieved only in parts of India. 
We estimated the results of expanding DOTS through 
UPF to cover 90 percent for an Indian population of 1 
million (table 11.8). The total number of lives saved 
would be about 80 per 1 million per year, and the health 
benefits would be concentrated among the bottom two 
income quintiles (80 percent), as TB has a higher inci-
dence among these socioeconomic groups. The total 
number of private expenditures averted by the program 
would be about US$30,000 per 1 million population per 
year, and the bottom two quintiles would benefit from 
about 40 percent of the private expenditures averted. 
The total financial protection provided for this popula-
tion sample (measured as a money-metric value of 
insurance) would be about US$10,000, 80 percent of 
which would accrue to the bottom two quintiles. The 
total (incremental) treatment costs incurred by UPF for 
the sample would be about US$65,000. 
This analysis illustrates how UPF can be used to 
improve financial protection and technical efficiency by 
eliminating the purchase of lower-quality treatments. It is 
only a limited take on greater possibilities. For example, a 
detailed assessment could provide more comprehensive 
estimates of TB costs (for example, households’ transpor-
tation costs, earnings, and productivity impacts). The 
focus here is on the OOP cost of treatment and excludes 
the cost of earnings reduced by the disease. For example, 
the number of working days lost due to TB can range 
from 30 to 90 in South India (Muniyandi and others 2006; 
Muniyandi and others 2008). Indirect costs from lost 
earnings can be substantial (Ananthakrishnan and others 
2012), which would—in the absence of other forms of 
social insurance—increase the insurance benefits pro-
vided by UPF. 
A limitation of focusing on the financial cost of treat-
ment is that individuals do not get care for other reasons 
as well, including lack of information about TB and 
its treatment. Primary health centers in India may be 
difficult to reach due to poor travel conditions (Muniyandi 
and others 2006), be overcrowded, and not respect the 
dignity of patients. Health services may not always be 
available, even after informational and financial barriers 
have been removed: increasing coverage may thus not be 
feasible, and the extent of subsequent health gains from 
UPF may be significantly reduced in the absence of 
supply- side intervention. If demand for TB treatment for 
any of these reasons does not match disease incidence, 
the level of coverage achievable will be constrained. 
Yet, using ECEA, Verguet, Laxminarayan, and Jamison 
(2015) demonstrated that the potential benefits of UPF 
for health and financial risk protection would accrue 
primarily to the poor. Reductions in OOP expenditures 
would also benefit the poor because UPF crowds out 
private financing of the inferior treatments frequently 
purchased by persons with income constraints. Lowering 
the costs of borrowing for the poor could potentially 
achieve some of the health gains of UPF, but at the cost 
of leaving the poor more deeply in debt (table 11.9).
SUMMARY AND RECOMMENDATIONS 
While much progress has been made over the past several 
decades, particularly in reducing mortality, TB remains a 
major infectious disease, whose severity is exacerbated by 
the growing problem of multidrug-resistant TB, exten-
sively drug-resistant TB, and co-infection with HIV/AIDS. 
Progress in TB control requires early and accurate case 
detection, rapid commencement of and adherence to 
effective treatment, and prevention of transmission. 
Table 11.8 Public Finance of Tuberculosis Treatment to 
90 Percent Coverage in India, by Income Quintile
per million population
Outcome Total
Income Quintile
I II III IV V
TB deaths averted 80 40 25 12 3 0
Private expenditures 
crowded outa 29 6 6 7 6 4
Insurance valuea 9 5 2 1 1 0
Note: TB = tuberculosis.
a. Figures expressed in 2011 US$, thousands.
Table 11.9 Borrowing to Finance Tuberculosis 
Treatment in India, by Income Quintile
per million population
Outcome Total
Income Quintile
I II III IV V
TB deaths averted 29 13 10 5 1 0
Private expenditures 
crowded outa −25 −12 −8 −4 −1 0
Insurance valuea 0 0 0 0 0 0
Note: TB = tuberculosis.
a. Figures expressed in 2011 US$, thousands.
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The great challenge is to reduce transmission by identify-
ing and treating patients with TB who are asymptomatic, 
unaware of their status, or unable to gain access to 
treatment.
This chapter offers four overarching recommenda-
tions: (1) strengthen the current WHO End TB Strategy 
to emphasize active case finding in targeted high-burden 
countries; (2) strengthen health systems in those coun-
tries, particularly emphasizing community-based care; 
(3) strengthen information systems; and (4) invest far 
more in research to develop the tools necessary to con-
trol TB. Fundamentally, it is necessary to revise the cur-
rent global TB control strategies in most high-burden 
countries and to make significant new investments in 
health systems and research. 
Rethinking and Revising the DOTS Strategy
Since the WHO designated tuberculosis as a global emer-
gency in 1993, the DOTS strategy has been the mainstay 
of TB control worldwide. It is based on the premise that 
patients with TB will be sufficiently ill to seek care from 
the health system and, if appropriately treated, be cured 
and that transmission will be reduced. Since 1994, the 
DOTS strategy has significantly improved the diagnosis 
and treatment of individuals identified with tuberculosis 
in all countries and reduced mortality. The prevalence 
and treatment of drug-susceptible TB is a “best buy” at 
US$100–US$500 per case cured. Treatment of MDR TB 
remains limited and more expensive. Yet the decline of 
TB incidence globally, particularly in the 22 highest- 
burden countries, has lagged the declines in HIV/AIDS 
and malaria and is far below the MDG targets set by the 
Stop TB Partnership to reduce TB incidence, prevalence, 
and mortality by 50 percent compared with a baseline of 
1990. With TB exceeding HIV/AIDS and malaria as the 
largest cause of death from any single infectious disease 
and drug resistance increasing, it is critical to reconsider 
how to control the epidemic more effectively. 
DOTS has the great advantage of being a single, unify-
ing global strategy that, in principle, can be applied to all 
patients in all countries. Yet, while effective in countries 
with strong health systems, DOTS is failing to bend the 
incidence curve rapidly, especially in LICs with high TB 
burdens and weak health systems. Management of TB has 
been particularly challenging in LMICs with high inci-
dence and prevalence of co-infection with HIV/AIDS, 
which makes treatment more difficult and relapse or 
reinfection more common. Of particular concern is the 
limited impact of DOTS on the effective control of MDR 
TB, which requires complex diagnostic testing and is 
enormously expensive (US$5,000–US$10,000 per case 
cured) and only partially effective. TB, especially MDR 
TB, represents a serious threat to health personnel in 
high-burden countries. Even with high patient treatment 
compliance, in these contexts, DOTS as commonly imple-
mented is not reducing the transmission and incidence of 
disease sufficiently rapidly. As this chapter discusses, sub-
stantial numbers of individuals with TB have tubercle 
bacilli in their sputa and yet are asymptomatic and not 
likely to report to a health facility and thus be detected by 
passive case finding. 
In this context, the WHO has revised and promulgated 
the End TB Strategy, which emphasizes patient-centered 
care, treatment for all patients with drug-susceptible and 
drug-resistant TB, increased community engagement, and, 
for the first time, an explicit focus on research. Consistent 
with the End TB Strategy (WHO 2015a), this chapter sug-
gests that a stratified approach with improved targeting in 
high-burden countries will be necessary in these contexts. 
Such a diversified and better-targeted strategy, should seek 
to accomplish the following: 
1. Identify high-transmission countries and hot spots 
within countries where targeted efforts can be more 
effective and cost-effective. 
2. Increase the capacity for surveillance. 
3. Strengthen early TB detection and diagnosis by active 
case finding in certain countries and populations. 
4. Provide rapid diagnosis and enable more rapid initi-
ation and better maintenance of treatment for both 
drug-susceptible and multidrug-resistant TB. 
5. Expand preventive therapy of the contacts of TB 
patients, children, and HIV-positive individuals. 
6. Combine these strategies with an approach rooted in 
community-based delivery of TB services and support, 
wherever possible. 
7. Improve the drug supply chain to improve access 
to TB treatments that have very small markets, and 
improve information technology to enable more 
effective control.
8. Significantly increase resources for research on devel-
oping new diagnostic technologies, development and 
testing of new drug regimens, and new vaccines to 
prevent TB.
All of these recommendations, while at some variance 
with previous DOTS protocols, are fully consistent with 
the new WHO End TB strategic goals (WHO 2015a). 
The new Stop TB Partnership’s Zero TB Initiative seeks 
to apply these recommendations to demonstrate in a 
small number of high-burden cities that a comprehen-
sive program of active case finding, effective treatment, 
and prevention in households can be effective in limiting 
transmission and reducing the incidence of TB (Stop TB 
Partnership 2016). 
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Expanding Active Case Finding 
In high-burden, low-income countries, particularly those 
with a high incidence and prevalence of TB and HIV/AIDS 
co-infection, earlier and more comprehensive case finding 
and treatment are required. Passive case finding and 
screening of populations for classic symptoms clearly fail 
to detect a major proportion of existing TB cases, which 
are asymptomatic or unknown to the health system— 
representing up to one-third or 3 million cases—leading to 
continued transmission of TB infection. In low-burden 
countries where DOTS is effective in reducing incidence, 
prevalence, and mortality, the current approach should be 
expanded, and investments in active case finding are not 
likely to be cost-effective. But, in high-burden countries, 
targeted introduction of active case finding with modern 
rapid and point-of-care diagnostic tests and mobile 
X-radiography for screening populations could signifi-
cantly improve early diagnosis and early institution of 
treatment and dramatically reduce transmission. As this 
chapter discusses, TB treatment regimens are lengthy and 
not without drug-related adverse events, which, in weak 
health systems, create challenges to maintaining consistent 
adherence to recommended drugs (Schaaf and others 
2009; Verma and others 2004). Health systems that can 
provide patient support, including mechanisms to incen-
tivize treatment completion, can bolster the effectiveness 
of active case finding.
Strengthening Health Systems 
With drug-resistant TB now a global crisis, early diag-
nosis and effective treatment, either through improved 
access to bacterial culture and drug-sensitivity testing 
(Dowdy and others 2008; Uys and others 2009) or 
through rapid molecular diagnostics (Lin and others 
2012), are essential to reduce the burden of drug- 
resistant TB in high-prevalence settings. Modeling 
studies suggest that these interventions could be highly 
cost- effective, because they provide not only potentially 
life-saving care but also prevent further spread of 
drug-resistant disease (Menzies and others 2012). 
Modeling studies also suggest that infection-control 
interventions can be very cost-effective (Basu and others 
2007), especially when aimed at health care workers 
and the patients responsible for most transmission 
(Andersson 2006; Woolhouse and others 1997).
Although some new diagnostics and care delivery 
models have emerged, the uptake of new tools and inno-
vations for TB control has been suboptimal in weak health 
systems (Cobelens and others 2012). New tools such as the 
Xpert MTB/RIF assay enable rapid and effective diagnosis 
of TB and MDR TB (Boehme and others 2010; Boehme 
and others 2011; Chang and others 2012), do not require 
highly skilled health workers (Rachow and others 2011), 
and have been demonstrated to be cost-effective (Vassall 
and others 2011). However, their rapid introduction has 
been hindered by weak health systems, specifically weak 
supply chain management systems, weak information 
systems linking diagnostic data to the site of treatment, 
and the need to address false-positive indications of 
rifampicin resistance (Dowdy and others 2011; Kirwan, 
Cárdenas, and Gilman 2012; Lawn and others 2011; Scott 
and others 2011; Trébucq and others 2011).
Increased numbers of better trained and motivated 
health workers at multiple levels, better information sys-
tems, and functioning logistics and supply chains are criti-
cal if TB is to be effectively controlled. TB transmission can 
be prevented through investments in infection control in 
clinics and hospitals; preventive therapy for household and 
HIV-positive contacts; better-designed housing for low- 
income populations; and better nutrition for at-risk 
populations. Efforts like these require technical and finan-
cial support, not only in TB programs per se, but also in 
complementary activities that support the delivery of TB 
services. Without improving health systems, extending the 
scope and targeting of TB programs, and providing addi-
tional technical and financial support, it is questionable 
how significantly and rapidly high-burden countries can 
improve TB control. 
Expanding Community-Based Care 
While in many countries, TB treatment has traditionally 
been hospital-based, in an increasing number of set-
tings community-based treatment has been shown to 
be as clinically effective and significantly more cost- 
effective, even when compared with clinic-based 
management of TB. Efforts should be undertaken 
to transition health systems from hospital-based to 
community-based care in countries where doing so is 
feasible. Community-based care and treatment are 
effective and may offset some of the increases in financ-
ing required for active case finding. It will be important, 
in countries with large private health care providers, to 
develop public-private partnerships to engage the pri-
vate sector in offering the best possible diagnostic and 
treatment protocols. Strengthening health systems to 
support more effective community-based TB care—
including investing in community-based health work-
ers, information systems, and supply chains—can have 
significant impact, not only on TB, but also on other 
infectious and chronic diseases, including HIV/AIDS 
and noncommunicable diseases such as diabetes and 
cardiovascular disease, which similarly require long-
term or continuous treatment. 
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Strengthening Research and Development
The current tools for combatting TB are woefully inade-
quate, yet funding for TB research lags that for HIV/
AIDS and malaria. Reducing the burden of TB and MDR 
TB will require greater funding for more intensive 
research into new approaches to point-of-care diagnosis, 
shorter and more effective treatment regimens for both 
TB and MDR TB, and better service delivery. But the 
current drug pipeline is thin. There is an urgent need for 
new drugs and regimens that will be cost-effective and 
affordable. Of particular urgency is the need to develop 
new multidrug regimens that shorten the duration of 
treatment, increase the number of cures of drug- 
susceptible TB, and, ideally, increase the number of cures 
of both drug-susceptible and drug-resistant TB. A small 
number of new drugs appear promising in this regard, 
but require further clinical evaluation. New regimens 
capable of effectively treating both drug-susceptible and 
drug-resistant TB would reduce the need for expensive 
drug-sensitivity testing and could be highly cost- effective. 
Several molecular tools are being developed that could 
allow prediction of risk for patients with latent infection 
to progress to active disease and, possibly, of when treated 
cases are truly cured. This approach could enable preven-
tive treatment of individuals at high risk of progression 
to disease. The same molecular tools may be able to iden-
tify host gene signatures that would identify protective 
immune responses that could become biomarkers for 
predicting the efficacy of new vaccines. 
Developing more effective vaccines to prevent TB 
infection, disease, relapse, or reinfection will be essential, 
since even a modestly successful vaccine would be highly 
cost-effective. BCG remains the most widely used vac-
cine in the world; while its ability to prevent severe child-
hood consequences of TB is cost-effective, its impact on 
preventing disease in adults is questionable at best. 
Preventing infection and disease is the major goal of 
vaccine research, and, given the challenges to case detec-
tion, drug resistance, and cure, it remains uncertain 
whether TB can be eliminated as a global public health 
problem without an effective preventive vaccine. 
Drug, device, and vaccine companies are essential to 
developing the new tools required for TB, but they have 
few incentives to invest in a disease that occurs primarily 
in resource-poor countries where the returns on invest-
ments in long-term development and trials will be few, 
if any. Public-private collaborations could make a major 
difference to developing new technologies for TB.
The Bottom Line
TB remains the largest cause of death from an infectious 
disease, and, in contrast to HIV/AIDS and malaria, the 
incidence is not declining at a rate required to bring this 
epidemic under control. This chapter urges that the tra-
ditional strategy to control TB most commonly imple-
mented in many countries, which has been successful in 
low-burden countries of the Americas and Europe, 
needs to evolve into a more stratified and targeted 
approach in order to meet the needs of high-burden 
populations where it has not been effective in controlling 
transmission and reducing incidence of TB. The WHO’s 
End TB Strategy now emphasizes differences in the epi-
demic in different countries and the need for research to 
develop new tools (WHO 2015a, 2015c). The recom-
mendations of this chapter are fully consistent with the 
WHO’s End TB Strategy. 
This chapter argues that new investments are needed 
to make health systems more responsive and effective by 
providing greater access to improved technologies for 
rapid diagnosis and to drug-sensitivity testing. It advo-
cates for introducing new modalities, such as active case 
finding and community-based care in high-burden set-
tings. Finally, it emphasizes the urgent need for greater 
investments in research to develop new tools for diagno-
sis, drug regimens for treatment, and vaccines for pre-
vention. Such investments will be costly—and more 
funding will be required to extend current efforts and 
enable the new approaches recommended here—but 
ultimately highly cost-effective for both individuals and 
countries. Only with new thinking and new approaches 
will it be possible to transform TB control to a level that 
can achieve the ultimate goal of eliminating TB as a 
global public health problem. To reduce significantly the 
largest cause of death from infectious disease in the 
world and to improve the lives of people who suffer from 
it, greater financial investments will be necessary and 
indeed justified.
NOTES
World Bank Income Classifications as of July 2014 are as follows, 
based on estimates of gross national income (GNI) per capita 
for 2013: 
• Low-income countries (LICs) = US$1,045 or less 
• Middle-income countries (MICs) are subdivided: 
(a) lower-middle-income = US$1,046 to US$4,125 
(b) upper-middle-income (UMICs) = US$4,126 to US$12,745
• High-income countries (HICs) = US$12,746 or more.
 1. For example, http://reference.medscape.com/drug 
- interactionchecker or http://www.hiv-druginteractions.org.
 2. For the WHO recommendations, see http://www.who.int 
/hiv/topics/tb/art_hivpatients/en.
 3. Described at http://www1.nyc.gov/assets/doh/downloads 
/ pdf/tb/tb2015.pdf. 
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 4. For example, OpenBoxes (https://openboxes.com) and 
OpenLMIS (https://www.villagereach.org).
 5. Sproxil (https://www.sproxil.com).
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